¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/4/6 ¤W¤È 10:43:51²Ä 8260 ½g¦^À³
www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/therapeutic-medicines-coronavirus-covid-19

Therapeutic medicines against the coronavirus infection Covid-19

One group of medicines does not fight viruses directly, but instead promotes the body¡¦s own virus defence: interferons. They are variants of the body¡¦s own messenger substances that are produced genetically. Biochemists divide these messenger substances into several subgroups, of which the alpha and beta interferons are important against SARS-CoV-2:

Alpha-Interferons: In a series of studies with Covid-19 patients, medicines with the active ingredients interferon alpha-1b, interferon alpha-2b (from the Cuban company BioCubaFarma and the Cuban-Chinese company Changchun Heber Biological Technology), peg-interferon-alpha-2a (produced by Roche), peg-interferon-alpha-2b or novaferon (from the Chinese company Genova Biotech) were used alone or in addition to other medicines. In some cases, the respective alpha-interferon was administered in inhalable form. All these medicines have, at least in some countries, been approved for the treatment of certain viral infections, for example hepatitis B or C. BioCubaFarm has indicated that it can supply large quantities of its medicine worldwide.

Beta-Interferons: Medicines containing interferon beta-1a and interferon beta-1b are currently being tested in trials against Covid-19. The German company Merck is making its interferon beta-1a medicine available for a larger study by the INSERM institute in France. Neither medicine has been approved for antiviral therapy in the EU, but in laboratory tests interferon beta-1a was able to stop the multiplication of the related SARS viruses. For an inhalable form of interferon-beta-1a, the British company Synairgen has received approval for a study with Covid-19 patients.

«aª¬¯f¬r·P¬VªºªvÀøÃĪ«Covid-19

¤@²ÕÃĪ«¤£¬Oª½±µ¹ï§Ü¯f¬r¡A¦Ó¬O¼W±j¤HÅé¦Û¨­ªº¯f¬r¨¾¿m¯à¤O¡G ¤zÂZ¯À¡C¥¦­Ì¬O¤HÅé¦Û¨­³q¹L°ò¦]²£¥Íªº«H¨Ïª«½èªºÅÜÅé¡C¥Íª«¤Æ¾Ç®a±N³o¨Ç«H¨Ïª«½è¤À¬°´X­Ó¨È²Õ¡A¨ä¤¤£\©M£]¤zÂZ¯À¹ïSARS-CoV-2¨ã¦³­«­n·N¸q¡G

£\-¤zÂZ¯À¡G¦b°w¹ïCovid-19±wªÌªº¤@¨t¦C¬ã¨s¤¤¡A±Ä¥Î¤F¨ã¦³°®ÂZ¯À£\-1b¡A¤zÂZ¯À£\-2b¡]¨Ó¦Û¥j¤ÚBioCubaFarma¤½¥q©M¥j¤Ú¤¤°ê¤½¥qChangchun Heber Biological Technology ªº¦³®Ä¦¨¤À¡^ªºÃĪ«¡A»E¤A¤G¾J¤zÂZ¯À-alpha-2a¡]ù¤ó¤½¥q¥Í²£¡^¡Apeg- ¤zÂZ¯À-alpha- 2b©Înovaferon¡]¨Ó¦Û¤¤°êGenova Biotech¤½¥q¡^³æ¿W¨Ï¥Î©Î»P¨ä¥LÃĪ«¤@°_¨Ï¥Î¡C¦b¬Y¨Ç±¡ªp¤U¡A¬ÛÀ³ªº£\-¤zÂZ¯À¥H¥i§l¤J§Î¦¡µ¹ÃÄ¡C¦Ü¤Ö¦b¬Y¨Ç°ê®a¡A©Ò¦³³o¨ÇÃĪ«³£¤w³Q§å­ã¥Î©óªvÀø¬Y¨Ç¯f¬r·P¬V¡A¨Ò¦p¤A«¬©Î¤þ«¬¨xª¢¡CBioCubaFarmªí¥Ü¡A¥¦¥i¥H¦b¥þ²y½d³ò¤º¨ÑÀ³¤j¶qÃĪ«¡C

£]-¤zÂZ¯À¡G§t¦³°®ÂZ¯Àbeta-1a©M°®ÂZ¯Àbeta-1bªºÃĪ«¥Ø«e¥¿¦b°w¹ïCovid-19ªº¸ÕÅ礤¶i¦æ´ú¸Õ¡C¼w°êÀq§J¤½¥q¥¿¦b±N¨ä°®ÂZ¯À£]-1aÃĪ«´£¨Ñµ¹ªk°êINSERM¬ã¨s©Ò¶i¦æ§ó¤j³W¼Òªº¬ã¨s¡C¼Ú·ù§¡¥¼§å­ã³o¨âºØÃĪ«¥Î©ó§Ü¯f¬rªvÀø¡A¦ý¦b¹êÅç«Ç´ú¸Õ¤¤¡A¤zÂZ¯À£]-1a¯à°÷ªý¤î¬ÛÃöSARS¯f¬rªºÁc´Þ¡C¹ï©ó¥i§l¤J§Î¦¡ªº¤zÂZ¯À-£]-1a¡A­^°ê¤½¥qSynairgen¤wÀò±o§å­ã¥Î©óCovid-19±wªÌªº¬ã¨s¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G»þ³·¾~10148547  µoªí®É¶¡:2020/4/5 ¤U¤È 07:29:27²Ä 8259 ½g¦^À³
¡i²z¬ì¤j¨ûªº²M©ú³s°²¦Û¦vŪ®Ñ¤é°O¡j

²M©ú³s°²§Ú¨S¦³¥h¾Á¤BªF¤jªù¥_´ä´Â¤Ñ®c¤HÀ½¤H¡A

°£¤F¦b®a¶¶¤â¹wÁʤE¤ù¤f¸n¡A®½´Úµ¹¸q¤j§Q¤Ñ¥D±ÐÆFÂå·|¥~¡A¶¶«KÃö¤ß¤F¤@¤UªZº~ªÍª¢ªº¥ÎÃĵo®i¡C

¦]¬°¤§«e¦³­q¾\ÃöÁä¦r(MPN/ COVID-19)¡A¬Ý¨ì¤F¤@­Ó¬Û·í¦³·N«äªº¸ê®Æ¡C

www.mpnvoice.org.uk/coronavirus-covid-19-advice-and-information/coronavirus_covid_19_advice_for_people_with_mpns.aspx

²Ä¤T¤Î¥|ÂI¬Û·í¦³½ì¡A¤£±M·~´í½Ķ¦p¤U

²³æ¨Ó»¡¡A®Ú¾Ú­^°êNHSªº«ü¥Ü¡A¹L¥h¬ã¨sµo²{ªA¥ÎJakaviªºMF¯f¤H§K¬Ì¨t²Î¤ñ¸û¯Ü®z¡A®e©ö¨ü¨ì¯f¬r·P¬V¡A

©Ò¿×ªº¯f¬r·íµM¤]¥]¬A²{¦b¥þ²y¤j¬y¦æªºªZº~ªÍª¢¡A

¦]¦¹¨Ï¥Î Jakaviªº¯f¤HÀ³¸Ó±Ä¦æ³ÌÄY®æªº¨¾¬Ì±¹¬I¡A

¨Ï¥Î¤zÂZ¯ÀªºMPN¯f±w«h¨S¦³³o­Ó°ÝÃD¡A¸ò¤@¯ë¤H¤@¼Ë´N¦n¡C

µ¥µ¥¡AÃĵتº¤zÂZ¯ÀBesremi¤£¬O¦³¦b¼Ú¬w³c½æ¶Ü?¦Ó¥B¬OPV²Ä¤@½u¥ÎÃÄ®º

www.gbimonthly.com/2019/05/45626/

¶¤F¤@°é¡A©¿µMı±o¤j¨û§Ú¤]À´©]Æ[¤Ñ¶H¡B¥à¬Û°_­·¤F¡C

¡]¨Ó»«½Ð´xÁn¹ªÀy¹ªÀy¡^

¼Ú¬wªºªZº~ªÍª¢¥Ø«e¨S¬Ý¨ì¬y¦æ³Ì°ª®p¡A¦è¯Z¤ú¸ò¸q¤j§Q³£ÁÙ¨S¦³´î½wªºÁͦV

¦pªG«ö·Ó³\¦h±M®a©Ò¨¥¡AªZº~ªÍª¢¥i¯à·|ªø´Á¬y·P¤Æ¡A¨C¦~¬î¥½¬Kªì³£·|¨Ó¤@ªi¬y¦æ¡A

¥¼¨ÓÂå®v¦bªvÀø PV ¯f¤H®É¡A·d¤£¦n·|¦Ò¶q¯f±w­±¹ï¥þ²y¬y¦æ¯fªº­·ÀI¡]¡H¡^

¶}¥ßµ¹¯f¤Hªº¥ÎÃĤWÀu¥ý¿ï¥Î Besremi ¦Ó«D Jakavi ¤F

¨º»òBesremi¬O¤£¬O¦³¾÷·|·m¨ìJakaviªº¥«³õ©O¡H

ÃĵØÃÄ·|¤£·|´N¦¹µo¤j°]©O¡H§Ú­ÌªºªÑ»ù¦³¨S¦³§Æ±æ©O¡H

Åý§Ú­ÌÄ~Äò¬Ý¤U¥h¡C

#¨¾¬Ì¶¶®É¤¤ #ªÀ¥æ¶ZÂ÷¤@¤½¤Ø #·R¦³¦h²`¶ZÂ÷´N¦³¦h»·

#·f­¼¤j²³¥æ³q¤u¨ã½ÐÀ¹¤f¸n¡@#Taiwancanhelp

#®½´Ú¸q¤j§Q³ÜÅøºû¤j¤O

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¥ý¥Í10149022  µoªí®É¶¡:2020/4/3 ¤W¤È 08:08:32²Ä 8258 ½g¦^À³
66¶ô¶R¤F10±i, ÁÂÁÂ¥à¬Û COVID-19ªº®É¶¡©Ôªø ¿ð¦­·|Á{§É¥Î·sªº¤zÂZ¯À ´Nµ¥¥xÆWÃÄÃÒ¤F ¤£ª¾¶i«×¦p¦ó
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/4/2 ¤U¤È 07:56:18²Ä 8257 ½g¦^À³
¦^ÅU¥H©¹ ¯uªº£¸°ï½èºÃ³£¬O°²ªº ¥u¬O®É¶¡©µ«á¹F¦¨¦Ó¤w

µM¦ÓªÑ»ù«o¤ñ¤§«e«K©y£¸­¿¥H¤W

­@¤ßµ¥«Ý2023§a ÁÙ¦³ªº¿i

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/4/2 ¤U¤È 01:24:30²Ä 8256 ½g¦^À³
¥H«eGºôGnet

¤@¤Ñ¨ì±ß³yÁÁ

»¡Ãĵجü°ê­n°µ¤T´ÁÁ{§É

»¡ªº¤H¤ß´q´q

¦p¤µ¤~ª¾

Gºô»¡ªº攞¬O°²

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/4/2 ¤U¤È 12:52:33²Ä 8255 ½g¦^À³
Ãĵجü°êÃÄÃÒ

¤£·|¦³¤°»ò°ÝÃD

¼Ú¬w³£®³¨ìÃÄÃÒ¤F

¬ü°êÁÙ·|¦³°ÝÃD¡H

¨º®É¤j®a¾á¤ß¬°¦óÁÙ¤£°e¥ó

¦p¤µ¤w¸g°eFDA¤F

´Nµ¥¦n®ø®§§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/4/2 ¤W¤È 11:45:26²Ä 8254 ½g¦^À³
·sÃļf¬d³£¬O¹q¸£§@·~

Ãĵؤw¸g±N©Ò¦³°e¼f¤å¥ó¡A¥Î¹q¸£ÀÉ®×

¶Çµ¹FDA

¦pªG¬O¬Ì±¡¤]¥i¥H¦b®a¿ì¤½

¼f¬d§@·~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/4/2 ¤W¤È 11:40:10²Ä 8253 ½g¦^À³
March 10, 2020: Coronavirus Disease 2019 (COVID-19) Update:

Foreign Inspections - After careful consideration,

the FDA is postponing most foreign inspections through April, effective immediately.

Inspections outside the U.S. deemed mission-critical will still be considered on a case-by-case basis.

FDA®ü¥~¬d¼t¥|¤ë¥÷«á©µ´Á¡C¨S¦³»¡·sÃļf¬d©µ´Á¡C

µ¥Ãĵؼf¬d³q¹L¡A¤~¬d¼t¥i¯à¨ì¤K¤ë¥H«á¤F¡A­Ó¤H±À´ú

¥i¯à¤£·|¨ü¨ì¼vÅT¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2020/4/2 ¤W¤È 11:18:30²Ä 8252 ½g¦^À³
¤£ª¾¤½¥q©Î¤j¤j¦³ºÞ¹D²z¸ÑFDA­ì¼f®Ö¶i«×¦³µL¨ü¬ü°ê¬Ì±¡¼vÅT¡H FDA¬ÛÃö¼f¬d·~°È¦³µL¦]¨¾¬Ì¹jÂ÷¦Ó¦³©Ò¦]À³¤Î¼vÅT¡H­ì­pµe¦ó®É¯àª¾¹D¬O§_³Q±µ¨üÀò±oÀu¥ý¥[³t¼f¹î¸ê®æ¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/4/1 ¤U¤È 06:28:20²Ä 8251 ½g¦^À³
¬Oªº

³o¬O¤wª¾ªº

­Y¦³¬ðµo§Q¦h§÷¦³¾÷·|Ãz½Ä

¥u¦³¶q»ù¥i¥Hª¾¹D(¤@©w¦³¤H¥ýª¾¹D)

Ps:¨º°¦ºÆª¯¬Ý¨ì¤F,¤@©w·|¦b¹j¾ÀÃö¦b«Î¤º¦Û¤v¨g§p,¯u¦³½ì!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/4/1 ¤U¤È 04:53:55²Ä 8250 ½g¦^À³
ªñ´Á¬ÛÃö½T»{¨Æ¶µ:

4¤ë: ¥xÆWÃÄÃÒ¬O§_¨ú±o? °â»ù¦h¤Ö?

5¤ë: FDA ¤½¥¬¬O§_Àu¥ý¼f¬d

6¤ë: ¬O§_¸Ó¥X³f¤F?

7~8¤ë:AOP ¬O§_¦³¤À¼í?

ÁÙ¦³º|¶Ü? Åý§Ú­Ì¤j®aÀ°¦£½T»{¤@¤U¶i«×...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/30 ¤U¤È 08:33:04²Ä 8249 ½g¦^À³
º¦¤F´X¤Ñ

Á`¸Ó¦^Àɤ@¤U

ÅýÀò§QªÌ¥X²M¤@¤U

¦A¦¸©¹¤W§ð°í

¦X²z±ÀÂ_¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2020/3/30 ¤U¤È 12:03:17²Ä 8248 ½g¦^À³
¤Ï¼uµ²§ô¤F¶Ü?

¤µ¤Ñªº½T¬Ý¤£¤ÓÀ´?

ÁÙ¬O¦³¥ô¦ó§QªÅ¥X?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/28 ¤U¤È 12:54:38²Ä 8247 ½g¦^À³
­»³·¨î药:关¤_¤½¥qÉOATHENEX,INC.签¸p±Â权协议¤Î¬Û关¨Æ项ªº¤½§i

data.eastmoney.com/notices/detail/300147/AN201912161371877448,JWU5JWE2JTk5JWU5JTliJWFhJWU1JTg4JWI2JWU4JThkJWFm.html

¹ï©¤¹d²ÓÃû¿ò¨ª»r»r¤½¶}!

¥xÆW©xµÄ:±ÂÅv¸ê°TÄÝ°Ó·~Ävª§¾÷±K¡A¬°«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¬G¤£¤©´¦ÅS!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/28 ¤U¤È 12:33:05²Ä 8246 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2020/3/23 ¤U¤È 04:43:53²Ä 8210 ½g¦^À³

.....

ÃĵØÀ³¸Ó¤£·|¦³¥H¤W¨ÖÁÊ(³Q¨ÖÁÊ)±¡¨Æ.

¤ñ¸û¥i¯àµo¥Íªº¬OAthenex­«Áʦ^KX01ªº¨È¬w±ÂÅv(¥xÆW°£¥~)???

²z¥Ñ:

...............................................................................................

...............................................................................................

¤@«Î¤G½æ???

2019-12-17 11:47:41·s¨Ê报 记ªÌ¡G¤ý¥d©Ô 编辑¡G¤ý³À

¤£¶W过1.8亿¬ü¤¸ ­»³·¨î药¡§®³¤U¡¨¤T´Ú¬ü国¦b¬ã·s药

·s¨Ê报讯¡]记ªÌ ¤ý¥d©Ô¡^12¤ë17¤é¡A­»³·¨î药发¥¬¤½§i¡A¤½¥qÉO¬ü国纳´µ达§J¤W¥«¤½¥qATHENEX,INC.¡]¥H¤U简称¡§Athenex¡¨¡^签¸p¤F¡m±Â权协议¡n¡A´NAthenex¦b¬ã产«~¤fªAµµ§ü¾J¡B¤fªA¥ì¥ß´À±d©MKX2-391软»Iªº¬ã发¡B°Ó业¤Æ进¦æ¦X§@¡A¦X§@总额将¤£¶W过1.8亿¬ü¤¸¡C­»³·¨î药称¡A¦¹¦¸¤Þ进将¤¥´I¤½¥qÀù¯g产«~组¦X¡AÉO现¦³¬ã发«~Ïú§Î¦¨ª`®g剂«¬¡B¤fªA剂«¬©M¥~¥Î剂«¬ªº¥þÂÐ盖¡C

传统¤¤¦¨药¥ø业转«¬¥Íª«医药领°ì

®ÚÕu双¤è协议¡AAthenex¦³偿±Â¤©­»³·¨î药¤W­z¦b¬ã产«~¡B¦b±Â权区°ì内¡]¤¤国内¦a¡B­»´ä©M¿D门区°ì¡^¤Î领°ì内独®a开®i°Ó业¤Æªº权§Q¡A¤Î为该µ¥°Ó业¤Æ¥Øªº¦Ó¨É¦³¬Û关ª¾识产权ªº权§Qµ¥¡C¦b©º±oAthenex¦P·N¦Z¡A­»³·¨î药¦³权¦b±Â权区°ì内¦A±Â权给²Ä¤T¤è¨Ï¥Î¤W­z±Â权产«~¤Î¬Û关权¯q¡A¥H开发©M°Ó业¤Æ±Â权产«~©M§Þ术¡C­»³·¨î药将¦VAthenex¤ä¥I¤£¶W过1.8亿¬ü¤¸ªº±Â权许¥i费¥Î¡B¬ã发¨½µ{¸O费¥Î¡B销°â¨½µ{¸O费¥Î¡F¥H¤Î¬Û应±Â权¨Ï¥Î费¥Î¤Î±±¨î权变§ó费¥Î¡C

.............

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§_¨ì©³°Õ10148994  µoªí®É¶¡:2020/3/27 ¤U¤È 08:06:45²Ä 8245 ½g¦^À³
160k*5k=8»õÁâ¡K©Ò¥H°ÝÃD¦b­þ¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/27 ¤U¤È 05:29:04²Ä 8244 ½g¦^À³
ÃĵتºP1101¤w¦b2012¦~Àò±o¬ü°ê©t¨àÃÄ»{ÃÒ¸ê®æ¡A¦]¦¹¦b¥Ó½ÐÃÄÃҮɨ̷ÓFDAªºÃÄÃҥӽЫü«n¥H©t¨àÃÄ»{ÃÒ¡B¤Î¥¼³Qº¡¨¬ªºÂåÀø»Ý¨Dªº²z¥Ñ¡A¦P¨B¦VFDA¥Ó½ÐÀu¥ý¼f¬d¸ê®æ¡A¥H¥[³tÃÄÃÒ¼f¬d®É¶¡¡A¹w­p¥H¼Ð·Ç¼f®Ö´Áªº¤Q­Ó¤ëÁYµu¬°¤»­Ó¤ë­pºâ¡A³Ì§Ö©ó²Ä¥|©u¨ú±oÃÄÃÒ¡C

¡@¨Ì¾Ú¬ü°ê©t¨àÃĪk®×¡A¾Ö¦³©t¨àÃÄ»{ÃÒªºÃĪ«ÁÙ¥i¥H§K°£ªñ300¸U¬üª÷ªº¥Ó½Ð¤âÄò¶O¡A¦ÛÃÄÃÒ®Öµo¤é°_§ó¨É¦³¤C¦~ªº¥«³õ±M½æÅv¡C

¡@Ãĵتí¥Ü¡A¥Ñ©ó¨u¯f¥«³õÄvª§ªÌ¤Ö¡A¤@¯ë«OÀI¤½¥q¤]¥i±µ¨ü¸û°ª»ù¦ì¡A¥Ø«e¦bPV¾AÀ³¯g¤¤³QFDA®Ö­ãªº¥ÎÃĶȦ³¬ü°êIncyte¤½¥qªºJakafi¡A¦b2014¦~Àò®Ö­ã§@¬°PV²Ä¤G½u¥ÎÃÄ¡C®Ú¾ÚIncyte¦~³ø¡A¨ä¨C¤H¨C¦~ÃÄ«~¶O¥Î¬°16¸U¾l¬üª÷¡A¥Ø«e¬ù¦³¤­¤d¾l¤H¨Ï¥Î¡C¡]³Ì«á¤@¥y ¨C¤H¨C¦~ÃÄ«~¶O¥Î¬°16¸U¾l¬üª÷¡A¥Ø«e¬ù¦³¤­¤d¾l¤H¡^³oª÷ÃB«çıªº©Ç©Çªº5000¤H¤@¦~´N½æ¥x¹ô200»õ¡H

¨ú¦Û¤é²±ÃÒ¨÷·s»Dºô

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/27 ¤U¤È 05:15:23²Ä 8243 ½g¦^À³
åF³½½¼¹À¦n¡A

¥xÆWÃÄÃÒ

¥u¯à²KÂI®ã¤õ

¬Ý¸ò衞ºÖ³¡°·«O§½«ç»ò½Í

¤w¸g¦b¥Î®¦·OÀøªk¤F¡A®ÄªG«Ü¤£¿ù

¤£¹L·§¦ô¤H¼Æ¤£¦h¡A¦~¦¬¤J6000¸U-¤W»õ§a¡I

Ãĵتº¦¬¤J¥D­nÁÙ¬O

¬ü°êÃÄÃÒ

ÁÙ¦³

¤é¥»ÃÄÃÒ

¦¬¤J¡A

¨º¬O¤Ñ¼Æ¡A§Ú¼Æ¤£ºÉ¡C

¤W¬Ý¦Ê»õ§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¨§¬ó10148458  µoªí®É¶¡:2020/3/27 ¤U¤È 04:44:29²Ä 8242 ½g¦^À³
¥xÆWÃÄÃÒ¬O«ü¼Ð©Ê¡A¥xÆW¥»¨Ó´N¤£¬O¥D­n¥«³õ¡AÀ³¸Ó°÷Áý¹¡10­Ó¤pªÑªF¡C[­Ó¤H²L¨£]
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/27 ¤U¤È 03:59:10²Ä 8241 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j

¥xÆWÃÄÃÒ®³¨ì

»æ¦³¦h¤jªü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/27 ¤U¤È 12:39:18²Ä 8240 ½g¦^À³
¤w¤WÂêºÞ²z

µ¥·|¨à¹j¾ÀºÊ·þª©ºÆª¯À³¸Ó¬Ý¨ì§Ú­Ì¼y¶P

·|©ô©ô´XÁn©O?

¤j®a²q²q

ǢǢǢ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿c¦³ªK10149122  µoªí®É¶¡:2020/3/27 ¤U¤È 12:30:30²Ä 8239 ½g¦^À³
§Æ±æ¯à°÷µ´¦a­«¥Í¡C¥[ªo!ÃĵØÂåÃÄ¡ã

»°§ÖÅý¥þ¥@¬É¬Ý¨£§Aªº»ù­È¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/27 ¤U¤È 12:10:16²Ä 8238 ½g¦^À³
º¦°±»ù¤w¶R¨ì

½Ðª½±µ¤WÂê

¤£­nµ¹ºÆª¯¯º¸Ü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/27 ¤W¤È 11:16:47²Ä 8237 ½g¦^À³
¤S¨Ó¤F

²{¦bº¦°±

ÁÙ¦b¥~­±³}³}

ÁÙ¤£¶i¨Ó

²{¦b¤£¶R

«Ý¦ó®É¡H

«Ý¤Ñ®ðÅܼö¡H

«Ý¥u¸C¶}²´·ú¡A·ö·öªº»¡¹Ú¸Ü¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/27 ¤W¤È 11:09:04²Ä 8236 ½g¦^À³
¯uªº«Ü¶Â·t ³¬µÛ²´¦A±¾º¦°±¶R¦n¤F

¡]¤S®t10¤¸¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/27 ¤W¤È 09:59:42²Ä 8235 ½g¦^À³
¥xÆWÃÄÃÒ­n¶}µP¤F¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/25 ¤U¤È 05:30:48²Ä 8234 ½g¦^À³
¤£­n³¬µÛ²´·ú¥ý«×¹L¬Ì±¡¦A»¡
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/25 ¤U¤È 04:38:38²Ä 8233 ½g¦^À³
§Ú­Ì³o¨Ç´²¤á¦pªG¥Ø«e·Q­n¸Ñ®M´N¬O¤À§å³¬µÛ²´¶R¤U¥h

§Ú¥´ºâ­«²{¦b¶}©l¦pªGº¦10¤¸´N¶i£¸±i ¦pªG¤U¶^´N¤£¶R

³o¼Ë¥i¥HÁקK¶V®M¶V²`

¡]¦Ü©ó¬°¦óº¦¤~­n¶R¡H­ì¦]«Ü²³æ ´N¬OªÑ²¼¨S°ÝÃD µM¦Ó¶^£¸ª½Åu¥­³o­·ÀI¤Ó¤j ¤@©w¦³§Ú­Ì¬Ý¤£¥X¨Óªº°ÝÃD¦b¡^

¤Wº¦©¹¤W±µ¤~¬O¤ý¹D ¤U¶^«÷Åu¥­­·ÀI¤Ó¤j

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤U¤È 01:41:53²Ä 8232 ½g¦^À³
«Øij¤j®a­n¥hÃö¤ß400¥H¤W¤jªÑªF¦b·F¤°»ò

ªÑ»ù:112 «ùªÑ¤ñ:57.96% Á`ªÑªF¤H¼Æ:11308¤H

ªÑ»ù:61.7«ùªÑ¤ñ:58.46% Á`ªÑªF¤H¼Æ:10984¤H

¤j©@¨S¦³¶]±¼,³q³q¦b¸Ì­±

¶]ªº¬O§A§Ú³oºØ´²¤á

Å¥±oÀ´ªº´NÅ¥±oÀ´

Å¥¤£À´±o»°§Ö½æ¤@½æ

¤U©P¤j©ó400±i«ùªÑ­Y¼W¥[

Å¥¤£À´±o«Ü§Ö§A´N·|À´!!!

¸ê®Æ¤é´Á ¶°«O

Á`±i¼Æ Á`ªÑªF

¤H¼Æ ¥­§¡

±i¼Æ/¤H >400±i

¤jªÑªF

«ù¦³±i¼Æ >400±i

¤jªÑªF

«ù¦³¦Ê¤À¤ñ >400±i

¤jªÑªF

¤H¼Æ 400

~600±i

¤H¼Æ 600

~800±i

¤H¼Æ 800

~1000±i

¤H¼Æ >1000±i

¤H¼Æ >1000±i

¤jªÑªF

«ù¦³¦Ê¤À¤ñ ¦¬½L»ù

20200320 225,114 10,984 20.49 131,663 58.49 63 18 7 6 32 50.05 61.70

20200313 225,114 11,120 20.24 132,429 58.83 65 18 7 5 35 50.92 82.30

20200306 225,114 11,252 20.01 132,516 58.87 65 18 7 5 35 50.98 102.00

20200227 225,114 11,277 19.96 132,518 58.87 65 18 7 6 34 50.56 101.00

20200221 225,101 11,292 19.93 132,500 58.86 65 18 7 6 34 50.55 105.00

20200214 225,101 11,266 19.98 132,736 58.97 65 18 7 5 35 51.07 108.00

20200207 225,097 11,268 19.98 132,883 59.03 65 18 7 5 35 51.11 103.00

20200131 225,078 11,300 19.92 132,915 59.05 65 18 7 5 35 51.14 104.00

20200117 225,054 11,363 19.81 132,927 59.06 66 18 8 4 36 51.16 116.00

20200110 219,386 11,379 19.28 127,449 58.09 65 18 8 4 35 49.94 115.00

20200103 219,386 11,308 19.40 127,159 57.96 64 17 7 5 35 50.02 112.50

20191227 219,376 11,318 19.38 127,471 58.11 64 16 8 5 35 50.08 101.00

20191220 219,376 11,297 19.42 128,170 58.43 65 16 9 5 35 50.17 100.50

20191213 219,376 11,307 19.40 128,259 58.47 65 16 8 6 35 50.20 99.90

20191206 219,376 11,254 19.49 129,024 58.81 66 17 8 6 35 50.22 108.00

20191129 219,376 11,294 19.42 129,023 58.81 66 17 8 6 35 50.17 111.50

20191122 219,376 11,245 19.51 129,360 58.97 66 16 8 6 36 50.67 111.00

20191115 219,376 11,228 19.54 129,423 59.00 66 16 9 5 36 50.71 110.00

20191108 219,376 11,252 19.50 129,476 59.02 66 16 9 5 36 50.74 113.00

20191101 219,376 11,253 19.49 129,518 59.04 66 17 8 6 35 50.31 114.50

20191025 219,376 11,253 19.49 129,586 59.07 66 17 8 6 35 50.35 114.50

20191018 219,376 11,169 19.64 129,262 58.92 65 16 8 6 35 50.42 114.50

20191009 219,376 11,143 19.69 129,286 58.93 65 16 8 6 35 50.43 108.50

20191004 219,376 11,126 19.72 129,358 58.97 65 16 8 6 35 50.46 111.00

20190927 219,376 11,120 19.73 129,405 58.99 65 16 8 6 35 50.48 112.00

20190920 219,376 11,083 19.79 129,448 59.01 65 16 8 6 35 50.50 113.50

20190912 219,376 11,039 19.87 129,397 58.98 65 16 10 4 35 50.53 115.00

20190906 219,376 11,035 19.88 129,629 59.09 65 16 10 3 36 51.02 121.00

20190830 219,373 11,084 19.79 129,631 59.09 65 16 10 3 36 51.02 118.00

20190823 219,373 11,019 19.91 130,033 59.28 65 14 12 3 36 51.13 117.50

20190816 219,352 10,972 19.99 130,494 59.49 66 15 10 5 36 51.12 121.50

20190808 219,306 10,973 19.99 130,328 59.43 66 16 10 5 35 50.65 129.00

20190802 219,306 11,095 19.77 130,296 59.41 66 16 10 5 35 50.62 130.00

20190726 219,283 11,156 19.66 129,951 59.26 66 16 11 4 35 50.62 129.00

20190719 219,283 11,153 19.66 130,144 59.35 67 17 11 4 35 50.47 118.50

20190712 219,278 11,042 19.86 130,090 59.33 67 16 11 5 35 50.47 112.50

20190705 219,277 11,043 19.86 129,902 59.24 67 17 10 5 35 50.40 118.00

20190628 219,273 11,005 19.92 129,931 59.26 67 17 10 5 35 50.40 120.50

20190621 219,273 11,015 19.91 129,633 59.12 67 16 11 4 36 50.66 118.00

20190614 219,273 11,014 19.91 129,890 59.24 68 17 10 5 36 50.53 123.50

20190606 219,470 10,951 20.04 130,514 59.47 69 18 10 5 36 50.59 118.50

20190531 219,470 10,997 19.96 129,961 59.22 67 18 9 4 36 50.98

20190524 219,470 11,012 19.93 129,787 59.14 67 17 10 5 35 50.34 120.00

20190517 219,470 11,013 19.93 130,848 59.62 69 18 11 5 35 50.31 103.50

20190510 219,470 11,192 19.61 130,835 59.61 69 18 12 3 36 50.70 142.00

20190503 219,470 11,195 19.60 130,719 59.56 69 17 13 4 35 50.08

20190426 219,436 11,187 19.62 130,854 59.63 69 16 14 3 36 50.51 153.00

20190419 219,361 11,123 19.72 131,095 59.76 70 17 14 4 35 50.00 158.50

20190412 219,352 11,101 19.76 131,236 59.83 70 17 14 4 35 50.07 154.00

20190403 219,302 11,082 19.79 130,268 59.40 68 15 13 4 36 50.33 155.00

20190329 219,299 11,030 19.88 130,413 59.47 68 14 14 4 36 50.33 161.00

20190322 219,299 10,987 19.96 130,116 59.33 68 14 13 4 37 50.48 163.50

20190315 219,294 10,885 20.15 129,616 59.11 68 14 13 4 37 50.26 165.00

20190308 219,285 10,737 20.42 129,760 59.17 68 14 13 4 37 50.31 167.00

20190227 219,282 10,547 20.79 130,024 59.30 68 14 13 3 38 50.96 170.00

20190222 219,281 10,414 21.06 129,981 59.28 68 14 13 3 38 50.94 174.50

20190215 219,281 10,145 21.61 130,511 59.52 69 15 13 3 38 50.95 178.50

20190130 219,281 10,070 21.78 131,799 60.11 71 16 13 4 38 51.01 175.00

20190125 219,271 9,989 21.95 132,063 60.23 71 16 14 3 38 51.10 175.50

20190118 219,265 9,860 22.24 132,098 60.25 71 15 15 3 38 51.08 170.50

20190111 219,257 9,811 22.35 132,104 60.25 71 15 15 4 37 50.64 175.50

20190104 219,233 9,756 22.47 131,780 60.11 71 16 13 5 37 50.53 174.50

20181228 219,233 9,624 22.78 131,876 60.15 72 17 13 5 37 50.38 174.50

20181222 219,227 9,578 22.89 131,767 60.11 72 17 13 5 37 50.36 177.00

20181214 219,217 9,303 23.56 131,478 59.98 71 15 14 5 37 50.39 187.50

20181207 219,217 9,295 23.58 131,504 59.99 71 15 14 5 37 50.37 184.00

20181130 219,417 9,389 23.37 131,090 59.74 70 14 14 5 37 50.40 181.50

20181123 219,411 9,439 23.25 131,158 59.78 70 14 14 5 37 50.41 174.00

20181116 219,411 9,471 23.17 131,708 60.03 71 15 13 6 37 50.44 180.50

20181109 219,377 9,531 23.02 132,181 60.25 71 15 13 6 37 50.67 172.00

20181102 219,377 9,580 22.90 131,838 60.10 71 15 14 5 37 50.63 170.50

20181026 219,367 9,568 22.93 131,821 60.09 70 16 12 5 37 50.96 164.00

20181019 219,299 9,634 22.76 132,057 60.22 71 17 12 5 37 50.95 171.00

20181012 219,292 9,506 23.07 132,238 60.30 70 17 12 5 36 50.93 162.00

20181005 219,292 9,609 22.82 131,911 60.15 69 17 11 4 37 51.33 176.00

20180928 219,292 9,676 22.66 131,151 59.81 67 15 11 4 37 51.35 179.00

20180921 219,285 9,621 22.79 130,948 59.72 66 14 10 4 38 51.88 184.50

20180914 219,274 9,658 22.70 130,953 59.72 66 14 11 4 37 51.54 176.00

20180907 219,270 9,732 22.53 131,023 59.75 66 14 11 4 37 51.56 172.50

20180831 219,270 9,849 22.26 130,460 59.50 65 12 12 4 37 51.48 181.50

20180824 219,270 9,887 22.18 130,812 59.66 65 12 11 5 37 51.51 180.50

20180817 219,268 9,703 22.60 130,879 59.69 65 12 11 5 37 51.53 173.50

20180810 219,268 9,736 22.52 130,670 59.59 65 12 11 5 37 51.42 173.00

20180803 219,246 9,737 22.52 130,793 59.66 65 12 11 4 38 51.94 176.00

20180727 219,183 9,706 22.58 130,716 59.64 65 12 11 4 38 51.92 172.00

20180720 219,154 9,672 22.66 131,173 59.85 66 13 11 4 38 51.92 174.00

20180713 219,154 9,734 22.51 130,863 59.71 66 14 12 2 38 51.92 183.50

20180706 219,129 9,826 22.30 131,268 59.90 67 15 12 2 38 51.98 184.00

20180629 219,129 9,985 21.95 131,142 59.85 66 14 10 2 40 52.77 200.00

20180622 219,129 9,479 23.12 131,845 60.17 65 12 10 3 40 53.12 190.00

20180615 219,129 9,381 23.36 131,895 60.19 65 12 11 2 40 53.19 182.00

20180608 219,129 9,492 23.09 132,222 60.34 65 12 11 2 40 53.33 173.50

20180601 219,129 9,571 22.90 132,194 60.33 65 12 11 2 40 53.33 177.00

20180525 219,129 9,602 22.82 131,846 60.17 65 12 11 2 40 53.19 171.50

20180518 219,129 9,641 22.73 131,831 60.16 65 12 11 2 40 53.21 172.00

20180511 219,129 9,776 22.42 131,458 59.99 65 12 12 1 40 53.06 177.00

20180504 219,129 9,907 22.12 131,414 59.97 65 12 12 1 40 53.06 179.00

20180427 219,060 9,845 22.25 131,805 60.17 65 12 12 1 40 53.28 177.00

20180420 219,025 9,853 22.23 132,065 60.30 65 12 12 1 40 53.39 177.00

20180413 219,015 9,824 22.29 131,909 60.23 65 12 12 1 40 53.31 168.50

20180403 219,009 9,822 22.30 131,479 60.03 64 11 12 1 40 53.34 171.00

20180331 219,009 9,814 22.32 131,622 60.10 64 11 12 1 40 53.40 175.50

20180323 219,008 9,822 22.30 131,211 59.91 64 11 12 1 40 53.24 169.50

20180316 219,008 9,670 22.65 132,277 60.40 64 11 11 3 39 53.16 182.00

20180309 218,993 9,618 22.77 132,715 60.60 65 12 12 3 38 52.95 180.50

20180302 218,990 9,543 22.95 132,448 60.48 64 11 13 2 38 53.07 173.00

20180223 218,990 9,559 22.91 132,519 60.51 64 11 13 2 38 53.11 163.50

20180214 218,990 9,527 22.99 132,414 60.47 64 11 13 2 38 53.06

20180209 218,990 9,421 23.24 132,496 60.50 64 11 12 3 38 53.08 173.00

20180202 218,989 9,591 22.83 131,795 60.18 64 11 12 3 38 52.75 159.00

20180126 218,989 9,671 22.64 131,518 60.06 64 11 12 4 37 52.26 151.50

20180119 218,981 9,669 22.65 131,390 60.00 64 11 13 3 37 52.28 148.00

20180112 218,978 9,713 22.54 130,602 59.64 63 12 11 3 37 52.25 146.50

20180105 218,969 9,678 22.63 129,803 59.28 61 10 11 3 37 52.31 142.00

20171229 218,964 9,689 22.60 129,890 59.32 61 10 11 3 37 52.30 143.00

20171222 218,953 9,682 22.61 129,978 59.36 61 10 11 3 37 52.29 145.50

20171215 218,953 9,687 22.60 129,911 59.33 61 10 10 4 37 52.23 144.50

20171208 218,952 9,625 22.75 129,998 59.37 61 10 10 4 37 52.26 145.00

20171201 219,225 9,662 22.69 130,414 59.49 61 10 10 4 37 52.41 146.00

20171124 219,185 9,676 22.65 130,423 59.50 61 10 10 5 36 51.98 148.50

20171117 219,033 9,706 22.57 130,107 59.40 61 10 10 5 36 51.88 150.00

20171110 219,011 9,789 22.37 129,972 59.35 62 11 10 6 35 51.11 151.00

20171103 219,009 9,714 22.55 129,808 59.27 63 12 11 5 35 51.02 150.00

20171027 219,007 9,807 22.33 129,957 59.34 63 12 11 5 35 51.09 142.00

20171020 219,007 9,780 22.39 129,986 59.35 63 12 12 4 35 51.13 143.50

20171013 219,007 9,765 22.43 129,382 59.08 63 13 12 3 35 51.02 146.50

20171006 219,007 9,793 22.36 129,096 58.95 63 13 12 3 35 50.84 148.50

20170930 219,007 9,880 22.17 128,766 58.80 63 13 12 3 35 50.65 145.00

20170922 219,007 9,966 21.98 127,915 58.41 63 13 12 3 35 50.19 146.50

20170915 219,006 9,958 21.99 127,812 58.36 63 13 12 3 35 50.16 150.00

20170908 219,002 9,994 21.91 127,658 58.29 63 13 12 3 35 50.14 149.00

20170901 219,000 10,047 21.80 126,931 57.96 62 13 11 3 35 50.12 146.00

20170825 218,962 10,111 21.66 126,600 57.82 61 12 11 3 35 50.19 143.00

20170818 218,951 10,115 21.65 127,486 58.23 63 14 11 3 35 50.21 140.00

20170811 218,936 10,209 21.45 127,359 58.17 63 14 11 3 35 50.16 143.00

20170804 218,935 10,268 21.32 127,008 58.01 63 14 11 3 35 50.11 144.50

20170728 218,935 10,216 21.43 127,480 58.23 64 15 11 3 35 50.11 151.00

20170721 218,920 10,134 21.60 127,164 58.09 63 13 12 3 35 50.05 148.00

20170714 218,917 10,112 21.65 127,052 58.04 63 13 12 4 34 49.62 142.50

20170707 218,888 10,143 21.58 127,342 58.18 63 12 12 5 34 49.59 144.50

20170630 218,884 10,151 21.56 127,493 58.25 63 11 11 6 35 49.92 147.00

20170623 218,884 10,202 21.46 127,307 58.16 63 11 11 6 35 49.83 143.50

20170616 218,884 10,252 21.35 127,075 58.06 63 11 11 6 35 49.72 139.00

20170609 218,884 10,280 21.29 127,155 58.09 63 11 11 6 35 49.76 142.50

20170603 218,884 10,246 21.36 127,174 58.10 63 11 11 6 35 49.76 146.00

20170526 218,893 10,259 21.34 127,076 58.05 63 11 12 5 35 49.74 145.50

20170519 218,893 10,226 21.41 126,966 58.00 63 11 11 6 35 49.61 144.00

20170512 218,893 10,199 21.46 126,823 57.94 63 12 11 6 34 49.32 144.50

20170505 218,893 10,177 21.51 126,892 57.97 63 12 12 5 34 49.41 149.50

20170428 218,851 10,136 21.59 127,009 58.03 63 12 12 4 35 49.91 150.50

20170421 218,850 10,098 21.67 126,936 58.00 63 12 11 5 35 49.87 156.00

20170414 218,826 10,144 21.57 125,803 57.49 61 11 11 4 35 49.92 150.50

20170407 218,817 10,177 21.50 125,663 57.43 61 11 11 4 35 49.87 157.00

20170331 218,817 10,098 21.67 124,942 57.10 60 10 11 4 35 49.73 156.50

20170324 218,817 10,103 21.66 124,883 57.07 60 10 11 4 35 49.72 163.50

20170317 218,817 10,134 21.59 124,488 56.89 62 13 11 5 33 48.42 170.50

20170310 218,817 10,347 21.15 123,163 56.29 61 13 11 5 32 47.87 172.00

20170303 218,809 10,621 20.60 122,588 56.03 60 12 11 5 32 47.91 165.50

20170224 218,809 10,752 20.35 122,299 55.89 59 12 10 5 32 48.01 162.50

20170218 218,803 10,884 20.10 122,102 55.80 59 12 11 4 32 47.97 159.50

20170210 218,773 11,051 19.80 121,553 55.56 58 11 11 5 31 47.47 151.00

20170203 218,684 11,149 19.61 121,324 55.48 58 11 12 6 29 46.67 144.00

20170126 218,672 11,131 19.65 121,319 55.48 58 11 12 6 29 46.68

20170120 218,655 11,145 19.62 121,148 55.41 58 12 11 6 29 46.68 142.00

20170113 218,617 11,079 19.73 121,318 55.49 57 12 9 7 29 47.04 142.50

20170106 218,546 11,055 19.77 121,322 55.51 57 12 9 7 29 47.09 157.00

20161230 218,535 10,898 20.05 121,383 55.54 57 12 9 7 29 47.09 161.50

20161223 218,526 10,819 20.20 121,429 55.57 57 13 8 8 28 46.74 163.50

20161216 218,508 10,752 20.32 121,121 55.43 57 13 9 7 28 46.58 165.50

20161209 218,606 10,728 20.38 121,105 55.40 57 12 9 9 27 46.07 171.00

20161202 218,606 10,099 21.65 120,728 55.23 57 13 9 7 28 46.52 187.50

20161125 218,606 10,060 21.73 121,539 55.60 59 16 8 7 28 46.65 185.50

20161118 218,606 10,106 21.63 121,665 55.65 58 14 9 7 28 46.84 188.50

20161111 218,603 10,066 21.72 121,927 55.78 57 11 11 7 28 47.08 177.50

20161104 218,592 10,227 21.37 122,124 55.87 57 11 12 6 28 47.16 162.00

20161028 218,589 10,188 21.46 121,933 55.78 57 12 11 6 28 47.14 165.00

20161021 218,589 9,888 22.11 122,673 56.12 58 12 11 6 29 47.54 170.00

20161014 218,557 9,682 22.57 123,629 56.57 59 14 11 6 28 47.50 167.00

20161007 218,557 9,649 22.65 123,616 56.56 59 14 11 6 28 47.49 187.50

20160930 218,552 9,624 22.71 124,519 56.97 61 17 10 7 27 47.02 195.00

20160923 218,549 9,786 22.33 123,390 56.46 58 14 9 8 27 47.06 200.00

20160914 218,535 9,874 22.13 123,511 56.52 58 14 9 7 28 47.51 178.00

20160910 218,535 10,018 21.81 123,257 56.40 58 14 9 7 28 47.43 182.00

20160902 218,502 9,995 21.86 123,652 56.59 59 14 10 8 27 46.96 162.00

20160826 218,476 10,062 21.71 123,633 56.59 59 14 10 8 27 46.96 170.50

20160819 218,464 10,166 21.49 123,439 56.50 59 16 9 7 27 46.97 180.00

20160812 218,464 10,219 21.38 123,308 56.44 59 15 10 7 27 46.98 184.50

20160805 218,452 10,401 21.00 122,800 56.21 58 15 9 7 27 46.99 186.50

20160729 218,436 10,613 20.58 122,679 56.16 58 15 10 6 27 47.01 184.00

20160722 218,436 10,243 21.33 125,126 57.28 62 21 8 6 27 47.35 199.00

20160715 198,401 6,999 28.35 123,533 62.26 58 16 8 6 28 52.72

20160707 198,356 6,941 28.58 123,614 62.32 58 16 8 6 28 52.73

20160701 198,337 6,686 29.66 123,539 62.29 57 16 8 6 27 52.73

20160624 195,869 6,344 30.87 121,121 61.84 51 16 8 6 21 52.13

20160617 195,869 6,400 30.60 120,698 61.62 50 15 8 6 21 52.15

20160608 195,869 6,182 31.68 121,921 62.25 48 15 7 6 20 53.07

20160604 195,869 6,186 31.66 122,028 62.30 48 14 8 6 20 53.06

20160527 195,869 6,102 32.10 122,708 62.65 48 14 7 7 20 53.28

20160520 195,869 6,098 32.12 122,675 62.63 48 14 8 6 20 53.28

20160513 195,869 6,110 32.06 122,691 62.64 48 14 8 6 20 53.28

20160506 195,869 6,128 31.96 122,737 62.66 48 14 8 6 20 53.30

20160429 195,755 6,139 31.89 122,679 62.67 48 14 8 6 20 53.34

20160422 195,739 6,143 31.86 122,773 62.72 48 14 8 6 20 53.38

20160415 190,707 5,881 32.43 120,414 63.14 47 15 7 7 18 53.14

20160408 190,662 5,910 32.26 120,618 63.26 47 15 7 7 18 53.25

20160401 190,662 5,904 32.29 120,612 63.26 47 15 7 7 18 53.26

20160325 190,657 5,863 32.52 120,612 63.26 47 14 8 7 18 53.26

20160318 190,625 5,790 32.92 120,605 63.27 47 14 8 7 18 53.30

20160311 190,582 5,669 33.62 120,694 63.33 47 14 8 7 18 53.39

20160304 190,564 5,646 33.75 120,699 63.34 47 14 8 6 19 53.97

20160226 190,542 5,622 33.89 121,018 63.51 48 15 8 5 20 54.39

20160219 190,520 5,630 33.84 121,152 63.59 48 15 8 6 19 53.88

20160205 190,509 5,616 33.92 121,420 63.73 49 16 9 5 19 53.96

20160130 190,509 5,597 34.04 120,949 63.49 48 16 8 5 19 54.03

20160122 190,509 5,584 34.12 120,907 63.47 48 16 8 5 19 54.02

20160115 190,509 5,539 34.39 120,878 63.45 48 16 8 5 19 54.04

20160108 190,458 5,466 34.84 120,069 63.04 46 14 8 5 19 54.05

20151231 190,458 5,509 34.57 119,651 62.82 45 13 8 5 19 54.06

20151225 190,458 5,350 35.60 120,315 63.17 46 14 8 5 19 54.16

20151218 190,391 5,345 35.62 119,946 63.00 45 14 8 5 18 54.01

20151211 190,377 5,269 36.13 120,456 63.27 46 15 8 5 18 54.05

20151204 190,355 5,268 36.13 121,360 63.75 47 16 8 5 18 54.21

20151127 190,352 5,025 37.88 121,783 63.98 47 16 7 5 19 54.82

20151120 190,352 4,765 39.95 122,241 64.22 47 15 9 4 19 55.01

20151113 190,350 4,704 40.47 121,777 63.98 46 15 9 2 20 55.74

20151106 190,349 4,718 40.35 121,771 63.97 46 15 9 2 20 55.74

20151030 190,326 4,713 40.38 121,770 63.98 46 15 9 2 20 55.76

20151023 190,322 4,716 40.36 121,406 63.79 45 13 10 2 20 55.78

20151016 190,300 4,720 40.32 121,549 63.87 45 13 10 2 20 55.84

20151008 190,284 4,723 40.29 121,564 63.89 45 13 10 2 20 55.84

20151002 190,283 4,734 40.20 121,566 63.89 45 13 10 2 20 55.84

20150925 190,283 4,724 40.28 121,651 63.93 45 13 10 2 20 55.89

20150918 190,248 4,735 40.18 121,747 63.99 45 13 10 2 20 55.95

20150911 190,238 4,709 40.40 121,983 64.12 45 13 10 2 20 56.07

20150904 190,212 4,739 40.14 122,029 64.15 45 13 9 3 20 56.10

20150828 190,163 4,745 40.08 122,118 64.22 45 13 9 3 20 56.16

20150821 190,125 4,781 39.77 122,146 64.24 45 13 9 3 20 56.19

20150814 190,120 4,785 39.73 121,639 63.98 44 12 9 3 20 56.19

20150807 190,105 4,753 40.00 122,290 64.33 45 12 10 3 20 56.22

20150731 190,075 4,767 39.87 122,161 64.27 45 13 9 3 20 56.23

20150724 190,043 4,776 39.79 122,157 64.28 45 13 9 3 20 56.24

20150717 190,012 4,769 39.84 122,376 64.40 45 12 10 3 20 56.27

20150709 190,001 4,765 39.87 122,373 64.41 45 12 10 3 20 56.27

20150703 189,943 4,779 39.75 122,364 64.42 45 12 10 3 20 56.29

20150626 189,904 4,749 39.99 122,144 64.32 45 12 10 3 20 56.31

20150618 189,895 4,757 39.92 121,655 64.06 44 13 8 3 20 56.47

20150612 189,848 4,758 39.90 121,635 64.07 44 13 8 3 20 56.50

20150605 189,728 4,775 39.73 121,175 63.87 43 12 8 3 20 56.53

20150529 189,712 4,747 39.96 121,179 63.88 43 12 8 3 20 56.54

20150522 189,712 4,727 40.13 121,434 64.01 43 12 8 3 20 56.67

20150515 189,712 4,720 40.19 121,462 64.02 43 12 8 3 20 56.69

20150508 189,712 4,677 40.56 121,483 64.04 43 12 8 3 20 56.66

* ÃC¦âÃѧO: ¬õ¦â-¦¨ªø, ºñ¦â-¤U­°, ¶Â¦â-«ù¥­

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬y¤ô10148302  µoªí®É¶¡:2020/3/25 ¤U¤È 12:40:27²Ä 8231 ½g¦^À³
²{¦b¶i³õ³Ì¨Î®É¾÷¡A¦¨¥»¦Ü¤Ö¤ñ§Ú«K©y80%¡A©ú¦~ªº¤µ¤Ñ¡A»¡¤£©wªÑ»ù´N½¤G½¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2020/3/25 ¤U¤È 12:22:12²Ä 8230 ½g¦^À³
ºN¶Â¦³ºN¶Âªº¦n¡A¦³¤ß³eÀ£ªº¤H¤]¤ñ¸ûÃø¾Þ§@¡A¨º¨Ç±¾º¦°±½æªº¬O½ä½æ°ªÀ£§C¦A¾ß¦^¡H ÁÙ¬O¯uªº©ñ±ó¤F¡H¥L­Ì»{¬°Ãĵدu¥u­È64.7¡H

Or¦³³±¿Ñ³eÀ£¡A¦b·QÔ£¬O§Ú­Ì¨Sª`·Nªº¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤W¤È 11:26:13²Ä 8229 ½g¦^À³
ªLªLÁ`Á`

§A³Ñ117±i¥i¥H½è©ã¤F

§AÂ÷Â_ÀY¤£»·¤F

¥[ªo°Ú

¤½¥q¸gÀçªÑ»ù¤]¬O«Ü­«­nªº

¤£µM§A¦Û¤v¤]·|¨ü®`ªü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/25 ¤W¤È 11:07:36²Ä 8228 ½g¦^À³
­ì¨Ó¦p¦¹......ÁÂÁ¡AÁÂÁ«ü¾É¡C

Ãø©Ç§Ú«ç»ò·Q³£·Q¤£³z¡H

¼Ú¬w®Ö­ãP1101¬OPV²Ä¤@½u¥ÎÃĬO¨Æ¹ê¡A¼Ú·ù¦U°ê¤]³£®Ö­ãÃÄ»ù¨C°w3000¼Ú¤¸¥H¤W¤]¤w¬O¨Æ¹ê¡A¤S¨C­Ó±wªÌ¤@¦~­n¥Î26°w......

ªÑ²¼³oºØ»ù®æÁÙ¦³¤H½æ¡H

­ì¨Ó¬O©È¸gÀçªÌ§â¤½¥q¸gÀç­Ë¤F...

¯uµLªk²z¸Ñ³o¨Ç¬ì¾Ç®aªº¸£¬O¦b·Q¤°»ò¡H

§â¤½¥q·d­Ë¤F...¦Û¤v¦³¤°»ò¦n³B...¡H

§â¦Û¤v¤@¥Íªº¨¯­W·´¦b¥¢¥h¸Û«HÃø¹D¯uªº¤£·|­pºâ¡A­pºâ...­È±o¶Ü¡H

¡m¦]¤p¥¢¤j¡n§a¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤W¤È 11:05:20²Ä 8227 ½g¦^À³
~4/8³£¬OºN¶Â

½Ð>400±iªº¤j¥D¤O

¥Î¤Oµ¹¥L©Ô

¤£­n«È®ð

¤l¼u¤£»Ý«Ü¦h

¤½¥q­n©ñÂI®ø®§¥X¨Ó

¨Æ¥b¥\­¿

¥ÓÁÊ»ù¤~·|¤£ÅÜ

OK?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤W¤È 10:44:07²Ä 8226 ½g¦^À³
¦]¬°

1.¼Ú¬wªºÅv§Qª÷©ì©ì©Ô©Ô

2.²{ª÷output>>input

3.¼W¸ê¤£¶¶§Q,¤j®a©ÈÂ_ª¤

4.¤½¥q¬£¤£Ä@·N©M¦³¤O¤H¤h¦X§@,¼W¸ê³£¥¢±Ñ,why?

¬Û«Hco co·d©w,ºÃ¼{¸Ñ°£,·|¤£¤@¼Ë

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/25 ¤W¤È 10:29:29²Ä 8225 ½g¦^À³
¹ê¦bµLªk²z¸Ñ...

²Ó¬d¾\ªñ¤éIncyte¤½¥¬ªº°]³ø¡Ajakafi¤@ÁûÃÄPV²Ä¤G½u¥ÎÃÄ+MF¤@½u¥ÎÃÄ¡A

¥þ²y¾P°â´N28»õ¬ü¤¸...¼Ú¬wÅv§Qª÷¦¬2.26»õ¬ü¤¸......

ÃĵجO¤@½u¥ÎÃÄ...¼Ú¬w¤w¸g¶}½æ¤F¡A´N¥H¼Ú¬wªºÅv§Qª÷¨Óºâ...Ãø¹D·|¤ñ²Ä¤G½u¥ÎÃÄ®t¶Ü¡H

ÁÙ¦³¬ü°êªº¾÷·|¡A¥xÆWªº¾÷·|¡A¤é¥»ªº¾÷·|...¤¤°êªº¾÷·|¡A¤S¦Û»s¦Û¾P......

¬°¤°»òªÑ»ù¦p¦¹ÁÙ·|¦³¤H­n½æ¡H¬°¤°»ò³oºØªÑ»ù·|¦³¤H·Q½æ¡H

µLªk²z¸Ñ¡H¯uªºµLªk²z¸Ñ...¡H½Ð°Ý¦³¤H¦³µª®×¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤W¤È 10:17:45²Ä 8224 ½g¦^À³
¥u¦]¬ì¾Ç®a¤£·|ª£ªÑ

­n¬Oµ¹¥H«eªÑ¥«F4¥[¤J

¤]³\¤j®a³£ÁÙ¨S¾÷·|°Ñ»P¤½¥q¦¨ªø

¤£¹L¦³¨ÇªÑ¥«°ª¤â»ó¤l¬O«ÜÆFªº

°½¶]¶i¨Ó¤£·|Åý§Aµo²{

ötº¦«á§A´N·|ª¾¹D¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/25 ¤W¤È 10:14:21²Ä 8223 ½g¦^À³
§Ú´N¤£«H£¸½uÃÄ·|½æ¿é¤G½uÃÄ

¶R¤Ó¤Ö±i¤F ¥»¨Ó¬O·Qµ¥¼W¸ê«á¦A¶R µ¥ªüµ¥µ¥¨ìªZº~ªÍª¢⋯

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/25 ¤W¤È 10:11:03²Ä 8222 ½g¦^À³
Ãĵز{º¦°±

ªÑ¥«¤íÃĵئn¦h¦n¦hªº¤½¹D

²{¥u¦³ÁÙ¤@­Ó¤½¹D

ÁÙ¦³¦n¦hªº¤½¹D

¤]·|¤@¤Ñ¤ÑªºÁÙ

¥[ªo💪

ÃĵءA¦A°ª½Õ¤@ÂI¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/25 ¤W¤È 10:07:18²Ä 8221 ½g¦^À³
¨Ó¤£¤Î¤F

¤À½L¯u³Â·Ð

ºâ¤F

¤£»¡¤F

¨Ó¥h±Æ¶¤¶R

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/25 ¤W¤È 09:18:21²Ä 8220 ½g¦^À³
¤À½L¥æ©öºN¶Â¦æ°Ê¤ñ¸û¦n°µ¤â¸}¡H

¡]¤£ºÞ¤F¸òµÛ¥ý¶i¤j¶R¶i¦n¤F¡^¸É£¸±i¬Ý¬Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/24 ¤U¤È 11:00:50²Ä 8219 ½g¦^À³
Ãĵس̪ñ«Ü°I¡A¤£¯à°÷¦A§C½Õ¤F¡C

¦A°h¤@¨B¡A´N°hµL¥i°h¤F¡C

§ï½s¤@­º¥´ªo¸Ö³Õ§g¤@¯º¡A¤£­n·í¯u¡C

¡]¥H«eÁÙ¯u¦³¤H·í¯u¡^

¤Ñ¤j¦a¤jÃĵؤj¡A

Incyte¦¨¦b¸}¤U¡A

Jakafi¤SºâÔ£¡A

Hu­«½m°Õ¡A

¥@¤W°ß¦³Ropeginterferon¤j¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2020/3/24 ¤U¤È 10:38:55²Ä 8218 ½g¦^À³
§C½Õ ­@¤ßµ¥ ¤@©w¥i¶W¶VINCYTE
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/24 ¤U¤È 10:04:24²Ä 8217 ½g¦^À³
jakafi 2019¦~¦b¬ü°ê¾P°âÃB¬°16.85»õ¬ü¤¸¡Aincyte¹w¦ô2020¦~¥i¾P°â18.8¡ã19.5»õ¬ü¤¸

jakafi 2019¦~¦b¥þ²y°£¤F¬ü°ê¥H¥~¦a°Ï¡A¾P°âÃB¬°11.14»õ¬ü¤¸

incite 2019¦~¦Û¿ÕµØ¨ú±oªºjakafiÅv§Qª÷¬°2.26»õ¬ü¤¸

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gandytom10148211  µoªí®É¶¡:2020/3/24 ¤W¤È 11:11:29²Ä 8216 ½g¦^À³
2020¦~3¤ë17¤é¡Aºû¤]¯Ç¡G 3¤ë11 ¤é¡A¬P´Á¤T¡A¥@¬É½Ã¥Í²Õ´¡]WHO¡^«Å¥¬¤j¬y¦æ¡A¥HÀ³¹ïCOVID-19¬Ì±¡¡C³o¬O¤@ºØÄY­«ªº°·±dª¬ªp¡A¼vÅTµÛ¥þ¥@¬É³\¦h°ê®a¡C§Ú­Ì­n¦V¨ü¼vÅTªº¤H­Ì¡A¥L­Ìªº¿Ë±­©M¬°§ïµ½·í«eª¬ªp¦Ó§V¤OªºÂåÅ@¤H­ûªí¥Ü³Ì²`¤Áªº¦P±¡¡C

ÀHµÛ³o¨Ç¤ÑCOVID-19ªºÄ~Äò¶Ç¼½¡A§Ú­Ì¥D­nÃöª`ªº¬O¥þ²y­û¤u©M±wªÌªº°·±d©M¦w¥þ¡C¹ï§Ú­Ì¦Ó¨¥¡A¦ÜÃö­«­nªº¬O»s©w«OÅ@³o¨Ç±¹¬I¨Ã½T«O

AOP Orphan¦b©Ò¦³°ê®a¶i¤@¨B¥¿±`¹B§@ªº±¹¬I ¡C¦Ò¼{¨ì³o¤@ÂI¡A§Ú­Ì¹ê¬I¤F¥H¤U¦æ°Ê¡A±q2020¦~3¤ë16¤é¬P´Á¤@¦Ü2020¦~4¤ë12¤é¥Í®Ä¡G

©Ò¦³AOP Orphan­û¤uªº¤@¯ë®È¦æ­­¨î¡C

AOP©t¨à·|ij±N¥H¼Æ¦r¤è¦¡¶i¦æ¡C

°£¦b¤½¥q·~°È¤¤¦ÜÃö­«­nªº³¡ªù¡]¨Ò¦p¨ÑÀ³ÃìºÞ²z¡AÃÄ«~¦w¥þ©M½è¶q«OÃÒ¡^¤¤¤u§@ªº¤H­û¥~¡A©Ò¦³AOP Orphan­û¤u§¡À³¦b®a¤u§@¡C

Ãö©ó§Ú­Ìªº­û¤u¦p¦ó«OÅ@¦Û¤v§K¨ü«aª¬¯f¬r·P¬Vªº¤º³¡«ü¾É¡C

¨î©w­p¹º¥H½T«O©Ò¦³°ê®a¶i¤@¨B«ùÄòªº​​¬r«~¨ÑÀ³¡C§Ú­Ì¥¿¦b»P·í¦a½Ã¥Í·í§½©M¬F©²¥Nªí¥H¤Î§Ú­Ì¦b¨ü¼vÅT°ê®aªº²£«~»s³y°Ó©M¤À¾P°Óºò±K¦X§@¡A¥H½T«O±wªÌ¤£¨ü¤zÂZ¦aÀò±oÃĪ«¡C

¡§§Ú­Ì¨C¤Ñ³£¦bºÊµø³oºØ±¡ªpªºµo®i¡A¨Ã¾¨³Ì¤j§V¤O½T«OÄ~Äò¬°¥@¬É¦U¦aªº±wªÌ´£¨Ñ¤£¶¡Â_ªºÃÄ«~©MªA°È¡C¦b²{¶¥¬q¡A§Ú­Ì¹w­p²£«~¤£·|µu¯Ê¡C¡¨ AOP Orphan­º®u°õ¦æ©xAndreas Steiner»¡¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/24 ¤W¤È 10:20:10²Ä 8215 ½g¦^À³
¥Ó½ÐFDAÃÄÃÒ¤£¶È¨S¦³¼y¯¬¦æ±¡¡AÁÙ¶^¨ì¦C¬°³B¸mªÑ²¼¡C

ÃĵؤS³Ð¬ö¿ý¡A¯u¬O®¢°d!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2020/3/24 ¤W¤È 10:02:50²Ä 8214 ½g¦^À³
¶^¤Ó²`~¤µ¤é¤@¶}½L·m¶i20±i.....¥[ªo¡A¬°4¤ë¥xÆWÃÄÃÒ·x¨­~°_¶]
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/23 ¤U¤È 07:21:53²Ä 8213 ½g¦^À³

·|­û¡GSunfive10145942 µoªí®É¶¡:2020/3/23 ¤U¤È 01:55:44²Ä 8201 ½g¦^À³

§Ú·Q¦³¤H¦bª±ªLÁ`

¡X¡X¡X¡X-/

¨S¦³¤H·|ª±ªLÁ`

¤]¨S¦³ªLÁ`¥iª±

ª±ªLªLºØºØ®t¤£¦h

¯Âºé¬OªZº~ªÍª¢±a¨Óªº®£·W

¬ü°ê®£·W¡A´Á³f¡AªÑ¥«¤H¨£¤H©ß

¥xÆW¤]¤@ºÛºÆ®£·W¦n¹³¥@¬É¥½¤é¤F

¤j³°¬Ì±¡¤j·§¥|¤ëÁͽw¡A¬ü°ê¥i¯à¤£¥Î¤G­Ó¤ë

´Ní©w¤F¡C

ÃĵØFDA¤w¸g°e¥ó¤F

¬ü°êÃÄÃÒ½T©w¦p¡e®à¤W®³¬a¡f¡A¥i¥H®³¨ì¡C

Ãĵذò¥»­±¤£ÅÜ

¥|¤ë¹w´Á¥i¥H¥ý®³¨ì¥xÆWÃÄÃÒ¡Aºâ¬Oªñ´Á¦n®ø®§

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/23 ¤U¤È 05:40:36²Ä 8212 ½g¦^À³
¥~¸ê3/17-23¡A¶È¶È½æ¥X3±i

«ùªÑ11.3%¡A

§ë«Hµu´Á¶i¥X¦­´N½æªº®t¤£¦h¤F

³Ñ¤Uªº

¤£¬O®£·W

´N¬O¯Ê¿ú

¸òÃĵتº°ò¥»­±¤@ÂIÃö«Y³£¨S¦³

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/23 ¤U¤È 05:37:40²Ä 8211 ½g¦^À³
ÃĵØÃĪí¥Ü¡A®Ú¾ÚDatamonitor¤½¥q¹w´ú¡A¥þ²y¤û¥ÖÅ~¥«³õ±q2009-19¦~ªº½Æ¦X¼Wªø²v¬°5.5%¡A¦Ü2019¦~ªº¥«³õ³W¼Ò¥i¹F47»õ¬ü¤¸¡A¤¤°ê¤j³°«h¬°¥D­n¥«³õ¤§¤@¡C¤¤°ê¤Hªºµo¯f²v¬ù¦³0.8%¥ª¥k¡A¦ô­p¦³¶W¹L¤d¸U¥H¤Wªº±wªÌ¡AÃĵØÃľ֦³KX01¤j¤¤µØµ¥¦a°Ïªº±ÂÅv¡A¦³¾÷·|·m§ð¤¤°ê¤û¥ÖÅ~¥«³õ°Ó¾÷¡C

..........................................................................................

..........................................................................................

Athenex®³¾P°â¤À¼í¡A¤£­Y¦Û­Ó¨à¦¬¦^µ¹¦Û¤v¦X¸ê¤½¥qÁȧó¦h!

«¥¤S¬OªF´ê¦è´ê¶Ã¶Ã²q¦a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/23 ¤U¤È 04:43:53²Ä 8210 ½g¦^À³
·|­û¡GEric10147757 µoªí®É¶¡:2020/3/23 ¤U¤È 01:47:17²Ä 8199 ½g¦^À³

¶^ªk¤]³\¬O¦³¤ß¤H¬G·NáèÀ£ªº

§Ú´¿¸g¸g¾ú¹L¤@°¦«ØX ³QÂEX¨ÖÁÊ«e¯u¶^°±½æ¤£±¼

...........................................................................................

...........................................................................................

ÃĵØÀ³¸Ó¤£·|¦³¥H¤W¨ÖÁÊ(³Q¨ÖÁÊ)±¡¨Æ.

¤ñ¸û¥i¯àµo¥Íªº¬OAthenex­«Áʦ^KX01ªº¨È¬w±ÂÅv(¥xÆW°£¥~)???

²z¥Ñ:

1.¤û¥ÖÅ~¥ÎÃÄ KX01

¤½¥q¨ú±o KX01¤Æ¦Xª«¦b¥xÆW¡B¤¤°ê¤j³°¡B´ä¿D¡B¬P°¨µ¥¦a°Ïªº±ÂÅv

...±ÂÅv¤è Athenex ¤½¥q¤w©ó¬ü°ê§¹¦¨¤é¥ú©Ê¨¤¤Æ¯g(AK)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¨Ã¶}©l­pµe¥Ó½Ð¬ü°ê NDA¡A

¥»¤½¥q¥ç­pµe¦b©ú¦~¤W¥b¦~¥Ó½Ð¥xÆWÃÄÃÒ¡C(¤½¶}»¡©ú®Ñ¤º®e¤Ö¥h¤¤°ê¤j³°¡B´ä¿D¡B¬P°¨¥Ó½ÐÃÄÃҩΪÌÁ{§É¹êÅç?)

2. 2018.07.03-Athenex»P°¨¤ÆÄ˧ë¸êªº»sÃĤ½¥q­»³·ºë·Ç1.1»õ¬ü¤¸¦X§@¶}µoTCR-T§ÜÀù§Þ³N

¦Ó¦b¦¹¤§«e¡AAthenex©M­»³·ºë·Ç´N°w¹ï¦h§Î©Ê½¦½è¥À²Ó­M½FªºKX-02ªº¬ãµo¤]¶i¦æ¤F¦X§@¡C

¦b¤G®a©ó¤j³°¦X¸ê¥ø·~«á¡A¨º±iAthenex¬ãµoºÞ½u¹Ï¤¤KX01¯Ê¤Ö¤¤°ê³o¤j¶ô¡A¤@¾ã­Ó¬Ý°_¨Ó©Ç!

kknews.cc/finance/v6ag8ba.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2020/3/23 ¤U¤È 04:14:46²Ä 8209 ½g¦^À³
¬Ý¤µ¤Ñªº¤½§i:

mops.twse.com.tw/mops/web/t05st01?encodeURIComponent=1&step=1&firstin=1&off=1&keyword4=&code1=&TYPEK2=&checkbtn=&queryName=co_id&TYPEK=all&co_id=6446&year=107&month=&b_date=01&e_date=31

¤½§i¥»¤½¥q¸³¨Æ·|³q¹L¹ï¬ü°ê¤l¤½¥q¼W¸ê3¥a¸U¬ü¤¸

(¸É¥R109.2.19­«°T)

¥»¤½¥q¦³»ùÃÒ¨éªñ´Á¦h¦¸¹F¤½¥¬ª`·N¥æ©ö¸ê°T¼Ð·Ç

¡A¬G¤½§i¬ÛÃö°T®§¥H§Q§ë¸ê¤HÁA¸Ñ(¸É¥R¸ê®Æ)

¥»¤½¥q¦³»ùÃÒ¨éªñ´Á¦h¦¸¹F¤½¥¬ª`·N¥æ©ö¸ê°T¼Ð·Ç

¡A¬G¤½

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSunfive10145942  µoªí®É¶¡:2020/3/23 ¤U¤È 02:45:36²Ä 8208 ½g¦^À³
®£·W¤U¶^®É, ¦h¤ÖªÑ»ù¬O¬ÝªÑ²¼ªºÁÈ¿ú¯à¤O! ÃĵØÁÙµLªkÁÈ¿ú, ¥u¦³³Q±þªº¥÷!! °ß¦³·s«aªÍª¢¦³¸Ñ, Ãĵؤè¯à³Ý®§ÀR«ÝFDA¨Î­µ!!!

/////////////////////////////////////////////////////////////////////////////

¤£¾A«ÜÀ´³o½g©MÃĵØÃĪºÃö«Y?? ¯à½Ð¤j¤jÁ¿©ú¥Õ¤@ÂI¶Ü?

////////////////////////////////////////////////////////////////////////////

·|­û¡GSunfive10145942 µoªí®É¶¡:2020/3/23 ¤U¤È 02:01:48²Ä 8203 ½g¦^À³

www.storm.mg/article/2433005

§Æ±æ¬O¯uªº¦³®Ä!! ³o¼ËÃĵشNÀ³¸Ó¥i¥H¤î¦å, ÀR«ÝFDAªº¨Î­µ¤F!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/23 ¤U¤È 02:38:29²Ä 8207 ½g¦^À³
ªk°ê°¨Áɤj¾Ç·P¬V¬ã¨s¤¤¤ßªºÁ{§É³ø§iÅã¥Ü¡A 20 ¦ì¨ü¸ÕªÌ±µ¨ü¨C¤é 600mg ¤fªA¾¯¶qªº«¶¹ç¡A»P 16 ¦ì¤ä«ù©ÊÀøªk¶i¦æ¤ñ¸û¡Aµo²{¦b¤¶¤J²Ä¤T¤Ñ«á¡A¯f¬rÂà³±²v´N¦³ÅãµÛ®t²§¡A¥B®t²§¤@ª½«ùÄòÂX¤j¨ì²Ä¤»¤Ñ¡C

[[¦Ó 20 ¦ìªA¥Î«¶¹çªº¨ä¤¤ [6 ¦ì ]¡AÃB¥~ªA¥Î§ÜÅðµßÃĪ«¤éµÎ¡]Azithromycin¡^¡A®ÄªG¤×¨Î¡A[ 6 ¦ì]¯f¤H¦b¤¶¤J²Ä¤­¤Ñ¥þ³¡Âà³±¡C

¥X²{100%¯«ÃÄ!?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õÁ`²Î10135593  µoªí®É¶¡:2020/3/23 ¤U¤È 02:37:07²Ä 8206 ½g¦^À³
¬Ý¦n±o¤H¥[´î¶R2±i ¤ß¤¤¬èÄ@P1101 ®ÄªG¨}¦n ¶¶§Q¤W¥« ³yºÖ¼s¤j¸s²³

¨ä¥L´N¥u¦³3­Ó¦r ­@¤ßµ¥

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/23 ¤U¤È 02:15:58²Ä 8205 ½g¦^À³
¤£¾A«ÜÀ´³o½g©MÃĵØÃĪºÃö«Y?? ¯à½Ð¤j¤jÁ¿©ú¥Õ¤@ÂI¶Ü?

////////////////////////////////////////////////////////////////////////////

·|­û¡GSunfive10145942 µoªí®É¶¡:2020/3/23 ¤U¤È 02:01:48²Ä 8203 ½g¦^À³

www.storm.mg/article/2433005

§Æ±æ¬O¯uªº¦³®Ä!! ³o¼ËÃĵشNÀ³¸Ó¥i¥H¤î¦å, ÀR«ÝFDAªº¨Î­µ¤F!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/23 ¤U¤È 02:04:10²Ä 8204 ½g¦^À³
§Ú¤£¬O»¡¹L40¦~§ë¸ê¤£¥Î«æ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSunfive10145942  µoªí®É¶¡:2020/3/23 ¤U¤È 02:01:48²Ä 8203 ½g¦^À³
www.storm.mg/article/2433005

§Æ±æ¬O¯uªº¦³®Ä!! ³o¼ËÃĵشNÀ³¸Ó¥i¥H¤î¦å, ÀR«ÝFDAªº¨Î­µ¤F!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/23 ¤U¤È 02:01:14²Ä 8202 ½g¦^À³
§Ú10¦~«e¤]¬O³o¼Ë ¶^¨ì10¦h¤¸µM«áÃz¥X1¸U¦h±i¤§«á´N£¸ª½½wº¦¨ì¥»¿ú38ÁÈ£¸¨Ç§Ú´N¶]¤F 6¡ã8¦~«áº¦¨ì100ªìÀY

¥t¤@Àɤ]¬O10¤¸ªìÀYº¦¨ì50 ¯u¤ßıªº§è ³o2Àɯuªº¬O¤ß¤¤¥Ã»·ªºµh ¦]¸êª÷»Ý¨D +¤W®MªÑ4¦~¦Ó½æ¥X¡]¤£¹L¨ä¶¡¦³°t®§¡^

¤ÏÆ[¥Í§ÞªÑ ¦pªG¤@ª½³B©ó¬ãµo¿N¿ú ¨º¯uªº¬O°ä¤Hªº§|

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSunfive10145942  µoªí®É¶¡:2020/3/23 ¤U¤È 01:55:44²Ä 8201 ½g¦^À³
§Ú·Q¦³¤H¦bª±ªLÁ`!!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/23 ¤U¤È 01:49:29²Ä 8200 ½g¦^À³
·|­û¡G¤ý¸I¥J10148138 µoªí®É¶¡:2020/3/23 ¤U¤È 01:25:22²Ä 8197 ½g¦^À³

³oªi¤U¨Ó°£¤F¦³¨ü´f¨ì¬Ì±¡ÃD§÷ªº ¨ä¥L³£¶^50%¥H¤W ¤£¥uÃĵئӤw

........................................................................................

·|­û¡GROGER588910148151 µoªí®É¶¡:2020/3/20 ¤U¤È 05:14:12²Ä 8179 ½g¦^À³

3/17¦³¤½§i¶ÀÁ`½è³],À³¸Ó¬O³Q°lú¡A¥u¦n¦A¼W¥[³]½èªÑ²¼!?

3/19¤W¥«Âd¤½¥q¸³ºÊ½è³]²§°Ê¤½§i

ÃĵØÃÄÁ`¸g²z ªL°êÄÁ 1,117 0 3,437 °ê®õ¥@µØ»ÈÀ]«e

ÃĵØÃĸ³¨Æªø¸â«C¬h 520 0 1,380 °ê®õ¥@µØ»ÈÀ]«e

.........................................................................

¯Ç¤J³o3¦~¤j½Lªº«ü¼Æ¦ì¶¥,

ÃĵتѻùµLºÃ¬ONo.1¶W¯Å¤jÄêªÑ!!!

¤£ª¾¨º¦ì¤j¤á¦p¦¹¼Ö¨£¤jªÑªF½è³]ªºªÑ²¼¤£°±³Q°l¥[¾á«O???

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/23 ¤U¤È 01:47:17²Ä 8199 ½g¦^À³
³o­ÓªÀ·|¬O¦Y¤HªºªÀ·|

³oºØ¶^ªk¤]³\¬O¦³¤ß¤H¬G·NáèÀ£ªº

§Ú´¿¸g¸g¾ú¹L¤@°¦«ØX

³QÂEX¨ÖÁÊ«e¯u¶^°±½æ¤£±¼

Ãa´NÃa¦b³o¸Ì

¬ðµM«Å¥¬¨ÖÁÊ

²Ä¤G¤Ñ³s¼Q´X¤Q¤Ñ

¶R³£¶R¤£¨ì(§Ú¦b³Ì«á¤@¤Ñ¶^°±®É±¾³æ³QÂEX§l¥ú)

³o´N¬OªÑ¥«

¥Ã»·¦³¤H¥ýª¾¹D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿c¦³ªK10149122  µoªí®É¶¡:2020/3/23 ¤U¤È 01:30:23²Ä 8198 ½g¦^À³
§Ú¶RªÑ²¼³Ìªø©ê¹L10¦~,1¡ã3¦~§Úµ´¹ï¬O¥i¥Hµ¥¡A¦ý¨S¦³§QªÅªÑ»ù³oºØ¶^ªk¡K¡K¥u§Æ±æ¤½¥q°]°È¤£­n¦³°ÝÃD´N¦n¡C¤Ñ¦öÃĵØÂåÃÄ¡ã¤]¯¬ºÖ¤j®a©M§Ú¯à¤ß·Q¨Æ¦¨¡ã
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/23 ¤U¤È 01:25:22²Ä 8197 ½g¦^À³
³oªi¤U¨Ó°£¤F¦³¨ü´f¨ì¬Ì±¡ÃD§÷ªº ¨ä¥L³£¶^50%¥H¤W ¤£¥uÃĵئӤw

¹j¾ÀªO¨º­Ó¤H¥u¬O­Ó»Ä¥Á£¸ªT¦Ó¤w Á¿¸Ü²@µL«Ø³]©Ê

10¦~«e¿ù¥¢£¸¾×¦Ê¦X¸òky¦Ê¦X ³o2Àɽæ¥X¤ÖÁÈ250¡ã300¸U ³oªi¬Ì±¡¤]¶^¤U¨Ó¤F

·Q¥[½X¤]¤£´± ¡]¤H¦b®£·W¤¤ ¯uªº¬Ý¤£²M¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/23 ¤U¤È 01:15:02²Ä 8196 ½g¦^À³
Å¥§Úªº¸Ü

¯Ê¿úªº¡A®£·Wªº

­n½æ¦h¤Ö¾¨¥i¯à½æ

¦n³B¬O§âµu½uÄw½X¬~¤@¬~

¤£ºâÃa¨Æ

ªø´Á2-3¦~¡A§Ö«h1¦~

ªÑ»ù·|¦^¨ìÀ³¦³»ù¦ì

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2020/3/23 ¤U¤È 01:06:14²Ä 8195 ½g¦^À³
¹j¾Àª©ªº´ý³J»¡20

¨º­Ó´ý³J¦³¬Ý¨ìÀ³¸Ó«Ü²n

§Ú²q¥L³Q¶Ë«Ü²`«Ü²`

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/23 ¤U¤È 12:55:36²Ä 8194 ½g¦^À³
¦A¶^¤U¥h´NÅÜĵ¥ÜªÑ¤À½L¥æ©ö¤F

ªO¤Í¦³¤H³Ìªñ·Q¥[½Xªºªº¶Ü¡H¡]¥Ø¼Ð»ù³]¦h¤Ö °Ñ¦Ò¬Ý¬Ý¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/23 ¤U¤È 12:43:03²Ä 8193 ½g¦^À³
¦V¤U¾Þ§@ÁÙ¬OÁȪü
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2020/3/23 ¤U¤È 12:28:47²Ä 8192 ½g¦^À³
¬O³eÀ£ÁÙ¬O¤£±o¤£³Q©è©ã断ÀY¡I«ç»ò¦³³o»ò¦h¥i¥H½æ¶^°±§r~¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2020/3/21 ¤U¤È 10:00:12²Ä 8191 ½g¦^À³
PV ©M ET ¦pªGªvÀø¤£¦n´N¥i¯à´c¤Æ¦¨post‐PV (PPV), myelofibrosis (MF) and post‐ET (PET) MF¡K..©Ò¥H¦p¦óPV«e´Áªº¥Ø¼Ð±wªÌ¤¤­°§CJAK2 allele burden¤Î¯e¯f´c¤ÆÀ³¬O Ropeginterferon «ùÄò­nÃöª`ªº­«ÂI»P»ù­È! «eÀY PV/ET ªvÀø§âÃö¦n, ²z½×¤W MF ±wªÌ´NÀ³¸Ó¤ñ¸û¤Ö (Incyte ¥Í·NÀ³¸Ó´N·|¦h¤Ö¨ü¼vÅT) ~ Incyte ¹ê¦bÀ³¸Ó¦n¦n´M¨D»P 6446 ¬YºØµ{«×ªºÁp·ù©Î¬O¥æ¤e«ùªÑ (­Ó¤Hµ¦²¤¤Û·Q¦Ó¤w!)

¥¦ (Ruxolitinib/Jakafi), ¹L¥h´X¦~ªº½T¬°Incyte³Ð³yÅãµÛÀ禬¦¨ªø»P¸ê¥»¥«³õµû»ù, ¦ý¬Ý¬Ý¤U­±´X½gªñ´Á¤å³¹, Jakafi¦ü¤]­±Á{³\¦h¬D¾Ô!

¤×¨ä¹ïMF, ­n¤£¬O¥«³õ¤´¦³³\¦h¥¼³Qº¡¨¬ªº»Ý¨D, 2019/08¬ü°êFDA¤£·|°w¹ï´¿¸g¦bÁ{§É³Q³Û¥d (¥i¯à²£¥Í¸£¤è­±ªº¯fÅÜ) ªº¥t¤@§í¨î¾¯ (fedratinib (Inrebic)) µ¹¤©¨Ã¦C¤W¥«¦ýªþ¤W(¶Â¼Ðĵ»y)! ~

¬Ý¬ÝJakafi¤W¥«¦h¦~¨Óªº¤@¨Ç°Æ§@¥Î³ø¾É, ©Î³\¥i¥Hª¾©¼ª¾¤v!

Management Strategies Set for Varying Patterns of Ruxolitinib Progression in Myelofibrosis

Lisa Astor

Published Online:4:00 PM, Thu March 19, 2020

www.targetedonc.com/news/management-strategies-set-for-varying-patterns-of-ruxolitinib-progression-in-myelofibrosis

´X­Ó¨å«¬ªºJakafi¨Ï¥Î¥¢±Ñ±¡ªp»P (¹ïµ¦)

1. ¶W¹L1/2¥H¤Wªº±wªÌµÊŦ¤ÏÀ³(ÁY¤p)¨S¦³Àò±o§ïµ½ (¹ïµ¦: a) ½Õ¾ã¾¯¶q«á, ¶È¤Ö³¡¤À±wªÌ¥i¥HÀò±o·sªºµÊŦ¤ÏÀ³»P§ïµ½; b) ³y¦å·F²Ó­M²¾´Ó c) Âà¥Î¥t¤@­ÓÃÄfedratinib (Inrebic)-2019/08 FDA ®Ö­ã)

2. ¿é¦å¨Ì¿à©Êªº³h¦å: (¹ïµ¦: »Ý­n8©P¿é¦å, ¨C¦¸4­Ó³æ¦ìªº¬õ¦å²y²Ó­M; ¦ý¬O³o¿é¦å©Ê³h¦åªº¦s¬¡²v¶È8­Ó¤ë)

3. ÄY­«¦å¤pªO´î¤Ö: ¦¹¯gª¬µo¥Í¬°¯f±¡²£¥Í´c¤Æªº²{¶H (¹ïµ¦: ­°§C¾¯¶q¬r©Ê©Î¬OÂà¨ä¥LªvÀø¤è¦¡)

4. ·íMF¯f±¡§ó´c¤Æµo¥Í®É, ¤£¨£±o¨C­Ó±wªÌ³£¾A¦X°µ³y¦å·F²Ó­M²¾´Ó

5. ¤Ö³¡¤À¨Ï¥ÎRuxolitinib«á·|²£¥Í²Ä¤G´c©Ê¸~½F, ex: ³¡¤À¬ã¨s«ü¥X¹³¬O«D¶Â¦â¯À½F¥Ö½§Àùªº²£¥Í

6. ·P¬V­·ÀI¼W¥[: ex: ¦b¤@¶µ¦WºÙJUMPªº¬ã¨s¤¤,¨Ï¥ÎruxolitinibªvÀø³Ì±`¨£·P¬V¬O¯p¯l¦õ´µ¯S¡B¤ä®ðºÞª¢©M§¿¸ô·P¬V,µo¯f²v¤À§O¬°8%¡B6.1%©M6%¡C

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

Raajit K. Rampal, MD, PhD

Published: Tuesday, Jan 14, 2020

www.onclive.com/onclive-tv/dr-rampal-on-unmet-needs-in-myelofibrosis-and-polycythemia-vera

1. ¬ù¤@¥bªº°©ÅèÅÖºû¤Æ±wªÌ¡A¥Îruxolitinib«á¦b1.5¦Ü3¦~¤ºÅý¯e¯f´c¤Æ¡C

2. ¦UÁ{§É¹êÅçÀ³¸Ó¦h¬ã¨s¤£¦PÃĪ«¹ï°©Åè¼W¥ÍMF©Î¬O¬õ¦å²y¼W¥ÍPV²£¥Í¯e¯fªº´c¤Æ±¡§Î

JAK Inhibition Continues to Push Progress (´c¤Æ) in Myelofibrosis

Ellie Leick

Published: Thursday, Sep 12, 2019

www.onclive.com/conference-coverage/soho-2019/jak-inhibition-continues-to-push-progress-in-myelofibrosis

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/21 ¤U¤È 02:29:13²Ä 8190 ½g¦^À³
bobby¡A

©pµo¤å«e¥ýÀˬd¥´¦r¦³¨S¦³¥´¿ù

¡e§ë¸ê¿éĹ³£¨S¬Æ»ò¥u­n§A¤é¤l°ª°ª¬P¬Pªº¹L´N«Ü­È±o¤Ï¥¿¤½¥q¤S¤£¬O§AªºÅý§O¤H¥h¶Ë¸£ºë¦n¤F¡f

°ª°ª¬P¬P¡A¥¿½TÀ³¸Ó

°ª°ª¿³¿³

¶Ë¸£ºë¡A¥¿½TÀ³¸Ó

¶Ë¸£µ¬¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/21 ¤U¤È 02:25:43²Ä 8189 ½g¦^À³
¤H®a°^Äm¨º»ò¦h§Ú­Ì´¡ªá´N¬Ý¤H®aªíºt¤Î¥i¤@¤j°ïªºÂø°T¦Û¤v­n·|¹LÂo
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/21 ¤U¤È 12:44:06²Ä 8188 ½g¦^À³
¤½¥q¬O¤WÂd¥«¤½¥q¡A¤£¬O§Úªº

¤]¤£¬O§Aªº¡A¤]¤£¬O¸³¨Æªø¡A°õ¦æªøªº

§ó¤£¬OªL®aªº¡A

¬O¤j®aªº¡A¬O§ë¸êªÑ¥Áªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/21 ¤U¤È 12:35:23²Ä 8187 ½g¦^À³
§ë¸ê¿éĹ³£¨S¬Æ»ò¥u­n§A¤é¤l°ª°ª¬P¬Pªº¹L´N«Ü­È±o¤Ï¥¿¤½¥q¤S¤£¬O§AªºÅý§O¤H¥h¶Ë¸£ºë¦n¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/21 ¤W¤È 11:19:10²Ä 8186 ½g¦^À³
¤pªL¡A

¡e¤µ¦~¥H¨Ó¡A¤]¬O¦³¤H¯àµutradeÃĵØÁȨì¿ú¡A¤SÁ׶}¤F³o´X¤ÑªºªÑ¨a!

ª±¿é¤F¥u©Ç§O¤H¡A¥Ã»·³£·|¬O¾|³D¡C°ª¤â¼F®`¤§³B¡A¦b©ó¿é¤F·|ÀË°Q¦Û¤v!¡f

²ö«D§A¬O°ª¤â¡A«ùªÑ¦¨¥»10¤¸¡H«ç»ò½æ³£·|ÁÈ¡C

§ë¸êªÑ²¼¿éĹ¡A¸ò¬O¤£¬O¾|³DµLÃö¡A§A³o¤@½|

´X¥Gª©¤WªºÃĵتѥÁ³£¬O¾|³D¤F¡C½Ð¤£­n¾Ç¹j¾Àª©

¶}¤f³¬¤f´N¬O........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/21 ¤W¤È 10:35:44²Ä 8185 ½g¦^À³
¸Ü»¡¤F¤@¥b¡A¤pªL¥H¬°¬O¦b¯º¥L

¤pªL§A´N©ñ¤U§a¡I§A¯u¹ê¨­¤À¡H

¥i¤£¤@¯ë¡C¨£¸Ñ¿W¯S¡A³s¹j¾Àª©§A¤]Æg¹Ä¡I

¤£¬O°ª©x´N¬O°ª¹¬¡C

¨ä¹ê¾ã¬q¸Ü»¡§¹¬O¡G

¤£»¡¤F

¤zÂZ¯À

¤û

²o¨ì¥_¨Ê

¤]¬O

¤û

¤zÂZ¯À

²o¨ì¥_¨Ê

ÁÙ¬O

¤zÂZ¯À

ÃĵؤzÂZ¯À

ÁÙ¬OPV¤@½uÃÄ

¤£ºÞ¯à¤£¯à¥Î©óªvÀøªZº~ªÍª¢

ÃĵؤzÂZ¯ÀÁÙ¬O³Ì¦nªº¤zÂZ¯À

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/21 ¤W¤È 09:49:20²Ä 8184 ½g¦^À³
¹j¾Àª©ªº¡A¼L¤ÚÁöż¡A¸£³U³£ÁÙ¤ñ¸û²M·¡¡C

©^ÄU»{²M¦Û¤vªº§ë¸êÄÝ©Ê¡A¼Ðº]°ò¥»­±§ë¸êªÌ¡A´N¤ÖÂI·Q¹³¡B¹ê¨Æ¨D¬O¡BÁ¿¨DÃÒ¾Ú¡A§ë¸ê¸ô¤W¤~¯àÁͦNÁפ¿¡C

·R¨n½L¤S¤£·Qªá®É¶¡¬ã¨sªº¡A¥i¥H·Q·Q¬O§_§Þ³N­±¾Þ§@¡BÄw½X­±¾Þ§@¤ñ¸û¾A¦X¦Û¤v?

¦Û¤v¯uªº¾A¦X¼Æ¦~ªºªø´Á§ë¸ê? ÁÙ¬O°µ°µµutrade¤]¤£¿ù?

¤µ¦~¥H¨Ó¡A¤]¬O¦³¤H¯àµutradeÃĵØÁȨì¿ú¡A¤SÁ׶}¤F³o´X¤ÑªºªÑ¨a!

ª±¿é¤F¥u©Ç§O¤H¡A¥Ã»·³£·|¬O¾|³D¡C°ª¤â¼F®`¤§³B¡A¦b©ó¿é¤F·|ÀË°Q¦Û¤v!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/20 ¤U¤È 10:35:24²Ä 8183 ½g¦^À³
¤£»¡¤F

¤zÂZ¯À

¤û

²o¨ì¥_¨Ê

¤]¬O

¤û

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2020/3/20 ¤U¤È 10:25:22²Ä 8182 ½g¦^À³
ºI¿ý·s«aªÍª¢·s»D³ø¾É¡G⋯8¦¯¦Ñ¯Î¹Á¸Õ¹L§Ü·R´þ¯f¬rªºÃĪ«¡A¤]¸Õ¹L«¶¹çÃþÃĪ«·m±Ï¡A³Ì«á±¡ªpÁÙ¬O¨S¦³¦nÂà¡A¥[¤W±Ñ¦å¯g¨Öµo¡A¤£©¯¹L¥@¡C

¦p¯u¡A½T¹ê¬O¦h¤è¹Á¸ÕªvÀø¡A©Ò¥H¤zÂZ¯À©Î³\¤]¬O¤£µL¥i¯à¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/20 ¤U¤È 10:01:55²Ä 8181 ½g¦^À³
¨Ìµ}°O±o¥h¦~»¡©ú·|¦³´£¨ì¥x¤¤¼t²£¯à,¤j¬ù¬O2¶g§å¦¸¥Í²£20gªºP1101?

(º¡¸ü¤£·³­×...)20g*26§å*3¯Z¨î=1560g/¦~ *1000=1560000mg /¦~

108¦~²£¶q 34,524,200 mg?

¤Ñ¦a¤§®t¬O«¥®t¿ùÁÙ¬O¤½¥qªº¼Æ¾Ú®t¿ù?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/20 ¤U¤È 09:18:26²Ä 8180 ½g¦^À³
·|­û¡G·s¶i10143606 µoªí®É¶¡:2020/3/18 ¤W¤È 11:54:51²Ä 8117 ½g¦^À³

¥H¤½¶}»¡©ú®Ñ75­¶ªº»¡©ú­pºâ¤U¨Ó¨C°w¥X³f»ù¤£¨ì¥x¹ô9000¤¸......

¼Ú¬w¥­§¡°â»ù¨C°w¦b¼Ú¤¸3000¤¸......©Ç¤£±o¸òAOP¦³ª§Ä³¤F¡I

...........................................................................................

·|­û¡G¶³²H­·»´10146472 µoªí®É¶¡:2020/3/18 ¤W¤È 10:08:28²Ä 8116 ½g¦^À³

¤½¶}»¡©ú®Ñ P.75

Besremi 108¦~ ¥X³f3.3 ¸U¤ä? ¥X³f»ù ¬ùNT$9¥a/¤ä?

3.3 ¸U¤ä­Y¤@¦~¥Î§¹, ¯f¤H¬ù¤W¤d¤H?

.............................................................................................

108 ¦~«×¥Í²£¶q­È

P1101 - - - -²£¶q 34,524,200 mg / ²£­È(«Y»s¦¨«~¦¨¥»)230,592¥a¤¸

¥~¾P¶q:33¥a¤ä /¥~¾P­È 293,464¥a¤¸

²£¶q 34,524,200 mg----1mg=1000ug(mcg)

34524200*1000 / 250(1¤äª`®gµ§250mcg(£gg)=¤£¥i«äijªº¶q,¼Æ¾Úªº³æ¦ìmg¥¿½T¶Ü?¿ù¦b¨º???

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/20 ¤U¤È 05:14:12²Ä 8179 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2020/3/19 ¤U¤È 12:26:47²Ä 8144 ½g¦^À³

ÃĵØÃĤjªÑªF½è³]ªºªÑ²¼¬O¤£¬O¤w¸g³QÂ_ÀY¤F?

3/17¦³¤½§i¶ÀÁ`½è³],À³¸Ó¬O³Q°lú¡A¥u¦n¦A¼W¥[³]½èªÑ²¼!?

«¥´N¬OªF¦è´ê¶Ã²q¡A¨DÃҽЪ½±µ°Ý¶ÀÁ`!!!

..............................................................................................

..............................................................................................

3/19¤W¥«Âd¤½¥q¸³ºÊ½è³]²§°Ê¤½§i

ÃĵØÃÄÁ`¸g²z ªL°êÄÁ 1,117 0 3,437 °ê®õ¥@µØ»ÈÀ]«e

ÃĵØÃĸ³¨Æªø¸â«C¬h 520 0 1,380 °ê®õ¥@µØ»ÈÀ]«e

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2020/3/20 ¤U¤È 02:34:10²Ä 8178 ½g¦^À³
¤p§ó¥¿«e PO¤å

> 1,000,000 & 100000 ¥H¤U¨â³B

¦³Ãö¤j¤j´£¨ì¨C¤ë»{¦C¦¬¤J¤p·P ....

²z©Ê¬Ý«Ý, ¥ô¦ó«È¤á¦V¨ÑÀ³°Ó­q³f, ¨ä¦¬¤J»{¦C¤è¦¡/¶O¥Î¦³¤@©wªº·|­p­ì«h·Ç«h»{¦C»P¿í´` ~ ¥»½g¤×¨ä´£¨ì¥Í§Þ·~,¥i°Ñ¦Ò IFRS 15 pdfµ²»y: (Note: °ê»Ú°]°È³ø§i·Ç«h¡]International Financial Reporting Standards¡AÁY¼gIFRS¡^(www.pwc.tw/zh/publications/bio-insights/pdf/bio-insights-1110.pdf) ,

www.twse.com.tw/ch/listed/download/IFRS000B45.pdf

¸Õ·Q, AOP¥i¯à¨C­Ó¤ë³£­n¨D¥X³f? ©Î³\­þ¤@¤Ñ½æ¨ì½¤F, °t¦X°w¾¯»P¥«³õ¦æ¾P©Ò»Ý, ­q³f»P¥X³f»P¦¬¤J»{¦CÀW¦¸¤~·|´£°ª, ­Y¨Ì·ÓIFRS15³W©w, ¤]­nµø¦X¬ù«ç»ò­q¥ß, °Z¯à¤@´[±¡Ä@Åý·~ªÌ«ö·Ó§ë¸ê¤H·NÄ@³v¤ë¥ô·N»{¦C? ¦bÁÙ¨S¦³»Ý¨D¤jÅD¶i°ª²£¯à½[°Ê²v¤§«e, ¦¹Ãþ°w¾¯ÃĤ]À³¸Ó¬O§å¶q¥Í²£«á´£¨Ñµ¹AOP¹w¦ô¤§¼Æ¤ë®w¦s©Ò»Ý¤~²Å¦X¸gÀ٥Ͳ£!?

¸Ü¤S»¡¹L¨Ó, ÃĵعL¥h¤­¦~¶R¶iªº (¤­¦~§¡»ù$146), ¥þ³¡¦í®M©Ð! ¥»¤ë´N±q2/28 101 ¶^¨ì40% ¨ì²{¦b61¡K.´X­Ó²{¶HÆ[¹î:

1 ªÑÅv¤À´²: ´Á¶¡2018/03~2020/0313: «ùªÑ >1,000,000ªÌ(±q40¤H¨ì35¤H), 800,001-1,000,000 (±q1¨ì5¤H), 600,001-800,000 (±q12¨ì7¤H), 400,001-600,000 (11¨ì18¤H), 200,001-400,000 (±q54¨ì55¤H) ¨ä¾l100,000¥H¤U¦U¯Å¶ZªºÅܤƮt²§¦b¦¹´Á¶¡¤£ºâ«Ü¤j, ¬Û«H­nÅX¨ÏªÑ»ù¤U¶^21­Ó¤ë¤O¹DÀ³¸Ó¦³­­§a !?

2 Æ[¹î¸³ºÊ¨Æ«ùªÑÅܤÆ: ´Á¶¡2018~2020: ±q106¦~³ø»Pªñ´Á¼W¸êªº³ø§iÆ[¹î¸³ºÊ«ùªÑÅܤÆ: a) ¦æ¬F°|°êµo°òª÷¨S°Ê22,066,296ªÑ, b) ¸³¨Æªø/Á`¸g²z/°õ¦æªø«ùªÑ «ùÄò¼W¥[ (À³¸Ó§t¤W¦¸¨p¶ÒÂê¤T¦~ªÑ¼Æ) c) Ä£µØ¬Á¼þºÞ©e·|«ùªÑ¤£ÅÜ 9,666,000ªÑ¡K.

3 ±q #1 Æ[¤§, ³o¨â¦~¨Ó, ¤@¨Ç­ì«ùªÑ >1000000¤Î 600001~800000¤jªÑªFÄw½X¬y¨ì¥«³õÀ³µL²§Ä³! ­ì¦]? µ¹¯S©w¤H§C±µ? ²ö®_¦Ï! ¤p´²¥u¦n¦Û¥Ñ·Q¹³!

4 ¸gÀçªÌ½è©ãªÑ²¼ÁöµMªÑÅv¨S¦³´î¤Ö¬Æ¦Ü¦]¬°¨p¶Ò¦Ó¼W¥[, ¦ý¬O½è©ãªÑ²¼¨ú±oªº²{ª÷¨s³º°µ¦ó§Q¥Î?

5 µ²½×:

5.1 ³o¨â¦~¥þ²y¥xªÑ½Ä°ª, 6446¨S¥÷, ªÑ¥«¹J¤T¤ë±O±þ, ³¡¤À¬Ì±¡·§©ÀªÑÁÙµyµy¦³©Ò¬°, ²´¬Ý¤G½uIncyte¬Q¤é¦¬½L¤]ÁÙ¦³USD 66.51, «¥­ÌPV ¤@½uªº·sÃÄ3/20/2020 NTD 61.7 ¤~®t30­¿¦Ó¤w¡K¡K

5.2 Jakafi¥Î©óªvÀøMF²Ä¤@½u¥ÎÃÄ2011/11/16ÀòFDA®Ö­ã©ó¬ü°ê¤W¥« 2011/11/18 (·í¤ÑªÑ»ùUSD 12.21)¡B¥Î©óªvÀøPV²Ä¤G½u¥ÎÃĤ]©ó201412/04ÀòFDA®Ö­ã©ó¬ü°ê¤W¥« (2014/12/05·í¤ÑªÑ»ùUSD 75.2), 2017¬Æ¦Ü¨Ó¨ì¾ú¥v°ªUSD147, «¥­Ì 6446 «ùÄò±´©³ ....

5.3 Jakafi©Î³\¦b¬üªÑ¥«³õ¦¨¼ô«×»P¾ãÅé¬ãµo, ½u«~½upipelinesÀò±o¬ü°ê¥«³õ°ª«×«C·ý, ©Ò¥HªÑ»ù¨Ã¨S¦³¦bÀò±oFDA approval «á´N§Q¦h¥XºÉ©Ô¦^, ·~ÁZ¤]«ùÄò©¹¤W¬Æ¦ÜÁÙ«ùÄòÁ»¿Ì PV front line¡K¤ÏÆ[¥xªÑ6446§r¡K.¤£³Ó®D¼N ¤£³Ó®D¼N ¤£³Ó®D¼N! Ãø¹D6446¤p´²­Ìº|¤F¤°»ò¤F¶Ü, ¦b¦k·Q¶Ü? ¤£·Q¬Ýªº´NÂ÷¶}Ðù, ¤£ªA¤£·Q´N¦¹Â÷¶}ªº, ´N¬èë¦Û¤v©R°÷ªøµ¥«ÝÀÆ¥ú¡K¥¦©Î³\¯uªº·|¨Ó, ¦ý¤]¥i¯àÁÙ¬O¦k·Q, You never know! ¦pªG·|°_­·, §Æ±æ§jªº¬OÁͶիùÄò¹³¤Wªº¥Ý­·¦Ó¤£¬OÆC¨aªºÁü­·!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2020/3/20 ¤U¤È 02:27:23²Ä 8177 ½g¦^À³
¦³Ãö¤j¤j´£¨ì¨C¤ë»{¦C¦¬¤J¤p·P ....

²z©Ê¬Ý«Ý, ¥ô¦ó«È¤á¦V¨ÑÀ³°Ó­q³f, ¨ä¦¬¤J»{¦C¤è¦¡/¶O¥Î¦³¤@©wªº·|­p­ì«h·Ç«h»{¦C»P¿í´` ~ ¥»½g¤×¨ä´£¨ì¥Í§Þ·~,¥i°Ñ¦Ò IFRS 15 pdfµ²»y: (Note: °ê»Ú°]°È³ø§i·Ç«h¡]International Financial Reporting Standards¡AÁY¼gIFRS¡^(www.pwc.tw/zh/publications/bio-insights/pdf/bio-insights-1110.pdf) ,

www.twse.com.tw/ch/listed/download/IFRS000B45.pdf

¸Õ·Q, AOP¥i¯à¨C­Ó¤ë³£­n¨D¥X³f? ©Î³\­þ¤@¤Ñ½æ¨ì½¤F, °t¦X°w¾¯»P¥«³õ¦æ¾P©Ò»Ý, ­q³f»P¥X³f»P¦¬¤J»{¦CÀW¦¸¤~·|´£°ª, ­Y¨Ì·ÓIFRS15³W©w, ¤]­nµø¦X¬ù«ç»ò­q¥ß, °Z¯à¤@´[±¡Ä@Åý·~ªÌ«ö·Ó§ë¸ê¤H·NÄ@³v¤ë¥ô·N»{¦C? ¦bÁÙ¨S¦³»Ý¨D¤jÅD¶i°ª²£¯à½[°Ê²v¤§«e, ¦¹Ãþ°w¾¯ÃĤ]À³¸Ó¬O§å¶q¥Í²£«á´£¨Ñµ¹AOP¹w¦ô¤§¼Æ¤ë®w¦s©Ò»Ý¤~²Å¦X¸gÀ٥Ͳ£!?

¸Ü¤S»¡¹L¨Ó, ÃĵعL¥h¤­¦~¶R¶iªº (¤­¦~§¡»ù$146), ¥þ³¡¦í®M©Ð! ¥»¤ë´N±q2/28 101 ¶^¨ì40% ¨ì²{¦b61¡K.´X­Ó²{¶HÆ[¹î:

1 ªÑÅv¤À´²: ´Á¶¡2018/03~2020/0313: «ùªÑ1,000,000ªÌ(±q40¤H¨ì35¤H), 800,001-1,000,000 (±q1¨ì5¤H), 600,001-800,000 (±q12¨ì7¤H), 400,001-600,000 (11¨ì18¤H), 200,001-400,000 (±q54¨ì55¤H) ¨ä¾l1,000,000¥H¤U¦U¯Å¶ZªºÅܤƮt²§¦b¦¹´Á¶¡¤£ºâ«Ü¤j, ¬Û«H­nÅX¨ÏªÑ»ù¤U¶^21­Ó¤ë¤O¹DÀ³¸Ó¦³­­§a !?

2 Æ[¹î¸³ºÊ¨Æ«ùªÑÅܤÆ: ´Á¶¡2018~2020: ±q106¦~³ø»Pªñ´Á¼W¸êªº³ø§iÆ[¹î¸³ºÊ«ùªÑÅܤÆ: a) ¦æ¬F°|°êµo°òª÷¨S°Ê22,066,296ªÑ, b) ¸³¨Æªø/Á`¸g²z/°õ¦æªø«ùªÑ «ùÄò¼W¥[ (À³¸Ó§t¤W¦¸¨p¶ÒÂê¤T¦~ªÑ¼Æ) c) Ä£µØ¬Á¼þºÞ©e·|«ùªÑ¤£ÅÜ 9,666,000ªÑ¡K.

3 ±q #1 Æ[¤§, ³o¨â¦~¨Ó, ¤@¨Ç­ì«ùªÑ >1000000¤Î 600001~800000¤jªÑªFÄw½X¬y¨ì¥«³õÀ³µL²§Ä³! ­ì¦]? µ¹¯S©w¤H§C±µ? ²ö®_¦Ï! ¤p´²¥u¦n¦Û¥Ñ·Q¹³!

4 ¸gÀçªÌ½è©ãªÑ²¼ÁöµMªÑÅv¨S¦³´î¤Ö¬Æ¦Ü¦]¬°¨p¶Ò¦Ó¼W¥[, ¦ý¬O½è©ãªÑ²¼¨ú±oªº²{ª÷¨s³º°µ¦ó§Q¥Î?

5 µ²½×:

5.1 ³o¨â¦~¥þ²y¥xªÑ½Ä°ª, 6446¨S¥÷, ªÑ¥«¹J¤T¤ë±O±þ, ³¡¤À¬Ì±¡·§©ÀªÑÁÙµyµy¦³©Ò¬°, ²´¬Ý¤G½uIncyte¬Q¤é¦¬½L¤]ÁÙ¦³USD 66.51, «¥­ÌPV ¤@½uªº·sÃÄ3/20/2020 NTD 61.7 ¤~®t30­¿¦Ó¤w¡K¡K

5.2 Jakafi¥Î©óªvÀøMF²Ä¤@½u¥ÎÃÄ2011/11/16ÀòFDA®Ö­ã©ó¬ü°ê¤W¥« 2011/11/18 (·í¤ÑªÑ»ùUSD 12.21)¡B¥Î©óªvÀøPV²Ä¤G½u¥ÎÃĤ]©ó201412/04ÀòFDA®Ö­ã©ó¬ü°ê¤W¥« (2014/12/05·í¤ÑªÑ»ùUSD 75.2), 2017¬Æ¦Ü¨Ó¨ì¾ú¥v°ªUSD147, «¥­Ì 6446 «ùÄò±´©³ ....

5.3 Jakafi©Î³\¦b¬üªÑ¥«³õ¦¨¼ô«×»P¾ãÅé¬ãµo, ½u«~½upipelinesÀò±o¬ü°ê¥«³õ°ª«×«C·ý, ©Ò¥HªÑ»ù¨Ã¨S¦³¦bÀò±oFDA approval «á´N§Q¦h¥XºÉ©Ô¦^, ·~ÁZ¤]«ùÄò©¹¤W¬Æ¦ÜÁÙ«ùÄòÁ»¿Ì PV front line¡K¤ÏÆ[¥xªÑ6446§r¡K.¤£³Ó®D¼N ¤£³Ó®D¼N ¤£³Ó®D¼N! Ãø¹D6446¤p´²­Ìº|¤F¤°»ò¤F¶Ü, ¦b¦k·Q¶Ü? ¤£·Q¬Ýªº´NÂ÷¶}Ðù, ¤£ªA¤£·Q´N¦¹Â÷¶}ªº, ´N¬èë¦Û¤v©R°÷ªøµ¥«ÝÀÆ¥ú¡K¥¦©Î³\¯uªº·|¨Ó, ¦ý¤]¥i¯àÁÙ¬O¦k·Q, You never know! ¦pªG·|°_­·, §Æ±æ§jªº¬OÁͶիùÄò¹³¤Wªº¥Ý­·¦Ó¤£¬OÆC¨aªºÁü­·!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/20 ¤U¤È 01:59:43²Ä 8176 ½g¦^À³
www.targetedonc.com/news/ropeginterferon-alfa2b-appears-effective-in-polycythemia-vera-without-splenomegaly

Ropeginterferon Alfa-2b Appears Effective in Polycythemia Vera Without Splenomegaly

Danielle Ternyila

Published Online:5:52 PM, Tue March 17, 2020

Based on the durable hematological and molecular response and the tolerability observed with ropeginterferon alfa-2b in the PROUD-PV trial, Gisslinger et al concluded that the agent is a safe for long-term treatment of PV with features distinct from hydroxyurea.

®Ú¾ÚPROUD-PV¸ÕÅ礤Æ[¹î¨ìªº«ù¤[¦å²G¾Ç©M¤À¤l¤ÏÀ³¥H¤Î¥Îropeginterferon alfa-2bÆ[¹î¨ìªº­@¨ü©Ê¡AGisslingerµ¥¤H±o¥Xµ²½×¡A¸ÓÃĪ«¥iªø´ÁªvÀøPV¡A¨ã¦³¤£¦P©óßm°ò脲ªº¯S¼x¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2020/3/20 ¤U¤È 12:34:29²Ä 8175 ½g¦^À³
www.youtube.com/watch?v=jz6yKgFgjFM
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿c¦³ªK10149122  µoªí®É¶¡:2020/3/20 ¤U¤È 12:34:08²Ä 8174 ½g¦^À³
¹ï¤½¥q¦³«H¤ß¡A³Ì­«­nÁÙ¬O«Ø¥ß©óªÑ»ù¡C

¶^¦¨³o¼Ë¤]¨S¤Ï¼u¡A¹ê¦b¦³ÂIºG¡C

¦b¦¹§Æ±æ¥»ª©¯d¨¥ªº¦U¦ìªÑªF¡A¤@©w­n°Ñ¥[¤µ¦~ªÑªF¤j·|¡A§â¦U¦ìªº·N¨£¤ÏÀ³µ¹¤½¥q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/20 ¤U¤È 12:33:33²Ä 8173 ½g¦^À³
¨S¬ì¾ÇÃÒ¾ÚªºÃĤ£¯à¶Ã¥Î¤£µM«á±wµL½a¤¤¦@ªº«Å¶Ç§O«H¤£µM¦Û¤v¥h¹ï©¤¸Õ¸Õ´Nª¾¹D·|¤£·|¬¡¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/20 ¤U¤È 12:23:07²Ä 8172 ½g¦^À³
«e´X¤Ñ¬Ý¨ì¤pªL¸òbobbyªºµo¨¥¡G

¡eªÍª¢ªº¨Æ´N¥æµ¹¤Ñ®ð¡K

§O¦Aµ¹ÃĵØÀ£¤O¤F¡C¡f

§Ú¾ã¤Ñ¯º¨ì¤£¦æ¡C

¤£¹L¤pªL¤]¸É¥R

ÁÙ¦³±MªvÃĪ«·ç°¶¦è¼w©M¬Ì­]

µ¥¨ì¤Ñ®ðÅܼö¡Aµ¥¨ì·ç°¶¦è¼w©M¬Ì­]¤W¥«

­n¦º¦h¤Ö¤H¡H¦ò¨t¨¾¬Ì¡A°ª¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/20 ¤U¤È 12:22:07²Ä 8171 ½g¦^À³
¤½¥q¤@¶µ´N¬O³o»ò§C½Õ....

©ú©ú©xºô¤]»¡:

¥»¤½¥qªºRopeginterferon alpha-2b¬°·s¤@¥Nªø®Ä«¬¤zÂZ¯À£\¡A¦X¨Ö¨ä¥LÃĪ«ªvÀø·s«aªÍª¢ªº®ÄªGÀ³¥i¹w´Á¡C

À³¥i¹w´Á

À³¥i¹w´Á

À³¥i¹w´Á

À³¥i¹w´Á

À³¥i¹w´Á...

¥»À³³oªi¬Ì±¡ªº³Ì¤j¨ü¯qªÌ, «o·d¨ì¶Ë²ª²Ö²Ö.... ÁÙ¤£·|¤ÏÀ»... ¯uªº¬O¬ì¾Ç®a¸£³U¯uªº¸ò§Ú­Ì³£¤£¤@¼Ë...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/20 ¤U¤È 12:20:11²Ä 8170 ½g¦^À³
www.telesurenglish.net/news/Cubas-Interferon-Alpha-2B-Successful-in-Treating-COVID-19-20200317-0015.html?fbclid=IwAR0CuF5dzPfvtDd4SyIDre2_BvFT-jB2pU-ixV-foVD8NSty0XvEzaQLwPo

Published 17 March 2020

News > Latin America

Cuba¡¦s Interferon Alpha 2B, Successful in Treating COVID-19

For 40 years, Cuba has been using a molecule named Interferon Alpha 2B , which has successfully been used to combat the new Coonavirus in China and elsewhere.

The world has an opportunity to understand that health is not a commercial asset but a basic right, Cuban doctor Luis Herrera, the creator of the Interferon Alfa 2-B medication, one of the most successful medications in the fight against COVID-19 told teleSUR Tuesday.

RELATED:

Chile¡¦s Communist Mayor to Import Cuban Meds to Fight COVID-19

Interferon has been known for more than 40 years: first, it was produced from original sources in local sites, then nationally and later in the United States and even Finland.

At the beginning of the 80s, an important professor from Houston came to Cuba and advised our President Fidel Castro than the Interferon we had here was a very interesting molecule for a different purpose, Herrera told teleSUR.

Then a group of people went to Finland to get training in the production of interferon, while people were also producing Interferon from recombined sources using genetic engineering.

The first one was Beta Interferon in Japan, and the second one was the family of Alpha Interferon by Genetec in California, according to the Cuban doctor.

One year later in Cuba, we cloned different genes of Interferon from local sites, and we started to produce Interferon in 1981 and 1982, which we used in the outbreak of dengue fever, and we presented the results in the United States in California.

One of the ways the virus can multiply inside the cells is by decreasing the levels of Interferon naturally produced in human cells. The molecule thus, through a different metabolic way, can create conditions to limit the replication of the virus.

During the MERS-CoV epidemic three years ago - another type of coronavirus - people realized that Interferon was decreased during the replication of the virus, highlighted Herrera.

In China, practically a few weeks after the beginning of the outbreak, people started to use Interferon in a way to avoid complications in people infected with the virus. According to Herrera, this molecule has some side effects but not too critical.

The main idea of Interferon is just to avoid complications, he told teleSUR. Young people and people with a good immuno-response perhaps don¡¦t need the medicine or people who won¡¦t have complications and respond to the virus-like any other flu, but old people or people susceptible to have a bad immuno-response will have better chances of avoiding complications by using Interferon.

He concluded that Cuba must participate in this solidarity movement with other nations, just the same way other countries have had solidarity with Cuba, especially with Latin American and African countries.

We have more physicians working abroad than practically any other country in the world, not because we are exporting anything but simply because we want to participate in building a world with better health conditions and living conditions.

·s»D >©Ô¤B¬ü¬w

¥j¤Úªº¤zÂZ¯ÀAlpha 2B¦¨¥\ªvÀø¤FCOVID-19

40¦~¨Ó¡A¥j¤Ú¤@ª½¦b¨Ï¥Î¤@ºØ¦W¬°Interferon Alpha 2Bªº¤À¤l¡A¸Ó¤À¤l¤w¦¨¥\¥Î©ó¦b¤¤°ê¤Î¨ä¥L¦a°Ï¹ï§Ü·s«¬«aª¬¯f¬r¡C

¥j¤ÚÂå¥Í¸ô©ö´µ•®J¹p©Ô¡]Luis Herrera¡^¬O°®ÂZCOVID-19ªº³Ì¦¨¥\ÃĪ«¤§¤@¡A¥L»¡¡G¡§¥@¬É¦³¾÷·|¤F¸Ñ°·±d¤£¬O°Ó·~¸ê²£¡A¦Ó¬O¤@¶µ°ò¥»Åv§Q¡C¡¨¬P´Á¤G§i¶DteleSUR¡C

¬ÛÃö¡G

´¼§Q¦@²£ÄÒ¥«ªø±N¶i¤f¥j¤ÚÃÄ«~¥H¹ï§ÜCOVID-19

¤zÂZ¯Àªºª¾¦W«×¤w¶W¹L40¦~¡G­º¥ý¡A¤zÂZ¯À¬O±q·í¦aªº­ì©l¨Ó·½¥Í²£ªº¡AµM«á¦b¥þ°ê­S³ò¤º¥Í²£¡A«á¨Ó¦b¬ü°ê¬Æ¦ÜªâÄõ¥Í²£¡C

®J¹p©Ô¹ïTeleSURªí¥Ü¡G¡§¦b80¦~¥Nªì¡A¤@¦ì¨Ó¦Û¥ð´µ´°ªº­«­n±Ð±Â¨Ó¨ì¥j¤Ú¡A¨Ã¦V§Ú­ÌªºÁ`²Îµá¼wº¸•¥d´µ¯Sù¡]Fidel Castro¡^´£¥X«Øij¡A¦Ó¤£¬O§Ú­Ì¦b³o¸Ì¾Ö¦³ªº¤zÂZ¯À¬O¤@­Ó¦³½ìªº¤À¤l¡C

¡§µM«á¤@¸s¤H¥h¤FªâÄõ¡A±µ¨ü¦³Ãö¤zÂZ¯À¥Í²£ªº°ö°V¡C¡¨»P¦¹¦P®É¡A¤H­ÌÁ٨ϥΰò¦]¤uµ{±q­«²Õ¨Ó·½¥Í²£°®ÂZ¯À¡C

¥j¤ÚÂå¥Í»¡¡A²Ä¤@­Ó¬O¤é¥»ªºBeta¤zÂZ¯À¡A²Ä¤G­Ó¬O¥[§QºÖ¥§¨ÈªºGenetec¤½¥qªºAlpha¤zÂZ¯À®a±Ú¡C

¡§¤@¦~«á¡A§Ú­Ì¦b¥j¤Ú±q·í¦a¦aÂI§J¶©¤F°®ÂZ¯Àªº¤£¦P°ò¦]¡A¨Ã©ó1981¦~©M1982¦~¶}©l¥Í²£°®ÂZ¯À¡A¨Ã±N¨ä¥Î©óµn­²¼öªºÃzµo¡A¨Ã¦b¬ü°ê¥[§QºÖ¥§¨È¦{®i¥Ü¤Fµ²ªG¡C ¡¨

¯f¬r¥i¥H¦b²Ó­M¤ºÁc´Þªº¤@ºØ¤è¦¡¬O­°§C¤HÃþ²Ó­M¤¤¤ÑµM²£¥Íªº¤zÂZ¯À¤ô¥­¡C¦]¦¹¡A¤À¤l¥i¥H³q¹L¤£¦Pªº¥NÁ¤覡³Ð³y±ø¥ó¨Ó­­¨î¯f¬rªº½Æ¨î¡C

¦b¤T¦~«eªºMERS-CoV¬y¦æ´Á¶¡¡]¥t¤@ºØ«aª¬¯f¬r¡^¡A¤H­Ì·NÃѨì¤zÂZ¯À¦b¯f¬r½Æ»s¹Lµ{¤¤´î¤Ö¤F¡C

¦b¤¤°ê¡A¬Ì±¡Ãzµo´X¶g«á¡A¤H­Ì¶}©l¨Ï¥Î°®ÂZ¯À¡A¥HÁקK·P¬V¸Ó¯f¬rªº¤Hµo¥Í¨Ãµo¯g¡C¾Ú®J¹p©Ô»¡¡A³oºØ¤À¤l¨ã¦³¡§¤@¨Ç°Æ§@¥Î¡A¦ý¤£¬O«ÜÃöÁ䡨¡C

¥L¹ïTeleSURªí¥Ü¡G¡§¤zÂZ¯Àªº¥D­n«ä·Q¬OÁקK¨Ãµo¯g¡C¡¨ ¡§¦~»´¤H©M§K¬Ì¤ÏÀ³¨}¦nªº¤H¥i¯à¤£»Ý­nÃĪ«¡A¤]¤£·|¹³¨ä¥L¬y·P¤@¼Ë¨ã¦³¨Ãµo¯g©M¹ï¯f¬rªº¤ÏÀ³¯à¤Oªº¤H¡A¦ý¬O¦Ñ¦~¤H©Î§K¬Ì¤ÏÀ³¸û®tªº¤H¨Ï¥Î°®ÂZ¯À±N¦³§ó¦nªº¾÷·|ÁקK¨Ãµo¯g¡C¡¨

¥LÁ`µ²»¡¡A¥j¤Ú¥²¶·»P¨ä¥L°ê®a¤@°_°Ñ¥[³o¤@¹Îµ²¹B°Ê¡A´N¹³¡§¨ä¥L°ê®a»P¥j¤Ú¡A¯S§O¬O©Ô¤B¬ü¬w©M«D¬w°ê®aªº¹Îµ²¤@¼Ë¡¨¡C

¡§§Ú­Ì¦b°ê¥~¤u§@ªºÂå¥Í¤H¼Æ¤ñ¥@¬É¤W´X¥G¥ô¦ó¨ä¥L°ê®a³£­n¦h¡A³o¤£¬O¦]¬°§Ú­Ì­n¥X¤f¥ô¦óªF¦è¡A¦Ó¶È¶È¬O¦]¬°§Ú­Ì·Q°Ñ»P«Ø³]¤@­Ó°·±dª¬ªp©M¥Í¬¡±ø¥ó§ó¦nªº¥@¬É¡C¡¨

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿c¦³ªK10149122  µoªí®É¶¡:2020/3/20 ¤U¤È 12:06:54²Ä 8169 ½g¦^À³
³o»ò¦nªºÃÄ¡A¤½¥q¯uªºÀ³¸Ó°ª½Õ¤@ÂI¡ã
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/20 ¤U¤È 12:05:21²Ä 8168 ½g¦^À³
¬Æ¦Ü§Ú¬Û«H¥¼¨Ó©Î³\·|¨Ì¨Çµïµ·°¨¸ñ ©ÎÂå®v¶}©l¬ã¨s·|¦³¤@¨Ç²Î­p¼Æ¾Ú«ü¥X

MPN¯f¤H¨Ï¥ÎinterferonªÌ ¦b¼Ú¬üªZº~ªÍª¢¤j¬y¦æ¤¤±w¯f²vÁͪñ©ó¹s

´N¾÷¨î¨Ó»¡µ´¹ï¦X²z ¦]¬°¤zÂZ¯À¬O±j¤Æ¦Û¨­§K¬Ì¨t²Î¨Ã³z¹L¬YºØ¾÷¨îªýÂ_¯f¬r·P¬V

¤zÂZ¯Àµ´¹ï¦³ªvÀøªZº~ªÍª¢¯f¬rªº¯à¤O ¦ý¯uªº»Ý­n¤½¥q¤j¤O±À¼s

¥|¤ë¨úÃÒ­è¦n·f¤W³oªiªÍª¢¼ö «ô°U¤½¥q¤@©w­nÅý¤j®a¤F¸Ñ¤zÂZ¯ÀªvÀø¯f¬rªº¼ç¤O

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/20 ¤W¤È 11:57:21²Ä 8167 ½g¦^À³
¤zÂZ¯À¥i¥H¦X¨ÖRemdesivirªvÀøªZº~ªÍª¢¡H

·ç¼w¦è­³¡]­^»y¡GRemdesivir¡^¡A¤SĶ­Û¦a¦è­³[1]¡A¬O¥Ñ¬ü°ê¦N§Q¼w¬ì¾Ç¤½¥q¶}µoªº¤@ºØ·s«¬¹êÅç©Ê¼sÃЧܯf¬rÃĪ«¡A¥Î¨Ó°w¹ï¥ìªi©Ô¯f¬r¤Î³Q»{¬°¥i¥H¦³®Ä§í¨î©I§l¹D¤W¥Ö²Ó­M¤¤SARS¯f¬r©MMERS¯f¬rªº½Æ»s¡C[2][3]³o¬O¤@ºØ®Ö苷»ÄÃþ¦üª««eÃÄ¡A¯à°÷§í¨î¨Ì¿àRNAªºRNA¦X¦¨酶¡]RdRp¡^¡C¾Ú2020¦~ªº¤@¶µ¬ã¨sÅã¥Ü¡A·ç¼w¦è­³©M¤zÂZ¯ÀIFNB1¡]­^»y¡GIFNb1-b¡^ªºÁp¦X¥ÎÃĹïMERS¦³ÅãµÛÀø®Ä¡C[4]¾¨ºÞ³o¤@ÃĪ«ÁÙ¦b°w¹ï¥ìªi©Ô¯f¬rªº¤T´ÁÁ{§É¸ÕÅ礤¡A¦³²q´ú»{¬°¥¦¬O²{¤µ¹ï2019·s«¬«aª¬¯f¬r³Ì²z·QªºÃĪ«[5]¡C

·ç¼w¦è­³¡]­^»y¡GRemdesivir¡^¡A¤SĶ­Û¦a¦è­³[1]¡A¬O¥Ñ¬ü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/20 ¤W¤È 11:56:07²Ä 8166 ½g¦^À³
Zeta : Continue! Interferon has prevented me from getting colds and flu for five years.

Zeta : Last cruise I took I went with 9 ladies. 7 of them got the flu. I did not. Continued with my interferon.

¨ä¹ê¤zÂZ¯À³oÃþ¥»¨Ó´N¦³§Ü¯f¬r¯à¤O

¦bÁy®Ñ¤WMPN½×¾Â¤¤¤]¦³ª©¤Í´£¨ì

¥L¦]¬°MPN­ì¦]¨Ï¥Î¤zÂZ¯À ¶W¹L¤­¦~¨S¦³±o¹L¬y·P

´N³s¤§«e¦b¶l½ü¦P¦æªº¤E¦ìªB¤Í¤¤ ¦³¤C¦ì¦b²î¤W±o¨ì·P«_ ¦ý¦]¬°¥¦¨Ï¥Î¤zÂZ¯ÀªºÃö«Y¨S¦³¤¤¼Ð

¤zÂZ¯À¹ï§ÜªZº~¯f¬r§Ú¬Û«Hµ´¹ï¦³¥Î³B

¥u¬O¬Ý¤½¥q«ç»òÅý¤j®aª¾¹D¦³³o¼Ëªº¯à¤O

¥|¤ë¥xÆW´N¥i¥H¨ú±oÃÄÃÒ¤F

©¡®É¤]³\¥i¥H¦b¥xÆW¥ý©ó¤@¨Ç±wªÌ¸Õ¥Î¬Ý¬Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2020/3/20 ¤W¤È 11:34:17²Ä 8165 ½g¦^À³
¥Ø«e±ÏªÑ»ù¤@©w­n¸òªvÀøªZº~ªÍª¢¦³Ãö«Y¤~¯à¤j´T¼u¤É,¥Ø«e¤zÂZ¯À¬OªvªZº~ªÍª¢ªº­«­nÃĪ«¦ÓÃĵتºªø®Ä¤zÂZ¯À¤@©w¬O¦³³Ì¦nªº®ÄªG,¬Æ¦Ü¥´¤@°w¦³¹w¨¾¤G¶g§K·P¬Vªº®ÄªG,³o°Ó¾÷¥i»¡¬OµL­­,¥u­nÃĵثť¬¯à§K¶O´£¨ÑÃĪ«µ¹¦U°ê¹êÅçµ¥±¹¬I,ªÑ»ù¥²¯à¥ß¬ñ¨£¼v,´Á±æ¦U¦ìªÑªF²ö¦A§¤¦u·T«°,¤@¤H¤@«H±Hµ¹Ãĵطþ«PÃĵئbªZº~ªÍª¢ªvÀø¤W¦³¿n·¥§@¬°,ªÑ»ù¥²¯à°_¦º¦^¥Í
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/20 ¤W¤È 11:21:12²Ä 8164 ½g¦^À³
§ÚÀ³¸Ó¸ò¼Ó¤Uªºavandia¤j¤jÀ»´x¤@¤U, ¯uªº¬O³o¼Ë... ¨Æ¹ê¦å²O²OÂ\¦b²´«e....

¦ý..... ¤½¥q¬Ýªº¨ì¶Ü?? Å¥±o¶i¥h¶Ü??!! §Æ±æ¤µ¹L³o¦¸¥i¥H¯u¤ßÅ¥¶i¥h.... «ô°U¤F!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/20 ¤W¤È 11:16:35²Ä 8163 ½g¦^À³
§ë¸ê¬ì¾Ç¬OµL»ùªº¤£­nµuµø§Y¨Ï½ß¥ú¤F¤]¨SÃö§Æ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/20 ¤W¤È 11:15:36²Ä 8162 ½g¦^À³
¤S¦h¤F¤@­Ó°ê®a¯uªº¬O¤Ó¦n¤F!!

©Ò¥H°ò¥»­±ÁÙ¬O­n¦^Âk¨ì·~ÁZ, ´N¬O§Ú¤§«e»¡¾A®Éªº©ñ¥X·s»D½Z,

¤µ¦~¥X³f®É¶¡, ¤j¬ù¦h¤Ö, ¤j¬ù¦¨ªø¦h¤Ö, ¼Ú¬w½æªºª¬ªp¦p¦ó... ³o¤~¬O¤j®a­nªº... ¦Ó¤£¬O±o¤F¤°»ò¤S¤°»ò¼ú...

«Ü¤[¥H«e¦³¤H°Ý¦n¹³¤@©w­nµ¥¤J±b¤~¯à¤½¥¬, ¤]¤£¯à¤@­Ó¤ë¤@­Ó¤ë¤½¥¬AOP ªº¥X³f¶q, ¦ý¨º³£¥u¬O»¡ªk°ÝÃD...

¹w¦ô¨Ã¤£¬Oµ´¹ï, ¨C®a¤½¥q¤£¬O³£·|¾A®É¹ï¥~¹w¦ô¶Ü?? µM«á¦A¨Óµo¥¿¦¡·s»D½Z¤@¤Á¤w¤½§i¬°·Ç... ¤£¬O¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/20 ¤W¤È 11:13:33²Ä 8161 ½g¦^À³
¥t¥~ §Æ±æ¤½¥q¯à°÷¶¶À³¥xÆW¸ê¥»¥«³õ«¬ºA ¦Ò¼{¾P°â¤À¼í¯à°÷§ï¬°¨C¤ë¤J±b

¦]¬°¥xÆW¸ê¥»¥«³õ¹ê¦b¤Ó­«µø¤ëÀ禬¦¨ªø¤F....

¤@©u¬Æ¦Ü¤@¦~ªº¶i±b¹ê¦b¶¡¹j¤Ó¤[ ÅýªÑ¥Á¸òªk¤H¨ä¹ê«ÜÃø½T¹ê°lÂܹê»Ú¾P°âª¬ªp¾É­PÃú¸Ì¬Ýªá

¦pªG¤½¥q¯à¬Ý¨ì³o½g¤å³¹ §Æ±æ¯à¦Ò¼{´`¤¤¸Î¼Ò¦¡

¬Ý¯à§_§ï¬°¨C¤ë¾P°â¤À¼í¤J±b

¥¼¨Ó¬ü°ê¾P°â¤]¬O¦p¦¹

¨C¤ë§@±bªº¤è¦¡ ³o¼Ë¸ê¥»¥«³õ¤~¯à§Y®É¤ÏÀ³ ©µ¿N§÷¤õ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/20 ¤W¤È 11:03:16²Ä 8160 ½g¦^À³
ÁöµM¶^¨ì»ó«CÁy¸~ ¦ýªÑ»ù³Ì²×ÁÙ¬O»Ý­n¤ÏÀ³°ò¥»­±

°lÂܤ@¤U¼Ú·ù¦U°ê¤w³°Äò¶}½æ ¼w°ê ¶ø¦a§Q ¸q¤j§Q ·ç¨å ¥[¤W³Ì·sªº ·Rº¸Äõ

µ¥¾P°â¤W¸ô ¥ýí©w²{ª÷¬y ´î¤Ö¤£¥²­n¶}¾P

ÅýªÑ¥Á«H¤ß¦^´_¤ñ¸û­«­n

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/20 ¤W¤È 10:58:55²Ä 8159 ½g¦^À³
www.hpra.ie/img/uploaded/swedocuments/latest_pharmacies_only_list.pdf?2

·Rº¸ÄõÃÄ«~ºÊºÞ§½³q¹L besremi ¶}½æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/20 ¤W¤È 10:56:39²Ä 8158 ½g¦^À³
¡m¤H¦º¯d¦W¡Aªê¦º¯d¥Ö¡n¡K

¬ì¾Ç®a·d±ox¦Wº¡¤Ñ¤U¡A¤Ò´_¦Ó¨¥............

¦p­Y¤£¦Û§ÚÀË°Q¡A¤@ª½ºÉ·d¨Ç¤p·d·d¥¢¥h¤F§ë¸ê¥«³õªº«Hµû......

µ²ªGÅý¦Û¤v«ùªÑ»ù­È¦]¤p¦Ó¥¢¤j¡A¬Æ¦Ü·´¤F¤½¥q¡A±wªÌªºÂåÀø¾÷·|......

¯u¸Ó¥Î¬ì¾Ç®aªº¸£­pºâ¡A­pºâ¬O±oÁÙ¬O¥¢¤F¡I¡I¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gonly10135877  µoªí®É¶¡:2020/3/20 ¤W¤È 10:38:46²Ä 8157 ½g¦^À³
¤¤°ê¬ì§Þ³¡©x­û¤é«eªí¥Ü¡A¤é¥»¥ø·~¶}µoªº§Ü¬y·PÃĪ«ªk¤Ç©Ô­³¡]Favipiravir¡A°Ó«~¦W¡GAvigan¡^¤w§¹¦¨Á{§É¬ã¨s¡AÅã¥Ü¥X«Ü¦nÀø®Ä¡A¥BµL©úÅã°Æ§@¥Î¡AŲ©ó¦w¥þ©Ê¦n¡BÀø®Ä©ú½T¡BÃÄ«~¥i¤Î¡A¤w«ØijºÉ§Ö¯Ç¤J¶EÀø·s«aªÍª¢¤è®×¡C

¤¤°ê°ê°È°|Áp¨¾Áp±±¾÷¨î17¤é¤U¤ÈÁ|¦æ¡uÃĪ«¬Ì­]©MÀË´ú¸Õ¾¯¬ãµo§ðÃö¡v°OªÌ·|¡A¤¤°ê¬ì§Þ³¡¥Íª«¤¤¤ß¥D¥ô±i¥ý¥Á»¡¡Aªk¤Ç©Ô­³¤w§¹¦¨Á{§É¬ã¨s¡AÅã¥Ü¥X«Ü¦nªºÁ{§ÉÀø®Ä¡C¥L»¡¡A¦b¦w¥þ©Ê¤è­±¡Aªk¤Ç©Ô­³¤w¸g©ó2014¦~¦b¤é¥»Àò§å±À¥X¥«³õ¡A¤W¥«¥H¨Ó¥¼¨£©úÅ㪺¤£¨}¤ÏÀ³¡F¦bªvÀø·s«aªÍª¢ªºÁ{§É¬ã¨s¤¤¡A¤]¥¼µo²{©úÅ㪺¤£¨}¤ÏÀ³¡C

±i¥ý¥Á«ü¥X¡A²`¦`¥«²Ä¤T¤H¥ÁÂå°|¶i¦æªk¤Ç©Ô­³Áp¦X¤zÂZ¯ÀªvÀø·s«aªÍª¢ªº¦³®Ä©Ê©M¦w¥þ©Ê¬ã¨s¡A¤J²Õ±wªÌ80¨Ò¡A¨ä¤¤ªk¤Ç©Ô­³²Õ35¨Ò¡A¹ï·Ó²Õ45¨Ò¡C

Âà³±©Ê®É¶¡©úÅãÁYµu

µ²ªGÅã¥Ü¡A¦b¯f¬r®Ö»ÄÂà³±©Ê¤è­±¡Aªk¤Ç©Ô­³ªvÀø²ÕªvÀø«á±wªÌ»P¹ï·Ó²Õ¬Û¤ñ¡AÂà³±©Ê®É¶¡¤¤¦ì­È©úÅãÁYµu¡A¤À§O¬°4¤Ñ©M11¤Ñ¡A¦³ÅãµÛ®t²§¡F¦b¯Ý³¡¼v¹³¾Ç§ïµ½¤è­±¡A»P¹ï·Ó²Õ¬Û¤ñ¡A§ïµ½²v¤À§O¬°91.43%©M62.22%¡C

¦Ü©óªZº~¤j¾Ç¤¤«nÂå°|ªºªk¤Ç©Ô­³ªº¹ï·ÓÁ{§É¬ã¨s¡A¤w§¹¦¨¦U120¨Ò¤J²Õ©MÁ{§ÉªvÀøÆ[¹î¡FÁ{§É¬ã¨sµ²ªGÅã¥Ü¡A¸ÕÅç²ÕªvÀø·s«aªÍª¢ªºÀø®ÄÅãµÛÀu©ó¹ï·Ó²Õ¡A¸ÕÅç²ÕÅãµÛÀu©ó¹ï·Ó²Õ¡A¤À§O¬°71.43%©M55.86%¡C

ªk¤Ç©Ô­³¬O¤@ºØRNA»E¦X酶¡]RdRp¡^§í¨î¾¯¡AÄÝ©ó¼sÃЧܬy·P¯f¬rÃĪ«¡A¥Ñ¤é¥»´I¤s¤Æ¾Ç¤u·~®è¦¡·|ªÀ¶}µo¡F2014¦~3¤ë¡A¤é¥»«p¥Í³Ò°Ê¬Ù§å­ãªk¤Ç©Ô­³¤ù¤W¥«¡A¥D­n¥Î©óªvÀø·s«¬©M´_µo«¬¬y·P¡C

¤¤°êªº®ü¥¿ÃÄ·~»P¤é¥»´I¤s¤Æ¾Ç¤u·~®è¦¡·|ªÀ¡A©ó2016¦~6¤ëñ­q¤Æ¦Xª«±M§Q¿W®a±ÂÅv¨óij¡CÀH«á¡A®ü¥¿ÃÄ·~»P¤¤°ê¤H¥Á¸Ñ©ñ­x­x¨ÆÂå¾Ç¬ã¨s°|¬rª«ÃĪ«¬ã¨s©Òñ­q§Þ³N¦X§@¨óij¡A¦X§@¶}µoªk¤Ç©Ô­³¶µ¥Ø¡C

¥t¤@¤è­±¡A¤é¥»ªF¨Ê¤j¾Ç¬ã¨s¹Î¶¤18¤é«Å¥¬¡A¤é¥»¶}µoªº«æ©Ê¯ØŦª¢ªvÀøÃĪ«¡u萘ªk¥q¥L¡v¡]Nafamostat¡^¡A¥i¦³®Äªý¤î·s«aªÍª¢¯f¬r¦bªì´Á¶¥¬q¶i¤J¤HÅé²Ó­M¡A¦³§U·P¬Vªì´Á¨¾¤î¯f±¡´c¤Æ¡A¥»¤ë¤º±N¶i¤JÁ{§É¹êÅç¡A¥H½T»{¨ä¦³®Ä©Ê¤Î¦w¥þ©Ê¡C

¥þ²y¦U°ê¬ì¾Ç®a¿n·¥¬ãµo·s«aªÍª¢¬Ì­]¡A¼w°ê¥Í§Þ¤½¥qCureVac­t³d¤HÀN´¶18¤éªí¥Ü¡A¸Ó¤½¥q¬ãµoªº¬Ì­]­Y¶i®i¶¶§Q¡Aªì®L§Y¥iÁ{§É¸ÕÅç¡A¦³±æ¦b¬î¤Ñ¤W¥«¡C

CureVac¤µ¦~¤@¤ë¶}©l¬ãµo·s«aªÍª¢¬Ì­]¡A¤é«e¶Ç¥X¬ü°êÁ`²Î¯S®Ô´¶¥´ºâ°ª»ù¶R¤UCureVacªº¬ì¾Ç®a©M§Þ³N¡A¬°¬ü°ê¿W®a¥Í²£¬Ì­]¡A¦ý¤w¾DCureVac§_»{¡C

¼Ú·ù«Å¥¬±N´£¨Ñ8000¸U¼Ú¤¸¸êª÷¤ä«ùCureVac¡A¸Ó¤½¥q«ü¥X¡A³oµ§¿ú±N¥Î¦bÁʶR¥Í²£³]³Æ¡A±N­ì¥i¦~²£4»õ¾¯¬Ì­]ªº²£¯àÂX¥R¦Ü40»õ¾¯¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃC10147871  µoªí®É¶¡:2020/3/20 ¤W¤È 10:12:37²Ä 8156 ½g¦^À³
¬ì¾Ç®a¬ã¨sºë¯«¦³¦nÃÄ«~¬O°ò¥»±ø¥ó¡A¤½¥q¿ï¾Ü¶i¸ê¥»¥«³õ´N¬O§Æ±æ®e©ö¨ú±o¤j²³¸êª÷¨Óµo®i¡A½Ð¬ì¾Ç®a­Ì§â°Ó¤H©Ê®æ¥[¤J ¨S¸êª÷¨S«H¤ß¥u¬O¦Û¤v»{¬°¤½¥q¦n¡A§ë¸ê¤H¤£»{¦P¨º´N¥¢¥h¤J¸ê¥»¥«³õªº·N¸q¤F¡C¤½¥q¤H­û­n»{¯u¬Ý«Ý
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/20 ¤W¤È 09:44:38²Ä 8155 ½g¦^À³
¶^¨ì¤U¥«¡H½æ¾x£« ³£°eÃÄÃÒ¼f¦X¤F ¤ñ¨º¨ÇÁÙ¦A°µ´X´Áªº¬Û¸û¤§¤U ¨º¨Ç¤£´N¦­­Ë³¬¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2020/3/20 ¤W¤È 09:41:56²Ä 8154 ½g¦^À³
°ò¥»­±§Ú­Ì³£»{¬°À³¸Óok! ¦ý¦³¨S¦³¨t²Î­·ÀI¡A²ö¦W¨ä§®ªºªø´Á§ë¸êªÌµ¥¤£¨ì°ò¥»­±¤ÏÀ³´N³Q¸ê¥»¹CÀ¸µ¹Ä묹±¼¡H

½è³]¤Ó¦hµL¤O°lúÂ_ÀY¡H

³Q­¢§C»ù¼W¸ê¨Sµ¹­ìªÑªF¿ï¾Ü³Q¾ã­Ó§ÆÄÀ½â½æ¡H¶^¤Ó¦h¶}©l½k«ä¶Ã·Q¡I §Úªø´Á«ù¦³±i¼Æ¤£¤Ö°Ú¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2020/3/20 ¤W¤È 09:20:52²Ä 8153 ½g¦^À³
¨S¿Ä¨é«ç»ò©ñªÅ¡H

²{ªÑ¶R½æ¡A»{½ß½æ¥X¦³¹H¤Ï¤°»ò³W©w¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GKilson10149103  µoªí®É¶¡:2020/3/20 ¤W¤È 09:14:49²Ä 8152 ½g¦^À³
¨C¤äªÑ²¼³£¦b¤Ï¼u °ß¿W³o¤äÁÙ¦bÄê ­n¶^¨ì¤U¥«¤F¬O¤£¬O¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/20 ¤W¤È 09:05:22²Ä 8151 ½g¦^À³
¦]¬°³o¤w¸gÄY­«¼vÅT¨ì¤½¥q¥H¤ÎªÑªFªºÅv¯q.... ¯uªº¤£¸Ó¬d¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/20 ¤W¤È 08:59:57²Ä 8150 ½g¦^À³
¸Ü»¡³o¤äªÑ²¼¨S¤HÅU, ¦ý±q³o¥b¦~¬Ý°_¨Ó, ¯uªº¬O¦³¤H¨è·N©ñªÅ¥L, ¤×¨ä³o´X¤Ñ§ó©úÅã.... ¤~·|©Ô±o³o»ò¨¯­W,..

¤½¥q¤£¥Î¬d¤@¬d¨ì©³¬O½Ö¦³¤°»ò¥Øªº... ½Ð¥L³Ü³Ü©@°Ø¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G»þ³·¾~10148547  µoªí®É¶¡:2020/3/20 ¤W¤È 04:01:58²Ä 8149 ½g¦^À³
¬Q¤Ñ¥x¿n¹q¤S¬O­û¤u±oªZº~ªÍª¢¡A¤S¬O°£®§ªº¡A©Ò¥H³sÀsÀY³£¼µ¤£¦í

²{¦b°ê¦w°òª÷«Å¥¬­n¶i³õÅ@½L¡A¤j®aÁ«ªºÀ³¸Ó¥i¥H¤Ö¤@ÂI¡A·Q¤J³õªº²{¦b¥i¥H»°§Ö¸ò­·¤@ªiÅo

udn.com/news/story/7251/4428288

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤U¤È 10:36:19²Ä 8148 ½g¦^À³
¥j¤Ú¡u¯«©_ÃÄ«~¡v §ð§JªÍª¢¤§Æ_¡H

2020-03-18 23:19 Áp¦X³ø ¶¾«Ø¤T¡þ¬F¤j·s»D¨t±Ð±Â¡]¥x¥_¥«¡^

¤@¤ë©³¡A¤¤°ê¤j³°¿ï¾Ü¤F¤ÊºØÃÄ«~¡A¹B¥Î©ó¶EªvCOVID-19ªÍª¢ªºÀøµ{¡C³Ìªñ¡A¡m¸gÀپǤH¡n¦C¥X¤­ºØ·~¤w´ú¸ÕªºÃÄ«~¡A«ü¨ä¨ã¦³¼ç¤OªvÀø¸ÓªÍª¢¡C¦b³o¨â²ÕÃij椤¡A³£¦³¥j¤Úªº¡ua2b¤zÂZ¯À¡v¡]¤UºÙa2b¡^¡C

¦b¤j¦h¼Æµo®i¤¤°ê®a©|¥¼¶i¤J¤§«e¡A¥j¤Ú¤w¦b¤@¤E¤K¤@¦~Äw³]¸ó¾Ç¬ìªº¥Íª«±M·~½×¾Â¡A¶È¤ñÁ|¥@²Ä¤@®a¥Íª«¬ì§Þ¥ø·~¡]ª÷¤sªºGenetech¡^±ß¤F¨â¦~¡C·í®É¡A¾A¥©¨â¥ó¨Æ±¡¨Öµo¡C

¤@¬Oµn­²¼ö¦b¤@¤E¤K¡³¦~©³¶}©l¹s¬P¦b¥j¤Ú¤¤³¡¡B¦è³¡»PªF³¡¥X²{¡A¦¸¦~¤­¤ë©x¤è½T»{¬y¦æ¡A¦Ü¤Q¤ë³Ì«á¯f¨Ò¤§«e¡A¦@¦³¤Ê¥|¸U¥|¤d¦h¤H·P¬V¡A°ª®p®É¤@¤é¼W¥[¤@¸U¤@¤d­Ó¯f¨Ò¡A«e«á­P¦º¤@¤K¡³¤H¡C¤G¬O¥j¤Ú¦Û¤vªº§V¤O»P©¯¹B¡C¤@¤E¤K¤@¦~¤T¤ë¡A¤»¦ì¥j¤Ú¤H«e©¹¾Ö¦³a2b¬ÛÃö§Þ³NªºªâÄõ¾Ç²ß¡A¸Ó°êÂå®v©Úµ´¥Ó½Ð¨ä§Þ³N±M§Q¡A°õ·N¶}©ñµ¹¥j¤Ú¤H¦b¤ºªº©Ò¦³¤H¨Ï¥Î¡C³o¨Ç¥j¤Ú¤H¶È¦b¤d´ò°ê¨ú¸g¤Q¤G¤é¡Aªð°ê¥|¤Q¤­¤Ñ«á¡A¦¨¥\¦Û¦æ´£·Ò¥Xa2b¡AÂå¾Ç¬ÉºÙ¤§¬°¡u¯«©_ÃÄ«~¡v¡A¤£¦ý¦¨¥\ªvÀø¡A¥B¦b¼sªx¹w¨¾±µºØ¤U¡Aµn­²¼ö±q¦¹¦A¨S¦³¦b®q°ê¬y¦æ¡A³ôºÙ¥[°Ç¤ñ®ü¦a°Ïªº¼Ò½d¡C

µn­²¼ö¥~¡Aa2bªºÀø®Ä¦b¹ïB»PC«¬¨xª¢¡B±aª¬¯p¯l¤ÎHIV-AIDSµ¥¯e¯f¡A¤]³£¤w¸g±o¨ìªÖ©w¡C¤G¡³¡³¤T¦~¤¤¥j¨â°ê¦X¸ê¦¨¥ßªø¬K®ü§Bº¸¥Í§Þ¤½¥q«á¡A¤w¦b¤G¡³¡³¤K¦~±À¥Xa2bª`®g²G¡A¥B«Ü§Ö±o¨ì»{¥i¡A¡u¤f¸O·¥°ª¡v¡C ¦p¤µ¡AÂå¬É»{¬°a2b¹ï©óÃþ¦üCOVID-19ªº¯f¬rªvÀø¡AÀ³¸Ó¦³®Ä¡A¥i¥Hªý¤î¯f±¡´c¤Æ»P­P¦ºªº¨Öµo¯g¡C

·í¦~ªº¯«©_¤§ÃÄa2b¡A³o¦¸¬O§_¯à°÷¦A¦¸¯«©_¡AÁ٫ݤÀ¾å¡C¤£¹L¡A°£¤Fªñ¾F¤ú¶R¥[°Ó½Ð¥j¤Ú¨ÓÀ°¦£ ¡A¤]¦³¤£¤Ö©Ô¤B¬ü¬w°ê®a¦p¤Ú®³°¨¡B©e¤º·ç©Ô¡B´¼§Qµ¥¦V¥j¤Ú¶i¤f¸Ó¶µ²£«~¡F¬Æ¦Ü¡A¹ï«¢¥Ë¨º«Ü¤£¤Íµ½¡B¥h¦~µ¥©ó¬OÅXÂ÷¥j¤ÚÂå¥Íªº¤Ú¦è¡A¤]¦]¬Ì±¡Âà´c¦Ó­n½Ð¥j¤Ú¬£»ºÂå¥Í¡C§ó»·ªº«nÁú»P¼w°ê¡A¤]³£¤w¨Ï¥Îa2b¡A¦b¨ä¤K¤d¦h»P¤E¤d¦h¯f±w¤¤¡A¦º¤`¤H¼Æ¬Û¹ï¸û§C¡A¤À§O¬O¤K¤Q¥|»P¤Ü¤»¤H¡C

¥j¤Ú¤]¬£»º¤@²ÕÂåÅ@¤H­û¡A¨ó¦P¤j³°±M®a«e©¹À°§U¸q¤j§Q¡F­^°ê¶l½ü¥¬¹pÀq¸¹¦b¦Y¤F¦h°ê³¬ªùü«á¡A³Ì«á¥Ñ¥j¤Ú±µ¯Ç°±¾a¨ä´ä¤f¡A¦³¤@¤d¦h­¼«È¡A§t¥|¤Q¤­¦ì½T¶E©Î»Ý¹jÂ÷ªº¤H¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2020/3/19 ¤U¤È 04:32:35²Ä 8147 ½g¦^À³
We¤j~¥»ª©¦³µù©ú¡AµL²z¥´À£½Ð¦Ü±z¶}ª©ªºª©°Ï¡AÁÂÁ±zªº¦X§@
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwe10146468  µoªí®É¶¡:2020/3/19 ¤U¤È 02:45:00²Ä 8146 ½g¦^À³
¹C¥Á¯u¬O²{¥@³ø ¤^°Q¿ú³£§ë¸ê6446¤F ³s¥hªü¤½©±ºN¨â§âªº¿ú ³£®½µ¹°ª级¬üÄyµØ¸Ç¬ì¾Ç®a¤F

´H­·¨ë°©¥´³¾ºj¤p¤ß·P«_¤F ¬Ý¨ì»¡¸Ü§¨¬v¤åªº¤H­n°{»·¨Ç ¸U¤@¤¤¤F¤°¯f¬r

³o½ú¤l´N¯u¬Ý¤£¨ì¸Ñ®M¤F🤣🤣🤣🤣🤣🤣🤣

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/19 ¤U¤È 01:06:30²Ä 8145 ½g¦^À³
Linbad,

§Ú¦^µª§Aªº°ÝÃD¡A¬O°ò©ó¸ê®Æªº»`¶°»P¨DÃÒ¡C

»¡§A¦³·Q¹³¤O¬O§Ú±q§Aªº±À½×©Ò¬Ý¨ìªº²{¶H¡C

(¨Ò¦p:¬O§_¥Îªº´N¬OÃĵتº¤zÂZ¯À¡H¦]¬°pesgays¦b¥xÆW¤w¸g°±¤î³c°â¤F)

(¨Ò¦p:Pegasys¦pªG¯à°÷¥Î©ó·sª¬«a¯f¬r¡A¥ÎÃĵØRopeginterferon¡AP1101 ¤£¬O®ÄªG§ó¦n¡H)

³Ì«á¤@¥y¸Ü­n§A¥h¶R¯«ÃĪѡAªº½T»Ä¤FÂI¡A¸ò§A­Pºp¡AªÍª¢ªº¸ÜÃD´N¤£¦A°Q½×¤F¡C

»{¦P¦³¦ìºô¤Í»¡ªº¡AªÍª¢ªº¨Æ´N¥æµ¹¤Ñ®ð(§Ú¸É¥RÁÙ¦³±MªvÃĪ«·ç°¶¦è¼w©M¬Ì­])¡A§O¦Aµ¹ÃĵØÀ£¤O¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/19 ¤U¤È 12:26:47²Ä 8144 ½g¦^À³
ÃĵØÃĤjªÑªF½è³]ªºªÑ²¼¬O¤£¬O¤w¸g³QÂ_ÀY¤F?

3/17¦³¤½§i¶ÀÁ`½è³],À³¸Ó¬O³Q°lú¡A¥u¦n¦A¼W¥[³]½èªÑ²¼!?

«¥´N¬OªF¦è´ê¶Ã²q¡A¨DÃҽЪ½±µ°Ý¶ÀÁ`!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤U¤È 12:19:06²Ä 8143 ½g¦^À³
¤pªL¡A

§A¤H«Ü»Ä

¤£¬O¤@¯ë¤Hª«¡C

¥Ì«ô¤U­·¡A¨ØªA¨ØªA¡C

½×¾Â¤£¬OÅý¤j®aºÉ¨ä©Ò¨¥ªº¡H

·N¨£¤£¦P¡AÀ³¸Ó¥i¥H²z¸Ñ

¤£¹³ÃĵءA¤@­Ó¤H»¡¤Fºâªº¤@¨¥°ó¡C

»Ä¤H®a·Q¹³¤O¤ÓÂ×´I

»Ä¤H®a¥h¶R¥i¥HªvÀøªZº~ªÍª¢ªº¯«ÃÄ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¿c¦³ªK10149122  µoªí®É¶¡:2020/3/19 ¤U¤È 12:14:54²Ä 8142 ½g¦^À³
§ÚÄY­«®M¨c¤¤¡A§Ú·Q½Ð°Ýªº¬OÃĵØÃĤjªÑªF½è³]ªºªÑ²¼¬O¤£¬O¤w¸g³QÂ_ÀY¤F¡A³o¼Ë¹ï¤½¥qªºÀç¹B·|¦³¤°»ò°ÝÃD?ÁÙ¦³¬F©²ªº¶}µo°òª÷¬O§_ÁÙ¯àª`¸ê¡]¦³¤W­­¶Ü¡^

?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/19 ¤U¤È 12:01:13²Ä 8141 ½g¦^À³
Linbad,

§A¹ïªvÀø·s«aªÍª¢ªº·Q¹³¤O«ÜÂ×´I¡A§Ú´N¤£¦A¦^´_¼â§A§N¤ô¤F¡C

©Î³\§A¥i¥H§â¦U°Q½×°Ï¡Aºô¤Í­Ì±À±R¯àªvÀøªÍª¢ªº¦UºØ¯«ÃĪѳ£¶R¤U¨Ó¡A¬Ý¥¼¨Ó¦³¨S¦³¾÷·|¤jÁÈ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/19 ¤W¤È 11:48:59²Ä 8140 ½g¦^À³
Linbad,

ÃĵؼW¸ê¦³§Æ±æ¦¨¥\¡H

-->§Ú¤£¬O¥b¥P¡A«ÜÃø¦^µª°²³]©Ê°ÝÃD

¦pªG¦ÑÃÄ·s¥Î ¤zÂZ¯À¨Ö¥Î¨ä¥LªºÃÄ ³£¨S¦³¾÷·|¤F¡C¼W¸ê»ù91.5¤¸ ¤£¹L®ü¥«¸Â¼Ó¦Ó¤w

-->PV ET´N¬O¤zÂZ¯Àªº¦ÑÃÄ·s¥Î¡A¨Ö¥Î¨ä¥LÃĤ]¦³¾÷·|¡A¥u¬O§O¾¬±æªÍª¢ªºÃD§÷

§A¦³§ë¸êÃĵتѲ¼¡HÁÙ¬O¶È¶È¬O¹C«È¡H

-->§ë¸ê¾Þ§@¨ú¨M©ó­Ó¤H¡C§Aª¾¹D§Ú¦³¤S¦p¦ó? §Aª¾¹D§Ú¨S¦³¤S¦p¦ó?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤W¤È 11:42:01²Ä 8139 ½g¦^À³
¤pªL¡A

¤£¦P·N¡C

§A»¡¡G¹ï§Ü·s«a¯f¬rÁÙ¬O¬èë±MªvÃĪ«»P¬Ì­]ªº¶}µo§a!

µ¥«Ý·sÃĤά̭]¥X¨Ó¡A³Ì§Ö¤£¥Î¤@¦~¥b¸ü¡H

²{¦b­«¯gªº¤£¬O§¤¥H«ÝÀÅ¡H¦å¬y¦¨ªe

Ãĵجãµo¤ÎÁ{§É¸ÕÅç¤Î®³¨ìÃÄÃÒªá¤F¦h¦~¡H

§A¥i´¿ºâ¹L¡C

À³«æ¤§¤U

¦ÑÃÄ·s¥Î¬O¥i¦æªº

¤zÂZ¯À¨Ö¥Î¨ä¥¦ÃÄ¡A¤]¬O¦³Àø®Äªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/19 ¤W¤È 11:14:19²Ä 8138 ½g¦^À³
¤µ¤Ñ±þÁn¶©¶© ³sª÷¿ÄªÑ¤]Âê¶^°± ¶^¨ì³£µL·P¤F

3¤ë¥÷¤£¬O­n¹ê¬I¹sªÑ¥æ©ö ¨ì®É«á¦A¤À§å¸É£¸¨Ç¦n¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤W¤È 11:00:05²Ä 8137 ½g¦^À³
¤pªL¡A

¦A½Ð±Ð¤@­Ó°ÝÃD

ÃĵؼW¸ê¦³§Æ±æ¦¨¥\¡H

¦pªG¦ÑÃÄ·s¥Î

¤zÂZ¯À¨Ö¥Î¨ä¥LªºÃÄ

³£¨S¦³¾÷·|¤F¡C

¼W¸ê»ù91.5¤¸

¤£¹L®ü¥«¸Â¼Ó¦Ó¤w

§A¦³§ë¸êÃĵتѲ¼¡HÁÙ¬O¶È¶È¬O¹C«È¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤W¤È 10:02:47²Ä 8136 ½g¦^À³
§ë¸êÃĵثܤ[«Ü¤[«Ü¤[¤F

¤@ª½³£¨S¦³½æ

³Ìªñ¦b¤@ª½¦b·Q¤@­Ó°ÝÃD

ÃĵتѻùÀHµÛªZº~ªÍª¢¯f¬r¤@ª½¸¨¡A

¤@ª½¸¨

¤@ª½¸¨

¤@ª½¸¨

¶¶«K²M¤@²MÄw½X

§Ú·Q¦pªGªÑ»ù¦b¤G¡A¤T¦~«á©Î¬O¤T¦~¤­¸ü

¬O§_­«·s¦^¨ì170¥H¤W¡H

¶È¶È¬ÝÃĵجü°ê¤l¤½¥qªº¦¬¤J¹w¦ô

¦b109-113¦~¦@¦³288»õÀ禬¡A¬Õ¾l38.5»õ

¤£§t¼Ú¬w¤À¼í¤Î¤é¥»À禬

¬Ý°_¨Ó¡A¬O¦³¥i¯à¹F¦¨ªº¡C

²{¦b§C©ó¦h¤Ö

¹ï§Ú¤@ÂIÃö«Y³£¨S¦³

§ÚÁÙ¦n

¤ßŦ°÷±j

¤£®t¿ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwe10146468  µoªí®É¶¡:2020/3/19 ¤W¤È 09:36:59²Ä 8135 ½g¦^À³
¶^¨ì¤G¤Q¤¸§Ú·|§Ôµh¦Ò¼{¶R¤@±i·í¤j¤j¤jªÑªF🤣🤣🤣🤣🤣🤣
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2020/3/19 ¤W¤È 09:22:58²Ä 8134 ½g¦^À³
3/13©xºôªº·s»D°ÊºA¤£ÃѦ³»¡©ú¤½¥q¤w¦æ¤å¥DºÞ¾÷Ãöªí©úÄ@µLÀv´£¨ÑÃÄ«~µ¹¬ÛÃöÂåÀø³æ¦ì°µ·s«aªÍª¢ªºªvÀø.....

¬°¦ó­n¤@ª½¤£§å§P©O?ÁÙ¬OÃĵإi¥H¬°©Ò±ý¬°?

¥x¿n.©M®õ¨®...ªÑ»ù¤]¬O¯O«CÁÉ,¨º¤]­n±Ð¥x¿n«ç»ò°µ»sµ{?©M®õ¨®«ç»ò½æ¨®¶Ü?

­Ó¤H¤£¾AÃĵتº¾ÖÅ@ªÌ,§ë¸ê·l¥¢¤]¬O·s¦A½ö

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/19 ¤W¤È 09:21:41²Ä 8133 ½g¦^À³
Linbad,

Pegasys¾P°â¡A¸òP1101´£¨Ñ®¦·OÀøªk¡A¨âªÌ¦³¦ó¬Û¤z°Ú? ¾AÀ³¯g¤S¤£¤@¼Ë!

Pegasys¦pªG¯à°÷¥Î©ó·sª¬«a¯f¬r¡AP1101¤£¬O®ÄªG§ó¦n¡H (????)

³o¬O­þ¨Óªº¬ì¾ÇÃÒ¾Ú? ¤£­n¥Î·Q¹³ªº¡C

¤zÂZ¯À¥u¬O¥Î¨Ó§@¬°¤ä«ù©ÊÀøªk(»Ý­n®É)ªº¿ï¾Ü¤§¤@¡A¹ï§Ü·s«a¯f¬rÁÙ¬O¬èë±MªvÃĪ«»P¬Ì­]ªº¶}µo§a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/19 ¤W¤È 09:15:39²Ä 8132 ½g¦^À³
Maia Anderson -Tuesday, February 4th, 2020

41 brand-name drugs slated to lose patent exclusivity this year

www.beckershospitalreview.com/pharmacy/41-brand-name-drugs-slated-to-lose-patent-exclusivity-this-year.html

ù¤ó¦ü¥G¦³¥Ó½Ð±M§Q©µªø,µ¥«Ý®Ö­ã?

§ë¸ê¤H¦]¬Ì±¡­P«H¤ß±Y¼ì,°ò¥»­±§Þ³N­±Äw½X­±§¹¥þ¨S¥Î.

µ¥«Ý¯«ÃÄ¥X²{!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/19 ¤W¤È 08:44:37²Ä 8131 ½g¦^À³
¤pªL¡A

Pegasys¦pªGÁÙ¦³¦b¥xÆW½æ¡A

¬°¦óÃĵإi¥H´£¨Ñ®¦·OÀøªk

µ¹¥xÆWPV±wªÌ¡H

¤Î¬ü°êPV±wªÌ¡H

¬d¹L¸ê®ÆPegasys´¿¸g¦b¥xÆW°±°â

Pegasys¦pªG¯à°÷¥Î©ó·sª¬«a¯f¬r

¥ÎÃĵØRopeginterferon¡AP1101 ¤£¬O®ÄªG§ó¦n¡H

Ãĵؤ@ÂI³£¤£§V¤O¬Ý¬Ý¡H

§Ú»{¬°¥i¥Hªº

¼W¸ê¦¨¥\»P§_¡A

´N¾aÃĵؤzÂZ¯À¬O§_¯à°÷¥Î©ó·s«aª¬¯f¬r

ªºªvÀø¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/19 ¤W¤È 08:41:18²Ä 8130 ½g¦^À³
1. Pegasys¦b¥xÆW¥u«O¯d90·L§J/0.5²@¤É¥]¸Ë¡C

¨ä¾l135»P180³\¥iÃÒ¹O´Á¤wµù¾P (¤]¬Ý¨ì°ê¥~¦³°±²£135/180¥]¸Ë°T®§¡A¥t¥~pegasys±M§Q¤µ¦~¨ì´Á)

info.fda.gov.tw/MLMS/H0001.aspx

2.°·«O¸p¤½§i:108¦~²Ä2©u³\¥iÃÒ¹O´Á«~¶µÂk¹s ¥Í®Ä¤è¦¡/¤é´Á108/08/01

www.tainanpharma.com.tw/adm/news/picture_img/d_20190925091549.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/19 ¤W¤È 08:17:29²Ä 8129 ½g¦^À³
¥xÆWù¤ó©xºôÁÙ¦³Pegasys¡A°·«O»ù¤@¤ä¬ù3¤d¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/18 ¤U¤È 10:28:15²Ä 8128 ½g¦^À³
andytom¤j...+1

¤µ±ß¸ò¤@¦ì·|­p®v«e½ú½Ð±ÐÃĵعw¦ôªº¤º®e...

±o¨ìªºµ²½×¬O³\¦h¤W¥«¤½¥q¡m¤l¡A¥À¡n¤½¥qªº°µªk¬Ò¬O¦p¦¹...

¦]¬°¤l¤½¥q¬O³]¦b¤£¦P°ê®a¡Aµ|¨î¤]¤£ºÉ¬Û¦P......µ¥µ¥­ì¦]¡A©Ò¥H§Q¼í¥Ñ¥À¤½¥q±±¨î¡K

¥H¤½¥qªº¤½¶}»¡©ú®Ñªº°]³ø¹w¦ô...

¦pªG±N¤j³¡¥÷ªº§Q¼í¬O¯d¦b¥À¤½¥qªºÀç·~¦¬¤J¡A¨º±N¨Ó¤½¥qªºÀò§Q¬O«D±`¦³¦Û«Hªº...

¡m«ùªÑ100%ªº¤l¤½¥q¡n»P¬O¡m»{¦C¼Ò¦¡¡n......

©Ò¥Hµ´¤j³¡¥÷ªº¦¬¯q»P§Q¼í·|ª½±µ¦b¥xÆWÃĵؤ½¥qªº°]³ø¤W¡A¦ý¥¼¨Ó³v¦~¥i»{¦Cªº§ë¸ê¦¬¯q¦¨ªø¬O«D±`ªºÅå¤H......

¤]¦³¥i¯à¥¼¨Óªº¤é¥»¥«³õÀ³¸Ó¤]¬O±Ä¨ú³o¼Ò¦¡¡C

¤]´N¬O¥À¤½¥q¥X³fµ¹¤l¤½¥q¥ýÁȤ@¤â¡A¬ü°ê»P¤é¥»ªº¤l¤½¥q¨C¦~¦AÃB¥~»{¦C¦¬¯q......¦p¦¹¤@³½¨â¦Y°Õ...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2020/3/18 ¤U¤È 08:13:24²Ä 8127 ½g¦^À³
´N»¡¤F¡A¤½¥q¸Ó½Ð¤@­Ó±M·~ªº°]°Èªø°µªø´Á³W¹º¡A

¥u¦³ÃÒú³¸gÅ窺¤p¥DºÞ©ÎªÌ»¡¦Û¥H¬°©x¤j¾Ç°Ý¤jªº°ª¼h¦³¯à¤O¥i¥H´ç¹L³o¦¸¦M¾÷¶Ü?

£¸ª½¥H¨Ó¨S¦³£¸­Ó±M·~ªº°]°Èªø°µªø´Á³W¹º¡A°ª¼h´N¬O³o¼Ë®³µÛªÑªFªº¿ú¡A¤j¤â¤j¸}ªºªá±¼

¿úÁÙ¨S¨ì¦ì¡A¤é¥»©M¤¤°êÁ{§É¤]³£ÁÙ¨S·d©w´NÅx¤j¿úÂX±i¤½¥qªº²Õ´

¤½¥qÁÙ´±»¡109¦~²Ä¤G©u·|²£¥Í¸êª÷¯Ê¤f

ºÞ²z¼h¨S°]°Èªø°µ°]°È±±ºÞÁÙ´±¸òªÑªF­n¿ú

¨S°]°Èªø°µªø´Á³W¹º©M°]°È±±ºÞ¡AºÞ²z¼h²{¦bªºªá¿ú¤è¦¡´N¬O£¸­Ó¸É¤£§¹ªº¶Â¬}

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/18 ¤U¤È 08:09:49²Ä 8126 ½g¦^À³

¦A¦¸­«ÂжK¤W¡A¤zÂZ¯À¯uªº¥i¥H¥Î¨ÓªvÀø·s«aª¬¯f¬r¡C

¡X¡X¡X¡X¡X

2019 ·s«¬«aª¬¯f¬r(2019-nCoV)·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ

¦æ¬F°|½Ã¥ÍºÖ§Q³¡¯e¯fºÞ¨î¸p ½s 2020 ¦~ 2 ¤ë 2 ¤é²Ä¤Gª©

¤E¡B °w¹ï 2019-nCoV ¤§§Ü¯f¬r»P¨ä¥LªvÀø

2019-nCoV ¤§§Ü¯f¬r»P¨ä¥LªvÀø

¥Ø«e¨S¦³¨Ó¦Û RCT ¬ã¨sªºÃÒ¾Ú¤ä«ù¥ô¦ó§Ü¯f¬rÃĪ«ªvÀøºÃ¦ü©Î½T¶E 2019-nCoV ·P¬V ¯f¨Ò

¡A¬ÛÃöÃÒ¾Ú¥D­n¨Ó¦Û¦P¬°«aª¬¯f¬rªº SARS »P MERS-CoV ¤§ªvÀø¸gÅç¡BÁ{§É»PÅé ¥~¸ÕÅçµ²ªG¡C¹ï SARS »P MERS-CoV¡AÁöµL WHO »{ÃÒªº¼Ð·ÇÀøªk

¡A¦ý´¿³Q¥Î©óªv ÀøªºÃĪ«¥]¬A¦hºØ§Ü¯f¬rÃĪ«(ribavirin, lopinavir/ritonavir, remdesivir)¡B¤zÂZ¯À (interferon-£\, interferon-£])¡B¯f±w«ì´_´Á¦å²M»P³æ®è/¦h®è§ÜÅéµ¥

¡C¦Ò¶q 2019-nCoV ­Ó®×Á{§ÉÄY­«µ{«×¡B¶Ç¼½¤O¡BªvÀø¥i¯àªº®Ä¯q»P­·ÀI¤ÎÃĪ«¾AÀ³¯g ¥~¨Ï¥Î¤§­Û²zijÃD¡A«Øij¸gÁ{§É±M®aµû¦ô»P¥R¤À§iª¾«á¡A¥i¦Ò¼{¹ï©ó¦~ÄÖ¡Ù18 ·³¤§½T ©w¯f¨Ò¡A°Ñ¦Òªí¤@ WHO Á{§Éªí²{¤ÀÃþ¡A¹ï¦³ÄY­«ªÍª¢©Î«æ©Ê©I§lµ~­¢¯g­Ô¸sªº±wªÌ¦b µo¯f¤Q¤é¤ºµ¹¤©ªvÀø¡C«Øij¥i¦Ò¼{¨Ï¥ÎªºÃĪ«¬° Lopinavir/Ritonavir (200mg+50mg/tablet) 2# PO BID¡A³æ¿W¨Ï¥Î¡A©Î¦X¨Ö¨Ï¥Î Interferon-£]1b 0.25 mg SC QOD5¡Aª½¨ì±wªÌ³sÄò¨â¦¸©I§l¹DÀËÅé(¦Ü¤Ö¶¡¹j 24 ¤p®É±ÄÀË)ÀËÅçµ²ªG§¡ ¬°³±©Ê¬°¤î¡AÀøµ{¦Ü¦h¤Q¥|¤Ñ¡C­Y±wªÌ¤wª¾¹ïªvÀøÃĪ«¹L±Ó¡A«h¤£«Øijµ¹¤©ªvÀø¡CµL ¨Öµo¯g¤§»´¯g©Î»´«×ªÍª¢±wªÌ¡A¶·§ó¼f·Vµû¦ô¬O§_¨Ï¥Î¦¹ÃþÃĪ«ªvÀø¡A«Øij¥i¿Ô¸ß·P ¬V¬ì±M¬ìÂå®v¡C

³Æµù:¤åÄm¦^ÅUÅã¥Ü¡ALopinavir/Ritonavir »P Interferon ¦bÅé¥~¸ÕÅ礤¹ï MERS-CoV ¦³§í

¨î©Ê®ÄªG ¡C¤HÃþÆ[¹î©Ê¬ã¨s«hÅã¥Ü¡A¨Ï¥Î Lopinavir/Ritonavir ¦X¨Ö Ribavirin¡A¬Û¸û©ó¶È

¨Ï¥Î Ribavirin¡A¥i­°§C SARS ¯f±w¦º¤`²v 3¡C¥Ø«e¶i¦æ¤¤¤§ MERS-CoV ªvÀøÁ{§É¸ÕÅç

(NCT02845843)«Y¦P®É¨Ö¥Î Lopinavir/Ritonavir »P Interferon-£]1b5¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/18 ¤U¤È 08:04:51²Ä 8125 ½g¦^À³
Ãĵئ³¦¨¥ß±M®×

§â¤zÂZ¯À¥Î¦bªZº~ªÍª¢¯f¬rªºªvÀø¡H

¦pªG¦³

¨º¤Ñ¤½§i¡A¨º­Ó°ê®a¥ÎÃĵؤzÂZ¯À

ªv¡ªZº~ªÍª¢

§Ú»{¬°¤é¥»¡A¬ü°ê¡A¥xÆW¡AÃĵئ³¤À¤½¥q¡A

Âå¬ÉÃö«Y¤]¬Û·í¦n¡A¥i¥H±À°Ê¬Ý¬Ý¡C

¦pªG¥ì®Ô¡A¸q¤j§Q¤]¥Î¨º»ò´N¤Ó´Î¤F👏

ÃĵؼW¸êÁÙ¬O­Ó°ÝÃD¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/18 ¤U¤È 06:54:58²Ä 8124 ½g¦^À³
´X¤Ñ«eªº¡e¦~¥N¦V¿ú¬Ý¡f

¥D«ù¤H¦³´£¨ì¥xÆW¦³´X¨Ò·s«aª¬ªÍª¢½T¶E¯f¨Ò

¬O¦ÑÃÄ·s¥Î

¥Î¤zÂZ¯ÀªvÀø²¬Â¡ªº¡]¤£ª¾¹D®ø®§¨Ó·½¡^

¬O§_¥Îªº´N¬OÃĵتº¤zÂZ¯À¡H

¦]¬°pesgays¦b¥xÆW¤w¸g°±¤î³c°â¤F

Ãĵثܦ­´N´£¨ÑP1101§@¬°¥xÆWPV±wªÌªº®¦·OÀøªk

¦~¥N¦V¿ú¬Ýªººô§}¡G

youtu.be/BKeCXls_q4o

®É¶¡25¤À

¦³´£¨ì¥xÆW«e´X¨Ò³£¬O¤zÂZ¯ÀªvÀø¦nªº

¦pªG¬OÃĵتº¤zÂZ¯À¯u¥i¥Hªv¡·s«aª¬ªÍª¢

Ãĵؤ]ºâ¬O°µ«Ü¤jªº¥\¼w

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10148886  µoªí®É¶¡:2020/3/18 ¤U¤È 03:27:05²Ä 8123 ½g¦^À³
»ù¦ì¨ì³o§C.µw°õ¦æ¼W¸ê.¤£´¼.¥i¦Ò¼{»È¦æ­É¶U.¥ý¸É¨¬¸êª÷¯Ê¤f.«Ý¦æ±¡¦^í¦A¼W¸êÁÙ´Ú...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/18 ¤U¤È 02:02:30²Ä 8122 ½g¦^À³
¨Ì¾a«Ü¤[¥H«áªº¹w¦ôÀ禬·í¶RªÑªº¨Ì¾Ú­·ÀI«Ü¤j°Ú
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2020/3/18 ¤U¤È 01:11:04²Ä 8121 ½g¦^À³
6446 ´N¹³¤@­Ó¯ÀÃC¤j¬ü¤k,¥i¯à¤ñ¦w¤ß¨È©MªL§Ó¬Âº}«G, ¦ý¥Xªù©M¤W¸`¥Ø³£¤£¤Æ§©, ©Ò¥H©O? ´CÅ餣·R,¤j®a¤£¬Ý
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2020/3/18 ¤U¤È 12:40:33²Ä 8120 ½g¦^À³
¬Ý°_¨Ó°ò¥»­±³£«Ü¦n

¦ýªÑ»ù«o«ÜÁV

­ì¦]¬Oªk¤H¤£¶R³æ¤Ï¦Ó°±·l

¤½¥qÀ³¸Ó­n¥hÅ¥¬Ý¬Ýªk¤H¦b·QÔ£

¦Ó¤£¬OÃö¦b¶ð¸Ì­±

¥»¯q¤ñ¬O¥«³õµ¹ªº¡A¥u¦³²b­È¬O¯uªº

Ãø¹D¤½¥q­n©éªÑ»ù²b­È¤ñ¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/18 ¤U¤È 12:35:31²Ä 8119 ½g¦^À³
9000¥x¹ôªºÃĽæ¥XÅÜ9¸U ³o¼Ë¤ò§Q¬O´X­w£«¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/18 ¤U¤È 12:03:12²Ä 8118 ½g¦^À³
­Ó¤H»{¬°¤½¥q·í°È¤§«æÀ³¸Ó¥ýí¦íªÑ»ù.. ²¦³º¸Ó½æªº, ·Q­n½æªº, ¤£±o¤£½æªº¤]À³¸Ó³£½æ¤F, ³Ñ¤U¤j³¡¤ÀÀ³¸Ó´N¬O³Ì®¼¤½¥qªº¤H¤F...

±µµÛ°t¦X«áÄòªº§Q¦h, ¤ñ¦pTFDA, ¥X³f·~ÁZ,..µ¥... ¤@¨B¤@¨B¦a¦¬¦^À³¸Ó¦³ªÑ»ù¤~¬O, ¤£­n¦AµS¿Ý¤F!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·s¶i10143606  µoªí®É¶¡:2020/3/18 ¤W¤È 11:54:51²Ä 8117 ½g¦^À³
¥H¤½¶}»¡©ú®Ñ75­¶ªº»¡©ú­pºâ¤U¨Ó¨C°w¥X³f»ù¤£¨ì¥x¹ô9000¤¸......

¼Ú¬w¥­§¡°â»ù¨C°w¦b¼Ú¤¸3000¤¸......©Ç¤£±o¸òAOP¦³ª§Ä³¤F¡I

¤½¥q¦³¶i¨B¤F¡A¶}©l¾Ç²ß¦p¦ó¤£«H¤f¶}ªe°µ¤H¤F¡I

ªÑ»ù±þ¨ì³o­Ó»ù¦ì¯u¤]¤£¶Q¤F¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶³²H­·»´10146472  µoªí®É¶¡:2020/3/18 ¤W¤È 10:08:28²Ä 8116 ½g¦^À³
¤½¶}»¡©ú®Ñ P.75

Besremi 108¦~ ¥X³f3.3 ¸U¤ä? ¥X³f»ù ¬ùNT$9¥a/¤ä?

3.3 ¸U¤ä­Y¤@¦~¥Î§¹, ¯f¤H¬ù¤W¤d¤H?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gandytom10148211  µoªí®É¶¡:2020/3/17 ¤U¤È 11:13:19²Ä 8115 ½g¦^À³
¯u¤£´±¬Û«H§Úªº²´·ú,»¡©ú®Ñ¤W©ú©ú»¡¬OÃĵػ{¦CPharmaEssentia USA ·l¯q,ÁÙ¦³¤H»¡¤ò§Q¤£¨ì¤­¦¨,¬O¤£·|¬ÝÁÙ¬O¬G·Nªº,Ãĵؽ浹PharmaEssentia USA ÃĪº§Q¼í¤£¥Îºâ¶Ü?¦Ó·sÃĤ@¯ë¤ò§Q³£9¦¨³o¥y¸ÜÀ³¸Ó¬O°Ñ¦ÒÃĵؽ浹AOPªº¤ò§Q§a!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©ú10146339  µoªí®É¶¡:2020/3/17 ¤U¤È 11:00:40²Ä 8114 ½g¦^À³
·PÁÂroger¤jªº«ü±Ð¡A¤p§Ì¤@®É²¨©¿¬Ý¿ù¤F¡A­ì¨Ó¬O¬ü°ê¤l¤½¥qªº¹w¦ôÀ禬¡A¹ê¦b©êºp°Õ¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/17 ¤U¤È 09:41:42²Ä 8113 ½g¦^À³
ªL¤j´Nª½±µÂW¯}¨º­Ó iview.sina.com.tw/post/22127690¬O°²·s»D¤£´N¦n Orz.

«¥¥¿¥©¦b¬Ý¤½¶}»¡©ú®Ñ¡A¦³¬Ý¨£´Nµ¹¥L½Æ»s¶K¤W.

³o¬q[¥H´Nªñ¶i¦æ¬ü°ê¦a°Ï[ÃÄÃÒ¥Ó½Ð]¤Î¦æ¾P¬¡°Ê]---«¥±À½×¤£¦X²z¤]¤£²Å¨Æ¹ê?

...............................................................................

...............................................................................

¥t°ò©ó¬ü°ê¬O¥þ²yÃÄ«~³Ì¤j¥«³õ¡A¬GÅܧó«á­pµe·s¼WÂà§ë¸ê¬ü°ê[¤l¤½¥q] PharmaEssentia USA Corporation¡A¥H´Nªñ¶i¦æ¬ü°ê¦a°Ï[ÃÄÃÒ¥Ó½Ð]¤Î¦æ¾P¬¡°Ê¡CP86

doc.twse.com.tw/pdf/202003_6446_B011_20200317_160005.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/17 ¤U¤È 08:50:09²Ä 8112 ½g¦^À³
ROGER, ±z¤´Â³ßÅw¦Û¤vªF´ê¦è´ê¶Ã²q¡A¨DÃÒ¬O­n¬d¸ß­ì©l¥X³Bªº¤º®e¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/17 ¤U¤È 08:43:19²Ä 8111 ½g¦^À³
Linbad, ¾Þ§@¨ú¨M©ó­Ó¤HÄÝ©Ê¡A¨S¦³¥¿½T»P§_¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/17 ¤U¤È 08:36:18²Ä 8110 ½g¦^À³
±qÃĵؤ½¶}¼W¸ê»¡©ú®Ñ

¥i¥H§PÂ_

ÃĵجO­È±oªø´Á«ù¦³

ªÑ»ù¤­¦~«á

¶R³£¶R¤£¨ì¡]ªüÁøªü¶ý¥Î»y¡^

¤£§Qµu´Á¾Þ§@

¤pªL¡A

³o¼Ë§PÂ_¬O§_¥¿½T¡H

½Ð§A¶}¥Ü¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/17 ¤U¤È 08:30:23²Ä 8109 ½g¦^À³
¡C¥t°ò©ó¬ü°ê¬O¥þ²yÃÄ«~³Ì¤j¥«³õ¡A¬GÅÜ

§ó«á­pµe·s¼WÂà§ë¸ê¬ü°ê[¤l¤½¥q] PharmaEssentia USA Corporation¡A¥H´Nªñ¶i¦æ

¬ü°ê¦a°ÏÃÄÃҥӽФΦæ¾P¬¡°Ê¡C

¤£¬O¤À¤½¥q!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/17 ¤U¤È 08:22:08²Ä 8108 ½g¦^À³
ÃĵØÃĨêí¥Ü¡A¥Ñ©ó¤½¥q¹ï©ó¨ú±o¬ü°êÃÄÃÒ·¥¨ã«H¤ß¡A¨ä¸³¨Æ·|©ó2017®Ö­ã«Ø¥ß¬ü°ê¤l¤½¥q¡A

¿n·¥¶i¦æÃÄÃҥӽФΦæ¾P¥¬§½¡C

......................................................

À³¸Ó¬O¥HPharmaEssentia USA°e¥ó¥Ó½Ð,¦p¦¹¥»°ê(¬ü°ê)ÂåÃĤ£¨ü­­.

¥¿½Tµª®×½Ð§ä¤½¥q!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2020/3/17 ¤U¤È 08:17:14²Ä 8107 ½g¦^À³
ºô¸ô¤WÂà¸üªº¶K¤å¡A¦Û¤v­n¦³¨DÃÒ§PÂ_ªº¯à¤O¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÀ³µL©Ò¦í10144738  µoªí®É¶¡:2020/3/17 ¤U¤È 07:59:59²Ä 8106 ½g¦^À³
1.·sÃĤ@¯ë¤ò§Q³£9¦¨¡A¦ý»¡©ú®Ñªº¤ò§Q<50%¡A«ÜÄê§a¡I

2.6550ª©¡Aª©¤Í¤À¨É

iview.sina.com.tw/post/22127690

¬ü°ê­¹Ãĺʧ½©P¤Gªí¥Ü¡A¥Ø«e¤w¸g¨M©w¨ì¤µ¦~¥|¤ë«e¼È°±±µ¨ü¥~°êÂåÃÄ¡BÂåÀø³]³Æ©Î­¹«~ªº¼f¬d¡C­È±o¤@´£ªº¬O¡A³o¤@¨M©w¤]·|³y¦¨FDA¦b¦L«×ªº¼f¬d¾÷ºc°±¤î¹B§@~~~

°e¥ó---->·|¼f¶Ü¡H ·|¼vÅT¦h¤[¡H

ºGºGºG

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/17 ¤U¤È 06:07:56²Ä 8105 ½g¦^À³
PharmaEssentia USA 109~113¦~¹w¦ô·l¯qªí

PharmaEssentia USA 109~113¦~¹w¦ô·l¯qªí

PharmaEssentia USA 109~113¦~¹w¦ô·l¯qªí

«Ü­«­n©Ò¥H­n¼g3¦¸!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©ú10146339  µoªí®É¶¡:2020/3/17 ¤U¤È 06:01:02²Ä 8104 ½g¦^À³
³o­Ó¹ê¦b¬Ý¤£À´¡A½Ð±Ð¦U¦ì¤j¤j¡G

109À禬¥u¦³1.3»õ¤¸¡H¥h¦~²Ä¤@¦~³£¤w¸g3»õ¤¸¤F­C¡I¤µ¦~¤Ï¦Ó­Ë°hÂP¡H

²{ª÷¬y¤J¦³6»õ¤¸¡A¨º4.7»õ¤¸¬O¤°»ò¡H¤£·|¬O¼Ú¬w¥X³fª÷ÃB¡A¦]¬°¨ºÀ³¸Ó­n¦C¦bÀ禬¡A©Ò¥H¡A¬OAOPªº±ÂÅvª÷¦¬¤J¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2020/3/17 ¤U¤È 05:06:56²Ä 8103 ½g¦^À³
¶Ò¸êª÷ÃB­qªº¶V§C¡A¤S·Q­n¹F¨ì¹w´ÁªºÁ`ÃB¡A¶Õ¥²¤S·|­n¼W¥[ªÑ¼Æ¤F¡A¾É­PªÑ¥»¤Ó°ª¤]¬O³Â·Ðªº¨Æ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/17 ¤U¤È 04:54:37²Ä 8102 ½g¦^À³
ÁÂÁ¤p´²¤á¤j¤j:

§Ú¬Ý¤F´X­Ó·P·Q:

1. PharmaEssentia USA 109~113¦~¹w¦ô·l¯qªí(109¦~¹w­p1.29»õ, ­Y¯à¹F¦¨À³¸ÓÀ°Ãĵعª´x¹ª´x)

³æ¦ì¡G·s¥x¹ô¤d¤¸

¶µ¥Ø 109 ¦~ 110 ¦~ 111 ¦~ 112 ¦~ 113 ¦~ ¦X­p

Àç·~¦¬¤J 129,360 1,788,864 4,092,704 8,246,561 14,551,152 28,808,641

Àç·~¤ò§Q 38,808 804,989 1,841,717 3,710,953 6,548,019 12,944,486

Àç·~(·l)¯q (807,422) (235,867) 477,885 1,913,351 3,814,127 5,162,074

µ|«e(·l)¯q (807,422) (235,867) 477,885 1,913,351 3,814,127 5,162,074

µ|«á(·l)¯q (807,422) (235,867) 377,529 1,511,547 3,013,160 3,858,947

«ùªÑ¤ñ²v 100% 100% 100% 100% 100% 100%

Ãĵػ{¦C§ë¸ê(·l)¯q (807,422) (235,867) 377,529 1,511,547 3,013,160 3,858,947

2.¸êª÷»Ý¨D¤§¥²­n©Ê (¥­±`´N­n¾i­D¤F... ´H¥V¨Ó®É¤~¦³¦×.. ¦p¤µ³Ñ¤£¨ì70, «ç»ò¿ì?!)

¥»¤½¥q­ÓÅé°]°È³øªíºI¦Ü108¦~©³±b¤W²{ª÷¤Î»È¦æ¦s´Ú(¥]§t¤T­Ó¤ë¥H¤W

¤§©w´Á¦s´Ú)¬° 1,364,725 ¥a¤¸¡A­Õ­Y¥»¤½¥q¥»¦¸¥¼¿ì²z²{ª÷¼W¸ê¡A¹w­p±N©ó 109

¦~²Ä¤G©u²£¥Í¸êª÷¯Ê¤f¡A¬G¥»¤½¥q¥»¦¸¶Ò¶°¸êª÷¦³¨ä¥²­n©Ê¡C

3.¹w­p¥þ¦~²{ª÷¬y¤J¶q:606,124¥a¤¸(´«¥y¸Ü»¡¤µ¦~¼Ú¬w¥X³f¥u¦³4.77»õ??)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2020/3/17 ¤U¤È 03:49:20²Ä 8101 ½g¦^À³
K¤j

¤½¶}»¡©ú®Ñºô§}

doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=6446&year=&seamon=&mtype=B&

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/17 ¤U¤È 03:45:27²Ä 8100 ½g¦^À³
·sªº¤½¶}»¡©ú®Ñ¦³ºô§}¥i¥H§ó·sµ¹¤j®a¶Ü??

»¡¨ì³o­Ó³s©xºôªº¤½¶}¤ëÀ禬¸ê°Tªº¥i¥H¿ù»~¤F!!¤@¤ëÀ禬©~µM¼Ð°O1.3»õ.. ³o»ò·V­«ªº¸ê®Æ«ç»ò·|³o¼Ë...

www.pharmaessentia.com/uploads/images/2020%E5%B9%B4%E7%87%9F%E6%94%B6MonRev-02.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¶³²H­·»´10146472  µoªí®É¶¡:2020/3/17 ¤U¤È 03:32:54²Ä 8099 ½g¦^À³
·sªº¤½¶}»¡©ú®Ñ¤w¤W¶Ç.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©ú10146339  µoªí®É¶¡:2020/3/17 ¤U¤È 12:50:20²Ä 8098 ½g¦^À³
§Ú­Ó¤HÃÙ¦¨Lin¤jªº¬Ýªk

¤½¥q´N¬O­n¦³¶}·½¸`¬yªº³W¹º´N¬O¤F¡I¤£ºÞ¬O¶}·½¡]¤½¶Ò©Î¨p¶Ò¡^¡AÁÙ¬O¸`¬y¡]´M¨D¦UºØ¦X§@ªº¥i¯à¡^¡A¤°»ò³£¦n¡C

2,3¦~«á©Î³\¦³¦n­·´º¡A¦ý¬OÁ`¬O¥²¶·¥ý¼µ¹L²{¦b³o¬qÁ}­W´Á°Ú¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/17 ¤U¤È 12:22:22²Ä 8097 ½g¦^À³
ªÑ»ù70©Î¬Oªi°Ê¤W¤W¤U¤U

­Ó¤H§PÂ_À³¸Ó¼È®É²{¶H

ªÑ»ù¤£·|¥Ã»·¨º»ò§C

¦pªGªø´Á¯à°÷¦^¨ì170¥H¤W

¤G¡B¤T¦~«á­è¦n®³¨ì¤é¥»ÃÄÃÒ

¦pªG²{¦b±ÂÅvµ¹¤p¤é¥»

¤£´Nµ¹¥L­ÌÀË«K©y¤F¡H

­n§ä¤H¦X§@

ET¤T´ÁÁ{§É¸ÕÅ礣¦p§äAOP

¤À¾á¶O¥Î¤Î­·ÀI

ªp¥B¼Ú¬w¦a°ÏET¤w¸g±ÂÅvµ¹AOP¤F

AOP°µÁ{§É¸ÕÅç¤]¦³¬Û·í¦¨¥\¸gÅç

§Úı±o¤ñ¸û¥i¦æ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p©ú10146339  µoªí®É¶¡:2020/3/17 ¤W¤È 11:50:31²Ä 8096 ½g¦^À³
ªÑ»ù170¡A¥i¥H¦³170ªº°µªk¡A»¨®ð¤z¶³---¬ü,¤é,Áú,¤¤,¥x³q¦Y

ªÑ»ù³Ñ70¡A¬O§_¦³70ªº°µªk¡H©Ô¹Ù¦ñ¨Ó¥´¸s¬[---¦p¡G§â¤é,Áúµ¥µ¥¡A±ÂÅv¥X¥h

³Ìª½±µªº®Ä¯q¡A¥i¥H¬Ù¤U¨Ó³\¦h¶O¥Î¡]¤é,Áúªº·~°È©¹«e±À®i¡^¡C¬Æ¦ÜÁÙ¦³¨Ç±ÂÅvª÷¡Añ¬ùª÷¥i¥H¦¬¡C¦Ó¥B¡A¥Ñ¦aÀY³D¨Ó½æ¡A»¡¤£©w½æªº§ó¦n¡A¤Ï¦Ó¥i¥HÁȧó¦h¡CÁ`¬O­n¦³¸U¤@½æ¤£¦nªº³ÌÃa¥´ºâ¡A¨º´N¦Ü¤Ö¦³¹Ù¦ñ¦@¦P¤ÀÅu­·ÀI¡A¤]¬O¤@ºØ«OÀIªº°µªk§a¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSunfive10145942  µoªí®É¶¡:2020/3/17 ¤W¤È 11:31:27²Ä 8095 ½g¦^À³
¥Í§ÞªÑ¡]¤×¨ä¬O·sÃĪѡ^³o»òºG¥u¦³¤@­Ó­ì¦]¡A´N¬Oµu®É¶¡¬Ý¤£¨ìÀò§Q¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSunfive10145942  µoªí®É¶¡:2020/3/17 ¤W¤È 11:23:02²Ä 8094 ½g¦^À³
©È¬OªLÁ`¼µ¤£¹L³oÃö!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/17 ¤W¤È 10:14:53²Ä 8093 ½g¦^À³
­n·Q·Q¬Ý¬°¦ó¦³¤U¤@­Ó30¦~ªº®Éµ{´Nª¾¹DªÑ²¼¶·ªø´Á«ù¦³¤F
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/17 ¤W¤È 09:48:38²Ä 8092 ½g¦^À³
¤p¥¿¥¿¡A

¦pªG§A­n¥ÎÁȪѲ¼ªº¿ú¶R©Ð

²{¦b®£©È¤£¦æ§a¡I

§Ú¬Ý2-3¦~«á¡AÀ³¸Ó¦³¾÷·|

¼ÖÆ[ÂI¡A·sÃĪÑÃĵرN·|¬O»âÀY¦Ï

¤£¹L¤]¤£§K«Uªº»¡

§ë¸ê¦³­·ÀI¡A¬ÕÁ«¦Û­t

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/17 ¤W¤È 09:36:10²Ä 8091 ½g¦^À³
¸Û«H¡A¸ê°T¤½¶}³z©ú¬O¸gÀ礽¥q

³Ì°ò¥»­ì«h¡C

Ãĵخ³¬ü°êÃÄÃÒ¤w¸g¨S¦³Äa©À

¦p±´¬a¨úª«¡A¨S¦³¤°»ò­·ÀI

ªø´Á«ù¦³¡A§Ú»¡2-3¦~À³¸Ó¥i¥H¦^¨ìÀ³¸Ó¦³ªº»ù¦ì

µu´ÁªÑ»ùÀH¬Ì±¡¤W¤W¤U¤U¡A§Ô¤£¦íªº»{½ß½æ¥X

¥H«á­n°l´N¨Ó¤£¤Î¤F¡C

Äw½X¬~¤@¬~¤]¬O¤£¿ù¡A§â¤@¨Çµu´Á«È¡A±½¦a¥Xªù

¹³§ë«H¦ÛÀç°Ó¤j¶q½æ¥X¡A

¥~¸ê¤@±i³£¨S¦³½æ¡A¤Ï¦Ó¤Ö¶q¶i³f

¥i¥H¬Ý¥X§ë«H¦ÛÀç°Ó¦]ÁZ®Äµu´Á¶i¥X¯S©Ê¡A¸ò¤@¨Ç´²¤á

§Ûµu½u¤@¼Ò¤@¼Ë¡C

·Q°_¤p®É«á¬Ý¥¬³UÀ¸

¥vÆv¤åªº¤f¥Õ¡G

®É¤]©R¤]¡A«D§^¤§¤£¯à°Ú¡I

¹ï·ÓÃĵتѻù¡A¤£¤]¬O«Ü¶K¤Á¡H

Ãĵإ[ªo💪¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¥ý¥Í10149022  µoªí®É¶¡:2020/3/17 ¤W¤È 09:09:11²Ä 8090 ½g¦^À³
¬Ý¬Ý¯E­ô ¤¤­ô ¬ü¤k Ãĵؤµ¤Ñ³o¼Ë¯uªº«D¾Ô¤§¸o ­þ°¦¤£¬O³s¶^¨ìÁx¥Ä³£¦R¥X¨Ó¤F...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/17 ¤W¤È 08:53:26²Ä 8089 ½g¦^À³
§Úı±o¸ê°TÁÙ¬O­n¦bºô¸ô¤W¤½¶}, ¤£¥Î©È³Q¦Y¨§»G, ²¦³º¤º³¡¤H¤h¤@©w¥Ã»·¤ñ§A¥ýª¾¹D... ¤£¬O¶Ü?!

³oÀɪѲ¼¤Ï¦Ó­n¤½¶}, ¦]¬°¤½¥q³£¤£Á¿, ¨ü¶Ëªº¥Ã»·¬O´²¤á, ©t¨àÃĨƥ󤣴N¬O¬¡¥Í¥Í¨Ò¥J¶Ü?

¤@¼Ë... §ÚÁÙ¬O·Qª¾¹D¤µ¦~¥X³f®É¶¡©M·~ÁZ... ¤½¥q¤£¥i¯à³£¤£ª¾¹D§a??¤£µM«ç»ò³Æ³f!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¸I¥J10148138  µoªí®É¶¡:2020/3/16 ¤U¤È 09:28:18²Ä 8088 ½g¦^À³
³oªiªZº~¯f¬r¨Óŧ ªÑ²¼¥«³õ±þÁn¶©¶© ¦ý¬O§Ú«Ü³[´e ³Ì¤£¨ü´º®ðÀô¹Ò¼vÅT¤§¤@ªº¤£´N¬O¥Í§ÞªÑ¶Ü¡H

¬°¦óµ¥¨ì§Q¦hÁÙ¬O¶^°± ³oªi§ë«H¯uªº¬O¨Ó¼âªoªº ±b­±¤WÁ«¨ì§Ú³£¤£´±ÂI¥X¨Ó¬Ý ¾ã­Ó«H¤ß³£¨S¦³¤F

°ß¤@¼y©¯ªº¬O¨S¦A¥[½X¤U¥h ­n¤£µM¯uªº­n¶]¸ô¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/16 ¤U¤È 08:39:46²Ä 8087 ½g¦^À³
·|­û¡G¤p¥¿¥¿10142326 µoªí®É¶¡:2020/3/15 ¤W¤È 10:32:56²Ä 8065 ½g¦^À³

www.youtube.com/watch?v=EtJghHdrtrY

Management of PV, the role of interferon

2020¦~1¤ë30¤é¼v¤ù14¤À34¬í³B Prof. Jean-Jacques Kiladjian

¦ü¥G¦³´£¤Î PegasysÂà´«¦¨ ROPEGINTERFERON±¡§Î?

¥i§_½Ðºô¤W¤j¤j¥N¬°Â½Ä¶½T»{¡CÁÂÁ¡C

..............................................................................................

..............................................................................................

Prof. Jean-Jacques Kiladjiany¦b³o½gªº¤å¦r±Ô­z¤ñYOUTUBE¼v¤ùªºµªÂÐÁÙ©ú²Ó¨Ç

www.pvreporter.com/ropeginterferon-effective-treatment-for-polycythemia-vera/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/16 ¤U¤È 07:41:58²Ä 8086 ½g¦^À³
·PÁÂROGER5889¤j»¡©ú¡A¥\¼wµL¶q¡CÁÂÁ¡C

¥t¥~¡A¸É¥R¤@ÂI¡Cfda¦ÜÃĵØÃĤ½¥q¬d¼t¡A¬O§_¨ü¬Ì±¡¼vÅT?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/16 ¤U¤È 06:34:03²Ä 8085 ½g¦^À³
[·|­û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2020/1/2 ¤W¤È 10:59:13²Ä 7783 ½g¦^À³

©t¨àÃĪº¿W½æ´Á¡A«Ü¦h¤H»~·|¬O­­¨îÂå¥Í¶}ÃÄ¡A¦ý¨ä¹ê¬OÃĺʳæ¦ì¦b¦~­­¤º¤£®ÖµoªvÀø¸Ó¯fªº¦PÃþÃĪ«¡AÂå¥Íªº¶}ÃÄ¥D¦ÛÅv¬O¤£¼vÅTªº¡C¨Ò¦p¡Apegasys ¦b ropeg ¨ú±oÃÄÃÒ«á¡AÂå¥ÍÁÙ¬O¯à¶}µ¹¯f¤H¥Î¡A¯S§O¬O¤@ª½¥Î pegasys ºû«ù«Ü¦nªº¯f¤H³q±`Âå¥Í¤£·|¥D°Ê´«¦¨ ropeg¡C

§Ú­Ó¤H»{¬°¡A¥Ñ pegasys ª½±µÂà¦Ü ropeg ªº¥D­nÃöÁä´N¬O«OÀI¤½¥qªºµ¹¥IºA«×¡C­Y«OÀI¤½¥q¥uµ¹¥I©x¤è®Ö¥iªºÃĪ«¡Aropeg ¤é«áªº¨Ï¥Î¤H¼Æ´N·|«Ü¦³·Q¹³ªÅ¶¡¡C ³o¤]¬O¦æ¾P¤W­º¥ý¸ÓµÛ¾¥ªº¦a¤è¡C

.............................................................................................................................................................................................

Âå¥Íªº¶}ÃÄ¥D¦ÛÅv¬O¤£¼vÅTªº¡C

¦]¬°pegasys¬O[ÂÂ]ÃÄ¡A¤£¬O·sÃÄ¡A«¥»~¸ÑOrz.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2020/3/16 ¤U¤È 06:20:18²Ä 8084 ½g¦^À³
·|­û¡G¤p¥¿¥¿10142326 µoªí®É¶¡:2020/3/16 ¤U¤È 05:16:49²Ä 8081 ½g¦^À³

........

(¤@)5¤ë15¤é¬O§_¯àÀò±oÀu¥ý¼f¬d¡G

5¤ë15¤éFDA¬O§_¤½¥¬µL¶·¸É¥ó¡A¥BÀò±oÀu¥ý¼f¬d¡A­Y¶¶§Q¦Ü¤Ö¥i¹w´Á11¤ë¤¤¦¯Àò±ofdaÃÄÃÒ¡C¦ý¹J¦~©³FDA¬O§_¶¶§Q¼f®Ö§¹²¦©Î¶¶©µ¡A¤£±o¦Óª¾¡C(¤¤¸ÎÃÄÃÒ¹J¸t½Ï¸`©µ«á3­Ó¤ë)¡C

(¤G)¼W¸ê¬O§_¶¶§Q¡G

¼W¸ê»ù91¤¸¡B¨p¶Ò»ù86¤¸¡C¦¹®ÉªÑ»ù74¤¸¡A¥BªÑ»ù¬O§_¦³¼µ?¤½¥q¼W¸ê¬O§_¤´ºû«ù²{¼W©Î§ï¥Î¨p¶Ò©Î¥Î¨ä¥L¤è¦¡¶Ò±o¸êª÷¡A¤´§_¶¶§Q§¹¦¨?ºÝ¿à¤½¥q´¼¼z¡C

(¥|) Pegasys¬O§_§¹¥þÂà´«¦¨ Ropeginterferon?

Pegasys¬O§_©ó2026¦~°±²£¡A½×ªÌ¤£¤@¡A¦³»{¬°2026¦~°±²£¡A¦ý¦³1¦ì¯f¤Í©óÁy®Ñ½×¾ÂªÖ©w»¡Pegasys°±²£«Y°²°T®§¡C¥t¥~¡A§Y¨ÏRopeginterferon¨ú±o¬ü°êÃÄÃÒ¡AÂå¥Í¬O§_´N¤£¯à¥H¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(Off-label use)¡A¶}¥ßPegasys¡A´£¨Ñ¯f¤H¨Ï¥Î? Prof. Jean-Jacques Kiladjian¦ü¥G»{¬°­Y¯f¤H¨Ï¥ÎPegasys­@¨ü©Ê¦n¥B¦³®Ä¡A¤£¨£±o­nÂà´«¦¨Ropeginterferon?³o­Ó°ÝÃD¡A­Ó¤H¨S¦³§â´¤¡AÁٽкô¤ÍÄÀºÃ¡C

..............................................................................................

..............................................................................................

(¤@)¤¤¸Î¦b5/3§¹¦¨°e¥ó¥Ó½Ð¡A7¤ëFDA¨ìÃÄ©ú¬d¼t¡A°w¹ï¬d¼tµ²ªG¡A¤¤¸Î©ó10¤ë25¤é°e¤J¦³ÃöÃÄ«~¥Í²£¤è­±ªº [¸É¥R] ¸ê®Æ¤Î[­×­q]­ì¥ý°e¥óªºª©¥»¡C¡CFDA¦bªì¨B¾\Ū«á¡A¨M©w»Ý­n¦h¤@¨Ç®É¶¡¨Ó§¹¦¨¼f¬d¸É¥Rªº¸ê®Æwww.genetinfo.com/investment/featured/item/12558.html

(¤G)ºÞ²zªÌ¨S¦³²ÎÄw¿Ñ¹º¤~¯à¡A¥u¬O¤@®É¹®­Æ»PAOPñ¬ù!

(¥|) a.©t¨àÃıM½æÅv:·í©t¨àÃÄ»{ÃÒªºÃÄ«~³Q®Ö­ã¤W¥««á¡A7¦~¤º¡A¦P¾AÀ³¯g (PV) ¤¤Ãþ¦üªº·sÃÄ (ªø®Ä«¬¤zÂZ¯À) ¤£±o

¶i¤J¥«³õ¡C

b. ®Ú¾Ú2018 ASH¬ü°ê¦å²GÂå¾Ç¦~·|¦³ÃöPegasys¨Ï¥Î¦bPVªº²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç³ø§i¡APegasys¨C©P¤@°w¡B°Æ§@

¥Î¤j¡B­@¨ü©Ê§C¡BÀø®Ä¤£ºâ¥X¦â¡A¥þ²y²Ä¤T´ÁÁ{§É¹êÅç¤]¤w¥þ­±°±¤î¡C(»¡¥Õ¸Ü´N¬OÁ{§É¥¢±Ñ)

±qªk³W»P±wªÌ¥ß³õ¨Ó¬Ý¡A·s¯f±w­Y­n¶}¥ßªø®Ä¤zÂZ¯À¡A¨º»òBesremi´N¬O°ß¤@¿ï¾ÜÀ³¸ÓµL»~¡A§_«h°£¤F±wªÌ¦sºÃ¤§¥~¡AÃĵؤ]À³¸Ó·|´£¥X«IÅv§i¶D¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gstarya10147863  µoªí®É¶¡:2020/3/16 ¤U¤È 05:54:50²Ä 8083 ½g¦^À³
Ãø±o»{¦P§Aªº¬Ýªk ¥Ø«e§Úªº±b­±¤W¤w¸g·l¥¢300¦h¤F ¹ê¦b°ª¿³¤£°_¨Ó ¤S¨S¦³²{ª÷¥[½X ¥u¯àµ¥­Ó¤T¤­¦~¬Ý¬Ý¤½¥qªº§@¬°¤F §Æ±æ¥H«á¯à¾ã­Ó½¤j¬õ

¥t¥~ ¦³°Q½×³oÀɪº¦a¤è¯uªº«Ü¤Ö ¦b¥~¸ê¤Î¤j¤á¨S¦³¯uªº¤Á¤J¤§«e ¸ê®Æ¶V¤¬³q¶V³z©ú ¹ï§A§Ú¨S¦³¬Æ»ò¦n³B ´²¤á¶V¦h ·Qª£µuªº¤H´N¶V¦h ¤j®a¥u·Q¤¬¦Y¨§»G ²¦³º²{¦b¨S¦³¹ê»ÚªºÀò§Q ¯Âºé¬O®ø®§­± ¥»¹Ú¤ñ ³oºØªwªj«Ü®e©ö¤@ÂW´N¯} °²¦p¬O¥H«á¯uªº¯à¨C¦~ÁÈ´X¤Q¶ô ¦³¯u¥¿ªº°ò¥»­±¥[«ù ´N¤£·|¹³²{¦b³o¼Ë ¤j®aªº¤ß¸Ì³£¤£½ñ¹ê¤F

¤j®a¤@°_¥[ªo ¼µ¹L¥h§a

////////////////////////////////////////////////////////////////

·|­û¡GLinbad10148532 µoªí®É¶¡:2020/3/16 ¤W¤È 11:31:54²Ä 8076 ½g¦^À³

¬~ËÎÄw½X¤]¬O¤£¿ùªº°Õ¡I

Ãĵجü°êÃÄÃÒ¥i¥H½T©w¥i¥H®³¨ì¤F

ÃÄÃÒ¨S¦³°ÝÃD

ªø´Á§ë¸ê¨¤«×¨Ó¬ÝÀ³¸Ó¨S¦³¤°»ò­·ÀI¤F

ªÑ»ù¤W¤W¤U¤U«Ü¥¿±`

¤£¹L¼W¸ê¤´µM§xÃø­«­«

¥©°üÃø¬°µL¦Ì¤§ª¤

®£©È¤]¬O§ë¸ê¤H¨S¦³«H¤ßªº¦a¤è

¯uªº¤£§ä°]°Èªø¡AÀ°¦£§ä¸êª÷¶Ü¡H§äª÷¥D¡H§äµ¦²¤¦X§@¹Ù¦ñ¡H

¯uªº¤£¬å±¼©Î¬O©µ«á­p¹º¡H

¸`¦çÁY­¹¦@´çÃøÃö¡H

¯uªº¤£¥D°Ê©MAOP©M¸Ñ¡HÅý¤À¼í¤Î¦­¤J±b

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gbobby10148884  µoªí®É¶¡:2020/3/16 ¤U¤È 05:40:42²Ä 8082 ½g¦^À³
¥xÆWªÑ¥«¤£¬O¥Î²qªº­n§¹¾ã°O¿ý©Ò¦³¦¨¥»¦A¶R¤£¬O¬Ý®ø®§
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/16 ¤U¤È 05:16:49²Ä 8081 ½g¦^À³
¥»¤é¶^°±­Ó¤H·P·Q¦p¤U¡G

¤@¡B¥ý¤J¬°¥D¡A¹w³]¥ß³õ¡G

±q¥h¦~¦~©³¡A¥H¬°¥i°eÃÒFDA¡A«á¦³©Ò©µÌX¡A²×©ó¬Q¤é°eÃÒ¡A¥H¬°¤µ¤é§Q¦h©ñ°e¶}½L¥²¥iº¦°±¡C·Q¤£¨ì³s¥­½L¥¼¦u¦í¡A³º¸¨±o¶^°±¡C

¤G¡B¥¼³]°±·l¡A¹êÄݤ£´¼¡G

­Ó¤H¹ï«ùªÑ¤w²£¥Í·P±¡¡A¥DÆ[¤W»{¬°«á¶Õ¬Ý¦n¡A¥¼ª`·N§Þ³N­±¤w½ªÅ¡A3¤ë12¤é»ù¶^¶q¼W¡AÅãµMªÅÀY¤wÄY­«¦¨§Î¡A¥¼¥ß§Y°±·l¡A¤´´Á«Ý§Q¦hµo»Ã¡A½TÄݤ£´¼¡C¤é«á¾Þ§@¥i¯à­n·f°t§Þ³N­±¡A¬°¤°»ò¦Ñ¬O¾Ç¤£·|°±·l¡C·Q­nªÑ²¼ÁÈ¿ú¶R©Ð¤l¡A¤£ª¾ÁÙ­nµ¥¦h¤[¡A²{¦b¥u§Æ±æªÑ»ù¦^¨ì¦¨¥»»ù¤£½ß§Y¥i¡C

¤T¡B­Y¦³ºô¤Í¦]°Ñ¦Ò­Ó¤HPO¤å¸ê°T¶RªÑ½ß¿ú¡A¦b¦¹­Pºp¡C³Ì·P©êºp¦V¦P¨Æ¤¶²Ð¦¹ªÑ¡A®`¦P¨Æ®M¨c¡A¤é«á¥i¯à¦b¥[µùĵ»y¡A¤£«OÃÒÁÈ¿ú¡A½Ð¦Û­t¬ÕÁ«¡Aµ½³]°±·l¡C

¥|¡BÃĵإ¼¨Ó°ÝÃD¡G

(¤@)5¤ë15¤é¬O§_¯àÀò±oÀu¥ý¼f¬d¡G

5¤ë15¤éFDA¬O§_¤½¥¬µL¶·¸É¥ó¡A¥BÀò±oÀu¥ý¼f¬d¡A­Y¶¶§Q¦Ü¤Ö¥i¹w´Á11¤ë¤¤¦¯Àò±ofdaÃÄÃÒ¡C¦ý¹J¦~©³FDA¬O§_¶¶§Q¼f®Ö§¹²¦©Î¶¶©µ¡A¤£±o¦Óª¾¡C(¤¤¸ÎÃÄÃÒ¹J¸t½Ï¸`©µ«á3­Ó¤ë)¡C

(¤G)¼W¸ê¬O§_¶¶§Q¡G

¼W¸ê»ù91¤¸¡B¨p¶Ò»ù86¤¸¡C¦¹®ÉªÑ»ù74¤¸¡A¥BªÑ»ù¬O§_¦³¼µ?¤½¥q¼W¸ê¬O§_¤´ºû«ù²{¼W©Î§ï¥Î¨p¶Ò©Î¥Î¨ä¥L¤è¦¡¶Ò±o¸êª÷¡A¤´§_¶¶§Q§¹¦¨?ºÝ¿à¤½¥q´¼¼z¡C

(¤T)ÃĪ«º¯³z²v¡G

¼w°ê¡B¶ø¦a§Q¡B´µ¬¥ºû¥§¨È¡B¤¦³Á¤Î¸q¤j§Qµ¥°ê¥¿¦¡¤W¥«¾P°â¡A¨ä¤¤¡A¸q¤j§QÃÄ»ù°ª¹F4,450¼Ú¤¸(¦ü¥G«Y¥H500­p»ù?¨Ã«D¥H250­p»ù?)±qFACEBOOK¯f¤Í¹ÎÅé¡A¼Ú¬w¯f¤Í¦³¨Ï¥ÎROPEGINTERFERON¡A­Ó¤H¥u¬Ý¨ì1¦ì¶ø¦a§Q¯f¤Í¡B2¦ì¼w°ê¯f¤Í¡A¦@3¦ì¯f¤Í¡C¬O§_ÁÙ¦³¨ä¥L¯f¤Í¨Ï¥Î¡A¥¼¦bÁy®Ñ½×¾Âµoªí¨Ï¥Î·P·Q¡A¤£±o¦Óª¾?·Pıº¯³z²v¥G¶i«×½wºC?§Y¥ò»Paop¨Ï¥òµô¶¶§Q¸Ñ¨M¡A¤À¼íª÷¥ç¦³­­?

(¥|) Pegasys¬O§_§¹¥þÂà´«¦¨ Ropeginterferon?

Pegasys¬O§_©ó2026¦~°±²£¡A½×ªÌ¤£¤@¡A¦³»{¬°2026¦~°±²£¡A¦ý¦³1¦ì¯f¤Í©óÁy®Ñ½×¾ÂªÖ©w»¡Pegasys°±²£«Y°²°T®§¡C¥t¥~¡A§Y¨ÏRopeginterferon¨ú±o¬ü°êÃÄÃÒ¡AÂå¥Í¬O§_´N¤£¯à¥H¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(Off-label use)¡A¶}¥ßPegasys¡A´£¨Ñ¯f¤H¨Ï¥Î? Prof. Jean-Jacques Kiladjian¦ü¥G»{¬°­Y¯f¤H¨Ï¥ÎPegasys­@¨ü©Ê¦n¥B¦³®Ä¡A¤£¨£±o­nÂà´«¦¨Ropeginterferon?³o­Ó°ÝÃD¡A­Ó¤H¨S¦³§â´¤¡AÁٽкô¤ÍÄÀºÃ¡C

¤­¡B¤pµ²¡G

ªÑ²¼½ß¿úÁ`¬O¤ß¦b²I¦å¡A«è¤£±o§O¤H¡A²¦³º¡A¸ô¬O¦Û¤w¿ï¾Ü¡C§Y¨Ï§Ö¼Ö¤£°_¨Ó¡A¤]­n¾Ç²ßÅý¦Û¤w§Ö¼Ö°_¨Ó¡A«O«ù¥­¦w°·±d¡C¤é«á§i¶D¦Û¤w¡A¥i¯àÁÙ¬O¥H§Þ³N­±¾Þ§@¬°¥D¡Aµ½³]°±·l¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/16 ¤U¤È 04:03:18²Ä 8080 ½g¦^À³
¡m¥ÍÂåªÑ¡nÃĵØÃĬü°êPVÃÄÃҥӽЧ¹¦¨¡A³Ì§Ö¦~©³¨úÃÒ

ÃĵØÃÄ (6446) ¤U¤ÈÁ|¦æ½u¤Wªk»¡·|®É«ü¥X¡A¦b¬ü°ê®É¶¡2020¦~3¤ë13¤é¦V¬üFDA´£¥XRopeginterferon alfa-2b¡]P1101¡^ªº°e¥ó¥Ó½Ð¡A¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia vera¡A²ºÙPV)¡A¦b¬ü°ê®É¶¡3¤ë15¤é³Ä±ß±µÀò¬ü°êFDA¥¿¦¡³qª¾°e¥ó½T®Ä§¹¦¨¡A³Ì§Ö¦b¤µ¦~²Ä4©u¨ú±oÃÄÃÒ¡C

==============> ¥[ªo!! ±µ¤U¨Ó´N¬Oµ¥µ¥µ¥....

==============> ÁÙ¬O­n¦A°Ý¤@¦¸, ¤µ¦~ªº¥X³f®É¶¡??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GWill Sung10149109  µoªí®É¶¡:2020/3/16 ¤U¤È 12:32:11²Ä 8079 ½g¦^À³
¹ê¦b¦n©_¤j®a½ß¿ú³£µL·P¡H§Ú½ß¤F´X¤Q¸U¹ê¦b¬O«Ü¦³·P
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/16 ¤W¤È 11:59:13²Ä 8078 ½g¦^À³
¶Â¤ÑÃZ¬OªZº~ªÍª¢¯f¬r¸v­h¥þ²y

ÃĵؤzÂZ¯À¥i¥H¦X¨Ö¨ä¥L¥ÎÃĪvÀø

Ãĵئ³¾÷·|¨ü¯q¡AªÑ»ù¤jº¦

«o¨ü¶ËºG­«

­ü§r¡I

¤£§@¬°§a¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤ý¥ý¥Í10149022  µoªí®É¶¡:2020/3/16 ¤W¤È 11:44:36²Ä 8077 ½g¦^À³
AOPÅv§Qª÷¤£ª¾¦ó®É¤J³U? ²{¦b²{ª÷¬°¤ý, ¥ý»â¤F¦ûí¸}¨B¤~¬O¤ý¹D
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/16 ¤W¤È 11:31:54²Ä 8076 ½g¦^À³
¬~ËÎÄw½X¤]¬O¤£¿ùªº°Õ¡I

Ãĵجü°êÃÄÃÒ¥i¥H½T©w¥i¥H®³¨ì¤F

ÃÄÃÒ¨S¦³°ÝÃD

ªø´Á§ë¸ê¨¤«×¨Ó¬ÝÀ³¸Ó¨S¦³¤°»ò­·ÀI¤F

ªÑ»ù¤W¤W¤U¤U«Ü¥¿±`

¤£¹L¼W¸ê¤´µM§xÃø­«­«

¥©°üÃø¬°µL¦Ì¤§ª¤

®£©È¤]¬O§ë¸ê¤H¨S¦³«H¤ßªº¦a¤è

¯uªº¤£§ä°]°Èªø¡AÀ°¦£§ä¸êª÷¶Ü¡H§äª÷¥D¡H§äµ¦²¤¦X§@¹Ù¦ñ¡H

¯uªº¤£¬å±¼©Î¬O©µ«á­p¹º¡H

¸`¦çÁY­¹¦@´çÃøÃö¡H

¯uªº¤£¥D°Ê©MAOP©M¸Ñ¡HÅý¤À¼í¤Î¦­¤J±b

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gavandia10146474  µoªí®É¶¡:2020/3/16 ¤W¤È 11:27:45²Ä 8075 ½g¦^À³
ÃĵØÃÄÁÙ¬O¦Ñ¼Ë¤l ¨C©ñ§Q¦h«OÃÒ¶}°ª¨«§C

¤ñ¸ûºGªº¬O²{¦b§¡½uªÅÀY±Æ¦C ¤U±´¤O¹D§ó±j§ó²r

¦³¥i¯à¤U±´¾ú¥v§CÂI45¤¸¶Ü

¥Ø«e«¬ºA´N¹³¬üªÑ¤@¼Ë

©Ò¦³§Q¦h ´N¹³§Ö¦ºªº¤H¥´±j¤ß°w ¥u·|¦º¿ß¸õ¤@¤UµM«áÄ~Äò¶^

°±·l½æÀ£ÁÙ¨S¦³§¹¥þ«Å¬ª

­n§Û©³ªº ¥i¯à­n½T©wµ¥«e¤@§å¤H¦º¥ú¤F Äw½X¨I¾ý¤§«á¤~¯à¶i³õ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2020/3/16 ¤W¤È 11:11:16²Ä 8074 ½g¦^À³
¨ä¹ê°ò¥»­±¤½¥q¤]³£°µ¨ì¤F

¤j®a¥u¬O©ê«èªÑ»ù¤£ª§®ð

¤½¥q¨S¦³¥D¤O¨S¦³ªk¤H»{¾i

³o´N¬OªÑ»ù³o¼Ëªº­ì¦]

¨C­Ó¤½¥q³£¦³¦Û¤vªºÀuÂI©M¯ÊÂI

¸gÀç¹Î¶¤¤]¬O

¤j®a¦pªG¤£Ä@·Nµ¹¤©´xÁn¤]¨SÃö«Y

²¦³ºªÑ»ùªº½T«ÜºG

¦ý¸gÀç¹Î¶¤§â²£«~¬ãµo¦n

ºâ¬O³Ì°ò¥»ªº°ò¥»­±

³Ñ¤U´N¬O®É¶¡ªºµo»Ã

¦Ü©ó¤§«e©Ò¦³ºô¸ô´CÅ黡¤£¥i¯à§K¤T´Á°eÃÄÃÒ

²{¦b¤]¤£·|¹Dºp

¤]¤£·|¸ÑÄÀ

´CÅé¬ü¨ä¦W¬OºÊ·þ

¦ý¹ê»Ú¤W¤]¬O³Õ¨úª¾¦W«×©Mª©­±

¤£¥i¯à¦³¤H¤Q¥þ¤Q¬ü

¤j®aÀ³¸Ó¦h¤@ÂI¹ªÀy

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gken10148595  µoªí®É¶¡:2020/3/16 ¤W¤È 10:58:29²Ä 8073 ½g¦^À³
³o´N¬O¤Ó¦³¦Û«Hªºµ²ªG, ¥­±`¤£¾i­D, µ¥¨ì´H¥V¨ÓÁ{®É¦ÛµM¼µ¤£¦í!!~~

¤£¹L³o¦¸FDA ²×©ó°e¥X¥h¤F, ¤]¦V«eÁÚ¦V¤@¤j¨B, ³Ì²×ÁÙ¬O­n·~ÁZ¤ä«ù, ·~ÁZ·~ÁZ,

¦³¤Hª¾¹D¤µ¦~ªº¥X³f®É¶¡¶Ü??!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2020/3/16 ¤W¤È 10:27:01²Ä 8072 ½g¦^À³
°­©P®`®Æ®Æ¤F~~~

ªÑ»ù¨S¦³³ÌºG,¥u¦³§óºG!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2020/3/16 ¤W¤È 09:31:44²Ä 8071 ½g¦^À³
¤w¸g¹F¨ì§ë«H±j¨î½æ¥X°±·lªº»ù¦ì

¥Ø«e¥u¯àµ¥·sªº¶R½L

©Î¬Oµ¥§ë«H½æ¥ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2020/3/16 ¤W¤È 09:25:22²Ä 8070 ½g¦^À³
(6446) ÃĵØÃħ¹¦¨BLA°e¥ó ¤w¦V¬ü°êFDA´£¥XPVÃÄÃÒ¥Ó½Ð

2020.03.16

ÃĵØÂåÃÄ©ó¬ü°ê®É¶¡2020¦~3¤ë16¤é§¹¦¨¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^´£¥XRopeginterferon alfa-2b¡]P1101¡^¤W¥«¬dÅçµn°O¥Ó½Ð¡]Biologics License Application, ²ºÙBLA¡^¡AªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]Polycythemia vera¡A²ºÙPV¡^¡C¤½¥q¦P¨B¦VFDA¥Ó½ÐÀu¥ý¼f¬d¸ê®æ¥H¥[³tÃÄÃÒ¼f¬d®É¶¡¡A¤@¥¹ÀòÀu¥ý¼f¬d±N¦³¾÷·|¦b¦~©³«eÀòFDAÃÄÃÒ¡A¦¨¬°¬ü°êªvÀøPV²Ä¤@¥B°ß¤@³Q®Ö­ãªº¤@½u¥ÎÃÄ¡C

Ropeginterferon alfa-2b¨Ï¥Î©óªvÀøPV ¤w¦b2012¦~Àò±o¬ü°ê©t¨àÃÄ»{ÃÒ¸ê®æ¡A²Å¦X´£¥XÀu¥ý¼f¬dªº±ø¥ó¡A¦³¾÷·|±N¼Ð·Ç¼f®Ö´Áªº10­Ó¤ëÁYµu¬°6­Ó¤ë¡C®Ú¾ÚFDAªº¼f¬d¬yµ{¡AFDA¦b¦¬¨ìBLA«á±N¦b60¤Ñ¤º¦^ÂЬO§_¦P·N¦¹¦¸¥Ó½Ð¶i¤J¹ê½è©Ê¼f¬d¶¥¬q¡A¨Ã§iª¾¬O§_µ¹¤©Àu¥ý¼f¬d¸ê®æ¡C¥t¨Ì¾Ú¬ü°ê©t¨àÃĪk®×¡A¾Ö¦³©t¨àÃÄ»{ÃÒªºÃĪ«ÁÙ¥i§K°£ªñ¤T¦Ê¸U¬üª÷ªº¥Ó½Ð¤âÄò¶O¡A¦ÛÃÄÃÒ®Öµo¤é°_§ó¨É¦³7¦~ªº¥«³õ±M½æÅv¡C

¨u¯f¥«³õÄvª§ªÌ¤Ö¡BÃĪ«¥«³õ©w»ù¤]¸û¤@¯ëÃĪ«°ª¡C¥Ø«e¦bMPN¾AÀ³¯g¤¤°ß¤@³QFDA®Ö­ãªºPV¤G½u¥ÎÃÄJakafi¦b2011¦~Àò­ã¥Î©óªvÀøMF¾AÀ³¯g¡B 2014¦~Àò­ã¥Î©óªvÀøPV¾AÀ³¯g¡C2019¦~Jakafi¦b¬ü°êªº¦~¾P°â¦~¦¨ªø²v20%¡APV¯f±w¦~¼Wªø²v¬°14%¡CÃĵØÃĪºRopeginterferon alfa-2b¦bÀòFDA®Ö­ã¤W¥««á¡A¦³±æµn¤W¬ü°ê¯f¤H¥ÎÃÄ«ü«n (NCCN Guideline)¡C¥[³t¶i¤J¬ü°ê¥«³õ¡A´£¤ÉÃÄ«~¦b¬ü°ê¥«³õªº¯à¨£«×¡C

Ropeginterferon alfa-2b¥Ø«e¤w¦b¼w°ê¡B¶ø¦a§Q¡B´µ¬¥ºû¥§¨È¡B¤¦³Á¡B¤Î¸q¤j§Qµ¥¼Ú¬w°ê®a¤W¥«¾P°â¡A¨ä¤¤¸q¤j§QÃÄ»ù°ª¹F4,450¼Ú¤¸¡CÃĵØÃĹw­p¤µ¦~¨ú±o¥xÆW¤Î¬ü°êPVÃÄÃÒ«á¡A¤U£¸¨B±N¶i­xMPN¥t¤@­Ó­«­n¾AÀ³¯gET¡A·m§ð¥þ²yMPN¥«³õ¡C

Ãö©ó°©Åè¼W¥Í©Ê¸~½F MPN

°©Åè¼W¥Í©Ê¸~½F (Myeloproliferative neoplasms¡A²ºÙMPN) ÄÝ©ó¨u¨£¯e¯f¡A¨ä¤¤³Ì±`¨£ªº¦³¬õ¦å²y¼W¥Í¯g¡]Polycythemia Vera¡A²ºÙPV¡^¡B¦å¤pªO¹L¦h¯g¡]Essential Thrombocythemia¡A²ºÙET¡^©M­ìµo©Ê°©ÅèÅÖºû¤Æ¡]Primary Myelofibrosis¡A²ºÙMF¡^¡C»F¦]©ó¯f¤HÅ餺±a¦³JAK2¡BCALR¡BMPL¡BTET2µ¥°ò¦]¬ðÅÜ¡A¾É­P°©Åè³y¦å·F²Ó­M¥\¯à¥¢¿Åªº¦å²G¸~½F¯e¯f¡C±wªÌªº¦@¦P¯S¼x°£¤F¦å²GÀˬd²§±`¥~¡AÁÙ¦³³y¦å¥¢¿Å¾É­Pªº¾®¦å¦å®ê¤Î¥X¦å¡B¯S©w¾¹©x¸~¤j¡A©Î¬OÀHµÛ¯fµ{µo®iÂন°©ÅèÅÖºû¤Æ©Î¥Õ¦å¯f¡C¾¨ºÞ¦U¦~ÄÖ¼hªº¤H³£¦³¥i¯à¿©±wMPN¡A¦ý60·³¥H¤WªºMPN±wªÌ¦]¯e¯f´c¤Æ¦º¤`ªº­·ÀI¸û¨ä¥L¦~ÄÖ¼h°ª¡C¡C

Ãö©ó¬õ¦å²y¼W¥Í¯g PV

¬õ¦å²y¼W¥Í¯g¡]Polycythemia Vera ¡A²ºÙPV¡^¬OMPN¤¤»PJAK2¬ðÅÜÃö«Y³Ì±K¤Áªº¦å²G¸~½F¯e¯f¡A¤j³¡¥÷ªºPV±wªÌ³£±a¦³JAK2¬ðÅÜ¡CPV±wªÌ°£¤F¦å²G¤¤¬õ¦å²y¼Æ¥Ø¹L¦h¥H¥~¡A¦³®É¤]¦ñÀH¥Õ¦å²y»P¦å¤pªO°¾°ª¡BµÊŦ¸~¤j¡B¥Ö½§·kÄo¡B¦å®êªý¶ë¦åºÞµ¥¯gª¬¡CPVªºªvÀø­«ÂI¬O½w¸Ñ¯gª¬¡B´î¤Ö¦å®ê§Î¦¨¤ß¦åºÞ¯e¯fªº­·ÀI¡A¥H¤Î´î½w¯fµ{¡AÁקK´c¤Æ¬°¤£¥i°fªº°©ÅèÅÖºû¤Æ©Î«æ©Ê¥Õ¦å¯f¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2020/3/16 ¤W¤È 06:25:59²Ä 8069 ½g¦^À³
¨Æ¹êµo¥Í¤é:109/03/14

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q©ó¬ü°ê®É¶¡2020¦~03¤ë13¤é§¹¦¨¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^´£¥X

Ropeginterferon alfa-2b¡]P1101¡^¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡]BLA¡^¡A

¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¥Í¯g¡]Polycythemia Vera¡A²ºÙPV¡^¡C

6.¦]À³±¹¬I:µo¥¬¥»­«¤j°T®§

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GRopeginterferon alfa-2b¡]P1101¡^

¤G¡B¥Î³~¡GRopeginterferon alfa-2b«Y·s¤@¥N³Ð·sªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Î©ó

ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌ¡C

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¬ü°êFDA¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð¡þ³q¹L®Ö­ã¡þ¤£³q¹L®Ö­ã¡þ¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)

µ²ªG¡þµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥ó¡G

¥»¤½¥q§¹¦¨¦V¬ü°êFDA´£¥XRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤§

¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡C

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG

¥¼¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò

­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG

¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç

¤è¦V¡G

¥»¤½¥q§¹¦¨¦V¬ü°êFDA´£¥XRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤§

¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡CRopeginterferon alfa-2b¥¼¨Ó¦p¦b¬ü°ê

Àò®Ö­ã¤W¥«±N¹ï¥»¤½¥qÀç¹B¦³¥¿­±¼vÅT¡C

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦Ò¶q¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A«O»Ù¤½¥q¤Î§ë¸ê¤H

Åv¯q¡A¼È¤£¤½¶}´¦ÅS¡C

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G¬ü°êFDA¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¼f®Ö¶¥¬q

(¤@)¹w­p§¹¦¨®É¶¡¡G

¨Ì·Ó¬ü°êFDA¤§¼f®Öµ{§Ç¡AFDA±N©ó¦¬¨ìBLA«áªº60¤Ñ¤º¼f®Ö¬O§_¨ü²z¦¹

¦¸¥Ó½Ð¡A¨Ã³W¹º¼f®Ö·|ij¤§®Éµ{¡C¥¿¦¡¼f®Ö®É¶¡±qFDA¦¬¨ìBLA«áªº²Ä60¤Ñ

°_ºâ¡A¼Ð·Ç¼f®Ö®Éµ{¬ù10­Ó¤ë¡AÀu¥ý¼f¬d¡]Priority review¡^®Éµ{¬ù

6­Ó¤ë¡CRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤w©ó2012¦~Àò±o¬ü°ê

©t¨àÃÄ»{ÃÒ¸ê®æ¡A¥»¤½¥q¦¹¦¸¦V¬ü°êFDA°e¥XBLA®É¤]¤w¦P¨B¥Ó½ÐÀu¥ý

¼f¬d¸ê®æ¡A FDA±N©ó¦¬¨ìBLA«áªº60¤Ñ¤º¦^ÂЬO§_¦P·N¦¹¦¸¥Ó½Ð¶i¤J

¥¿¦¡¼f¬d¶¥¬q¡A¨Ã§iª¾¬O§_µ¹¤©Àu¥ý¼f¬d¸ê®æ¡C¦pÀòÀu¥ý¼f¬d¡A¼f¬d

®É¶¡±N¥Ñ¼Ð·Ç¼f®Ö´Á10­Ó¤ëÁYµu¬°6­Ó¤ë¡C¹ê»Ú¼f¬d®É¶¡¤Î®Ö­ãÃÄÃÒ»P

§_¥HFDA¤§¥¿¦¡³qª¾¬°·Ç¡C

(¤G) ¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

¤»¡B¥«³õ²{ªp¡G(½Ð»¡©ú¥Ø«e¸Ó·sÃÄ©Ò¾AÀ³¯f¯g¤§¥«³õª¬ªp¡B²{¦³ªvÀø¬Û¦P¯f¯g

¤§¥D­nÃĪ«µ¥¸ê°T)

¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº¤@ºØ¡C¬ü°ê

MPN Research Foundation©ó2010¦~¶i¦æªº½Õ¬d¼Æ¾ÚÅã¥Ü¡A¦b¬ü°ê¬ù¦³15¸U

PV±wªÌ¡C¬ü°êPV±wªÌªº²{¦æªvÀø¤èªk¥]¬A©ñ¦å¡B§C¾¯¶qªü´µ¤ÇÆF¡B¥é³æ¥~

¨Ï¥Î¤§·Rªv½¦Ån¡]Hydroxyurea¡^»P¤zÂZ¯À¡A¤Î¤G½u¥ÎÃÄJakafi

¡]Ruxolitinib¡^¡C¥Ø«e¬ü°ê¦bPV¾AÀ³¯g¤W¨S¦³³QFDA¥¿¦¡®Ö­ãªº¤@½u¥ÎÃÄ¡C

¤C¡B¨ä¥LÀ³±Ô©ú¨Æ¶µ¡G·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A

¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2020/3/16 ¤W¤È 06:25:29²Ä 8068 ½g¦^À³
°e¬ü°êÃÄÃÒºO¡I

¥»¤½¥q¤w§¹¦¨¦V¬ü°êFDA´£¥XRopeginterferon alfa-2¡]P1101¡^

¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡]BLA¡^¡A¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^

1.¨Æ¹êµo¥Í¤é:109/03/14

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q©ó¬ü°ê®É¶¡2020¦~03¤ë13¤é§¹¦¨¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^´£¥X

Ropeginterferon alfa-2b¡]P1101¡^¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡]BLA¡^¡A

¾AÀ³¯g¬°¯u©Ê¬õ¦å²y¼W¥Í¯g¡]Polycythemia Vera¡A²ºÙPV¡^¡C

6.¦]À³±¹¬I:µo¥¬¥»­«¤j°T®§

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GRopeginterferon alfa-2b¡]P1101¡^

¤G¡B¥Î³~¡GRopeginterferon alfa-2b«Y·s¤@¥N³Ð·sªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Î©ó

ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌ¡C

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¬ü°êFDA¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð¡þ³q¹L®Ö­ã¡þ¤£³q¹L®Ö­ã¡þ¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)

µ²ªG¡þµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥ó¡G

¥»¤½¥q§¹¦¨¦V¬ü°êFDA´£¥XRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤§

¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡C

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG

¥¼¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò

­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG

¹F²Î­p¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç

¤è¦V¡G

¥»¤½¥q§¹¦¨¦V¬ü°êFDA´£¥XRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤§

¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¥Ó½Ð¡CRopeginterferon alfa-2b¥¼¨Ó¦p¦b¬ü°ê

Àò®Ö­ã¤W¥«±N¹ï¥»¤½¥qÀç¹B¦³¥¿­±¼vÅT¡C

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦Ò¶q¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A«O»Ù¤½¥q¤Î§ë¸ê¤H

Åv¯q¡A¼È¤£¤½¶}´¦ÅS¡C

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G¬ü°êFDA¤§¥Íª«ÃÄ«~¤W¥«¬dÅçµn°O¼f®Ö¶¥¬q

(¤@)¹w­p§¹¦¨®É¶¡¡G

¨Ì·Ó¬ü°êFDA¤§¼f®Öµ{§Ç¡AFDA±N©ó¦¬¨ìBLA«áªº60¤Ñ¤º¼f®Ö¬O§_¨ü²z¦¹

¦¸¥Ó½Ð¡A¨Ã³W¹º¼f®Ö·|ij¤§®Éµ{¡C¥¿¦¡¼f®Ö®É¶¡±qFDA¦¬¨ìBLA«áªº²Ä60¤Ñ

°_ºâ¡A¼Ð·Ç¼f®Ö®Éµ{¬ù10­Ó¤ë¡AÀu¥ý¼f¬d¡]Priority review¡^®Éµ{¬ù

6­Ó¤ë¡CRopeginterferon alfa-2b¨Ï¥Î©óªvÀøPV¤w©ó2012¦~Àò±o¬ü°ê

©t¨àÃÄ»{ÃÒ¸ê®æ¡A¥»¤½¥q¦¹¦¸¦V¬ü°êFDA°e¥XBLA®É¤]¤w¦P¨B¥Ó½ÐÀu¥ý

¼f¬d¸ê®æ¡A FDA±N©ó¦¬¨ìBLA«áªº60¤Ñ¤º¦^ÂЬO§_¦P·N¦¹¦¸¥Ó½Ð¶i¤J

¥¿¦¡¼f¬d¶¥¬q¡A¨Ã§iª¾¬O§_µ¹¤©Àu¥ý¼f¬d¸ê®æ¡C¦pÀòÀu¥ý¼f¬d¡A¼f¬d

®É¶¡±N¥Ñ¼Ð·Ç¼f®Ö´Á10­Ó¤ëÁYµu¬°6­Ó¤ë¡C¹ê»Ú¼f¬d®É¶¡¤Î®Ö­ãÃÄÃÒ»P

§_¥HFDA¤§¥¿¦¡³qª¾¬°·Ç¡C

(¤G) ¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

¤»¡B¥«³õ²{ªp¡G(½Ð»¡©ú¥Ø«e¸Ó·sÃÄ©Ò¾AÀ³¯f¯g¤§¥«³õª¬ªp¡B²{¦³ªvÀø¬Û¦P¯f¯g

¤§¥D­nÃĪ«µ¥¸ê°T)

¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¬°°©Åè¼W¥Í©Ê¸~½F¡]MPN¡^¯e¯fªº¤@ºØ¡C¬ü°ê

MPN Research Foundation©ó2010¦~¶i¦æªº½Õ¬d¼Æ¾ÚÅã¥Ü¡A¦b¬ü°ê¬ù¦³15¸U

PV±wªÌ¡C¬ü°êPV±wªÌªº²{¦æªvÀø¤èªk¥]¬A©ñ¦å¡B§C¾¯¶qªü´µ¤ÇÆF¡B¥é³æ¥~

¨Ï¥Î¤§·Rªv½¦Ån¡]Hydroxyurea¡^»P¤zÂZ¯À¡A¤Î¤G½u¥ÎÃÄJakafi

¡]Ruxolitinib¡^¡C¥Ø«e¬ü°ê¦bPV¾AÀ³¯g¤W¨S¦³³QFDA¥¿¦¡®Ö­ãªº¤@½u¥ÎÃÄ¡C

¤C¡B¨ä¥LÀ³±Ô©ú¨Æ¶µ¡G·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A

¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/15 ¤U¤È 10:33:28²Ä 8067 ½g¦^À³
2019 ·s«¬«aª¬¯f¬r(2019-nCoV)·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ

¦æ¬F°|½Ã¥ÍºÖ§Q³¡¯e¯fºÞ¨î¸p ½s 2020 ¦~ 2 ¤ë 2 ¤é²Ä¤Gª©

¤E¡B °w¹ï 2019-nCoV ¤§§Ü¯f¬r»P¨ä¥LªvÀø

2019-nCoV ¤§§Ü¯f¬r»P¨ä¥LªvÀø

¥Ø«e¨S¦³¨Ó¦Û RCT ¬ã¨sªºÃÒ¾Ú¤ä«ù¥ô¦ó§Ü¯f¬rÃĪ«ªvÀøºÃ¦ü©Î½T¶E 2019-nCoV ·P¬V ¯f¨Ò

¡A¬ÛÃöÃÒ¾Ú¥D­n¨Ó¦Û¦P¬°«aª¬¯f¬rªº SARS »P MERS-CoV ¤§ªvÀø¸gÅç¡BÁ{§É»PÅé ¥~¸ÕÅçµ²ªG¡C¹ï SARS »P MERS-CoV¡AÁöµL WHO »{ÃÒªº¼Ð·ÇÀøªk

¡A¦ý´¿³Q¥Î©óªv ÀøªºÃĪ«¥]¬A¦hºØ§Ü¯f¬rÃĪ«(ribavirin, lopinavir/ritonavir, remdesivir)¡B¤zÂZ¯À (interferon-£\, interferon-£])¡B¯f±w«ì´_´Á¦å²M»P³æ®è/¦h®è§ÜÅéµ¥

¡C¦Ò¶q 2019-nCoV ­Ó®×Á{§ÉÄY­«µ{«×¡B¶Ç¼½¤O¡BªvÀø¥i¯àªº®Ä¯q»P­·ÀI¤ÎÃĪ«¾AÀ³¯g ¥~¨Ï¥Î¤§­Û²zijÃD¡A«Øij¸gÁ{§É±M®aµû¦ô»P¥R¤À§iª¾«á¡A¥i¦Ò¼{¹ï©ó¦~ÄÖ¡Ù18 ·³¤§½T ©w¯f¨Ò¡A°Ñ¦Òªí¤@ WHO Á{§Éªí²{¤ÀÃþ¡A¹ï¦³ÄY­«ªÍª¢©Î«æ©Ê©I§lµ~­¢¯g­Ô¸sªº±wªÌ¦b µo¯f¤Q¤é¤ºµ¹¤©ªvÀø¡C«Øij¥i¦Ò¼{¨Ï¥ÎªºÃĪ«¬° Lopinavir/Ritonavir (200mg+50mg/tablet) 2# PO BID¡A³æ¿W¨Ï¥Î¡A©Î¦X¨Ö¨Ï¥Î Interferon-£]1b 0.25 mg SC QOD5¡Aª½¨ì±wªÌ³sÄò¨â¦¸©I§l¹DÀËÅé(¦Ü¤Ö¶¡¹j 24 ¤p®É±ÄÀË)ÀËÅçµ²ªG§¡ ¬°³±©Ê¬°¤î¡AÀøµ{¦Ü¦h¤Q¥|¤Ñ¡C­Y±wªÌ¤wª¾¹ïªvÀøÃĪ«¹L±Ó¡A«h¤£«Øijµ¹¤©ªvÀø¡CµL ¨Öµo¯g¤§»´¯g©Î»´«×ªÍª¢±wªÌ¡A¶·§ó¼f·Vµû¦ô¬O§_¨Ï¥Î¦¹ÃþÃĪ«ªvÀø¡A«Øij¥i¿Ô¸ß·P ¬V¬ì±M¬ìÂå®v¡C

³Æµù:¤åÄm¦^ÅUÅã¥Ü¡ALopinavir/Ritonavir »P Interferon ¦bÅé¥~¸ÕÅ礤¹ï MERS-CoV ¦³§í

¨î©Ê®ÄªG ¡C¤HÃþÆ[¹î©Ê¬ã¨s«hÅã¥Ü¡A¨Ï¥Î Lopinavir/Ritonavir ¦X¨Ö Ribavirin¡A¬Û¸û©ó¶È

¨Ï¥Î Ribavirin¡A¥i­°§C SARS ¯f±w¦º¤`²v 3¡C¥Ø«e¶i¦æ¤¤¤§ MERS-CoV ªvÀøÁ{§É¸ÕÅç

(NCT02845843)«Y¦P®É¨Ö¥Î Lopinavir/Ritonavir »P Interferon-£]1b5¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/15 ¤W¤È 10:40:50²Ä 8066 ½g¦^À³
Gwo Nouvèl, Interféron Alfa 2B tretman Cubain yo jwenn pou konbat CORONAVIRUS la

www.youtube.com/watch?v=076bETvTnVY

2020¦~2¤ë10¤é

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10142326  µoªí®É¶¡:2020/3/15 ¤W¤È 10:32:56²Ä 8065 ½g¦^À³
www.youtube.com/watch?v=EtJghHdrtrY

Management of PV, the role of interferon

2020¦~1¤ë30¤é

¼v¤ù14¤À34¬í³B Prof. Jean-Jacques Kiladjian

¦ü¥G¦³´£¤Î PegasysÂà´«¦¨ ROPEGINTERFERON±¡§Î?

¥i§_½Ðºô¤W¤j¤j¥N¬°Â½Ä¶½T»{¡CÁÂÁ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/14 ¤U¤È 09:56:13²Ä 8064 ½g¦^À³
¡mNature¡n¤l¥Z¡G´M§ä·s«¬«aª¬¯f¬r¡u¦ÑÃÄ·s¥Î¡vªº¼ç¦bÀøªk

2020.02.13 Àô²y¥Í§ÞÂø»x°OªÌ/§õªLÀõ ½sĶ

µoªí©ó 2020-02-13 §@ªÌ °OªÌ§õªLÀõ

¤é«e(10)¡A¤¤°ê¤¤«n¤j¾Ç´ð¶®¤½¦@½Ã¥Í¾Ç°|ªº§õ¼s­}¡]Guangdi Li¡^³Õ¤h»P¤ñ§Q®É¾|¨Z¤j¾ÇRegaÂå¾Ç¬ã¨s©Ò(Rega Institute for Medical Research, Katholieke Universiteit Leuven) ªºErik De Clercq³Õ¤h±q¹ïSARS©MMERSªºªvÀø¸gÅ礤¡A´£¥XÂǥѦÑÃÄ·s¥Îªº¤è¦¡¨Ó´M§ä·s«¬«aª¬¯f¬rªº¼ç¦bÀøªk¡C

¨Ã«ü¥X°ª¹F60¦hºØ¦³§Æ±æªº¼ç¦bÀøªk¡A¥]¬A¤w§å­ãªº¤é¥»´I¤h³n¤ùºX¤Uªº´I¤s¤Æ¾Ç¤u·~¬ãµoªº¬y·P§Ü¯f¬rÃĪ«Favipiravir¡B±`»P¤zÂZ¯À¦X¨ÖªvÀøC«¬¨xª¢ªº¤fªA§Ü¯f¬rÃĪ«Ribavirin©M¥Ø«e¥¿¦b¬ãµo¤¤ªº¦N§Q¼w¬ì¾Ç¤½¥q¡]Gilead¡^ªºRemdesivir©M¬ü°êÃļtBioCryst Pharmaceuticals³Ìªì¶}µo¥Î©óªvÀøC«¬¨xª¢ªºgalidesivirµ¥§Ü¯f¬rÃĪ«¡C¸Ó½×¤åµoªí©ó¡mNature Reviews Drug Discovery¡n¡C

·s«¬«aª¬¯f¬rÄÝ«aª¬¯f¬r¬ì¡]Coronavirinae¡^¡A¬°¤@¸s¨ã¥~®M½¤¡]envelope¡^³æÃ쥿ªÑ¡]single-stranded, positive-sense¡^ªºRNA £]-«aª¬¯f¬r¡C

¨ä»PSARS©MMERSÃþ¦ü¡A°ò¦]Å餤§t¦³«Dµ²ºc³J¥Õ¡Bµ²ºc³J¥Õ©M»²§U³J¥Õ¡C«Dµ²ºc³J¥Õ¥]¬A3-¯Ø¾®¨Å³J¥Õ酶¼Ë³J¥Õ酶¡]3-chymotrypsin-like protease¡^¡B¦ü¤ì¥Ê¯À³J¥Õ¤ô¸Ñ酶¡]papain-like protease¡^¡B¸Ñ±Û酶¡]helicase¡^¡B©MRNA¨Ì¿à©ÊRNA»E¦X酶¡]RNA-dependent RNA polymerase, RdRp¡^¡Cµ²ºc³J¥Õ¥]¬A´Æ¬ðÁÞ³J¥Õ¡]spike glycoprotein¡^¡C

³o¥|ºØ«Dµ²ºc³J¥Õ¬O¯f¬r¥Í©R¶g´Á¤¤ªºÃöÁä»Ã¯À¡A¦Ó´Æ¬ðÁÞ³J¥Õ¤S¬O¯f¬r¤J«I²Ó­M®É¤£¥i©Î¯Êªººc³y¡A¦]¦¹¡A³o¤­ºØ³J¥Õ½è³Q»{¬°¬O¶}µo§Ü¯f¬rÃĪ«ªº­«­n¹vÂI¡C

¦Ó±q·s«¬«aª¬¯f¬rªº°ò¦]§Ç¦Cªì¨B¤ÀªR¤¤Åã¥Ü¡A¨ä¥|ºØ«Dµ²ºc³J¥Õ¨ã¦³°ª«×«O¦uªº¯S©Ê(highly conserved)¡A¨Ã»PSARS©MMERSªº«Dµ²ºc³J¥Õ¨ã¦³°ª«×ªº°ò¦]§Ç¦C¬Û¦ü©Ê¡A¥B¦b³J¥Õ½èµ²ºc¤ÀªR¤¤Åã¥Ü¡A·s«¬«aª¬¯f¬r¡BSARS»PMERS»P§Ü¯f¬rÃĪ«µ²¦XªºÃöÁä¦ìÂI·¥¥i¯à¨ã«O¦u¯S©Ê¡A¦]¦¹¡A±N²{¦³ªºSARS»PMERSªº§Ü¯f¬rÃĪ«¥Î¨Ó¦ÑÃÄ·s¥Î¬O¤Q¤À¦X²zªº¡C

¥Ø«e¡A¤w³Q§å­ã©Î¥¿¦b¬ãµo¤¤ªº®Ö»ÄÃþ¦üª«ÃĪ«¥i¯à¨ã¦³ªvÀø·s«a¯f¬rªº¼ç¤O¡C¥¦­Ì¥]¬A¤é¥»´I¤h³n¤ùºX¤Uªº´I¤s¤Æ¾Ç¤u·~¬ãµoªº¬y·P§Ü¯f¬rÃĪ«Favipiravir¡B±`»P¤zÂZ¯À¦X¨ÖªvÀøC«¬¨xª¢ªº¤fªA§Ü¯f¬rÃĪ«Ribavirin¡B¦N§Q¼w¬ì¾Ç¤½¥q¡]Gilead¡^¬ãµo¤¤ªºRemdesivir©M³Ìªì¶}µo¥Î©óªvÀøC«¬¨xª¢ªºgalidesivir¡C

Favipiravir¬O¤@ºØ¤w¸gÀò§å¤W¥«ªvÀø¬y·Pªº³¾áIËïÃþ¦üª«¡A¥i¦³®Ä§í¨îRNA¯f¬rªºRdRp¡A¦p¥i§í¨î¥ìªi©Ô¯f¬r¡B¶À¼ö¯f¡]yellow fever¡^¯f¬r©}¤½¯f¬r¡]Chikungunya virus¡^¡B¿Õù¯f¬r¡]norovirus¡^¡B©M¸z¯f¬r¡]enterovirus¡^¡C³Ì·sªº¤@¶µ¬ã¨sÅã¥Ü¡A¦bÅé¥~ªº²Ó­M®è¸ÕÅ礤¡A¨ä¹ï·s«¬«aª¬¯f¬rªº¥b¼Æ¦³®Ä¿@«×(EC50)¹F¨ì61.88 £gM¡C

¥Ø«e¡A³o´Ú§Ü¯f¬rÀøªk¤w¸g¶i¤JÁ{§É¸ÕÅç¡A»P¤zÂZ¯À£\©Îbaloxavir marboxil¡]¤@ºØÀò§å§Ü¬y·PÃĪ«¡^Áp¥Î¡A¥HªvÀø·s«¬«aª¬¯f¬r±wªÌ¡C

Ribavirin¬O¤@ºØ¤wÀò§å¥iªvÀøC¨x¯f¬r¡]HCV¡^©M©I§l¹D¿Ä¦X¯f¬r¡]RSV¡^ªº³¾áIËïÃþ¦üª«¡C¥¦´¿¸g³Q¥Î©óªvÀøSARS©MMERS±wªÌ¡AµM¦Ó¦b°ª¾¯¶q®É¥i¯à¾É­PÄY­«³h¦å¡C³o´ÚÃĪ«¯à§_¹ï·s«¬«aª¬¯f¬r¨ã¦³®ÄªG©|¥¼±o¨ì½T©w¡C

Remdesivir¬O¦N§Q¼wªº¤@¶µ¥¿¦b¬ãµoªºÃĪ«¡A¥ý«e¦b²Ó­M©M°Êª«¸ÕÅ礤¹ï§í¨îMERS©MSARSªí²{¥X¨}¦nªº®ÄªG¡A¨Ã³Q¥Î©óªvÀø¥ìªi©Ô¯f¬rªºÁ{§É¸ÕÅ礤¡Cªñ´Áªº²Ó­M¬ã¨sÅã¥Ü¡A³o¤@­Ô¿ïÃĪ«¦b²Ó­M®è¤¤§í¨î·s«¬«aª¬¯f¬rªºEC50¹F¨ì0.77 £gM¡C¥Ø«e¡A¤w±Ò°Ê¨â¶µ3´ÁÁ{§É¸ÕÅç¡A¥Î©óÀËÅçRemdesivirªvÀø·s«¬«aª¬¯f¬r±wªÌªºÀø®Ä¡A¹w­p¦b¤µ¦~4¤ë§¹¦¨¡C

Galidesivir¡]BCX4430¡^¬O¤@´Ú³Ìªì¶}µo¥Î¨ÓªvÀøC¨x¯f¬rªº¸¢áIËïÃþ¦üª«¡C¥Ø«e¥¿¦b¦­´ÁÁ{§É¬ã¨s¤¤ÀË´ú¨ä¦w¥þ©Ê¨Ãµû¦ô¨äªvÀø¶À¼ö¯fªº®ÄªG¡C¦Ó¦bGalidesivirªºÁ{§É«e¬ã¨s¤¤¡AÅã¥Ü¥X¹ï¦hºØRNA¯f¬r¨ã¦³§í¨î©Ê¡A¨ä¤¤¥]¬ASARS©MMERS¡C

½×¤å¤¤«ü¥X¡A¦p¦ó¨³³t¶EÂ_·s«¬«aª¬¯f¬rªº¥Ø«e³Ì­«­nªºªº¬D¾Ô¡C¨Ã´£¥X°ª¹F60¦hºØ¦³§Æ±æªº¼ç¦bÀøªk¡A»{¬°¥Ø«e¤w¦³ªº§Ü¯f¬rÃĪ«¨ã³Æ¦w¥þ©Ê¥H¤Î¹ï¬ÛÃö«aª¬¯f¬rªº§í¨î¬¡©Ê¡A±N³o¨ÇÃĪ«¦ÑÃÄ·s¥Î¥i¯à¬OªvÀø·s«¬«aª¬¯f¬rªºªñ´Áµ¦²¤¡C

°Ñ¦Ò¸ê®Æ¡GLi and De Clercq, (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, doi: 10.1038/d41573-020-00016-0.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/14 ¤U¤È 09:31:47²Ä 8063 ½g¦^À³
²{¦b¬Ý°_¨Ó­«¯gªº¯f±w´N¬OÁÙ¨S¥Î¨ì¤zÂZ¯À¥i¯à´N±¾¤F¡H

-/////

¦³³o­Ó¥i¯à¡A¦]¬°¥Îªº¤zÂZ¯À¤£¬OÃĵتº¤zÂZ¯À

¦Ó¬O¤j³°¦Û¤v¥Í²£¡A¤£¯Âªº¤zÂZ¯ÀµLªk¥Î°ª¾¯¶q

¦Ó¥B°Æ§@¥Î¤j¡A±o¨ìªZº~ªÍª¢¡A§K¬Ì¨t²Î¾ã²Õ

¤w¸gÃa¤F¤F

¨º¦³¤O¶q¦A©Ó¨ü¨º»ò¤jªº°Æ§@¥Î¡H

ÃĵØP1101¡ARopeginterferon®³¨ì¼Ú¬wPV²Ä¤@½u

ÃÄÃÒ¡A¦³®Ä©Ê¦w¥þ©Ê¡A³Ì¤j¾¯¶q¡C¨º¬O¤j³°²£ªº¤zÂZ¯À

¥i¥H¤ñ¡HXX¤ñ鷄»L🦵¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/14 ¤U¤È 09:03:11²Ä 8062 ½g¦^À³
Ãĵبä¹ê¥i¥H¦¨¥ßªZº~ªÍª¢±M®×

µ²¦XAOP¡A¬ü°ê¤À¤½¥q¡A¤é¥»¤À¤½¥q¡A¤j³°¤À¤½¥q

¶i¦æ¤zÂZ¯À¥Î©óªZº~ªÍª¢ªºªvÀø

ÁÙ¬OÅ¥

Bobbyªº¸Ü¡F

§O¦Aµ¹¤½¥qµLªk¹F¦¨ªºÃB¥~­t¾á

ªÍª¢ªº¨Æ¥æµ¹®ð·Å³B²z¡H

ºÝ¬ÝªL°õ¦æªøªº´¼¼z¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLinbad10148532  µoªí®É¶¡:2020/3/14 ¤U¤È 08:45:00²Ä 8061 ½g¦^À³
¦Ü©óAOP¶È¶ÈÀò±oÃĵØPV¡AETµ¥±ÂÅv

­Y¬O¥Î¦bªZº~ªÍª¢

©Ò¦³Åv¤´ÂkÄÝ©óÃĵØ

©Ò¥HAOP¤£¯à°÷±NÃĵتº¤zÂZ¯À¥Î©óªZº~ªÍª¢ªvÀø

©Ò¥H¨º¨Óªº¤j¶q¶i³f¥Î©óªZº~ªÍª¢ªvÀø

¤£¹LÃĵإi¥H¦A¦¸¸òAOP¦X§@

¥²³ºAOP«Ü¼ôEMA¤Î¼Ú·ùªº¦æ¾P

¤£¹Lñ¬ù­n¤p¤ß

¤£­n¦A¤W·í¨üÄF¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤@­¶67891011121314¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!